



CPDD 70th ANNUAL SCIENTIFIC MEETING
The Caribe Hilton, San Juan, Puerto Rico
June 14-19, 2008

PROGRAM BOOK

BOARD OF DIRECTORS

Stephen T. Higgins, PhD, President
Thomas R. Kosten, MD, Past-President
Sharon Walsh, PhD, President-Elect
Stephen G. Holtzman, PhD, Treasurer
James C. Anthony, PhD
Patrick M. Beardsley, PhD
Steven R. Childers, PhD
Theodore J. Cicero, PhD
William L. Dewey, PhD

Toby K. Eisenstein, PhD
A. Thomas McLellan, PhD
Michael A. Nader, PhD
Edward V. Nunes, PhD
Alison Oliveto-Beaudoin, PhD
Linda J. Porrino, PhD
Richard A. Rawson, PhD
Maxine L. Stitzer, PhD
Dace S. Svikis, PhD

EXECUTIVE OFFICER

Martin W. Adler, PhD

SCIENTIFIC PROGRAM COMMITTEE

Sari Izenwasser, PhD, Chair
Sharon Walsh, PhD, Past-Chair
Martin W. Adler, PhD, *ex officio*
Ellen B. Geller, MA, *ex officio*
Anna Rose Childress, PhD
Sandra Comer, PhD
Mark Greenwald, PhD
Scott Hemby, PhD
Kathleen Kantak, PhD
Jennifer Tidey, PhD
Ellen Unterwald, PhD
Friedbert Weiss, PhD
Sandra Welch, PhD

Saturday, June 14, 2008

PRE-MEETING SATELLITES

*The International Study Group Investigating
Drugs as Reinforcers (ISGIDAR)*
Chaired by Elise Weerts

**San Cristobal
E/G**

*8th Annual Meeting Center for Substance Abuse Treatment (CSAT)
Science to Services and Services to Science:
The Identification and Adoption of Effective Practices
for Substance Abuse Treatment*
Chaired by Laura House

**San Cristobal
A/D**

*The 13th Annual NIDA International Forum on
Building International Research on Drug Abuse:
Progress through Collaboration*
Chaired by Steven Gust

**San Geronimo
A/C**

**CPDD REGISTRATION
Tropical**

Saturday, June 14	1:30 PM - 5:30 PM
Sunday, June 15	8:00 AM - 12:00 PM 2:00 PM - 5:30 PM
Monday, June 16	8:00 AM - 12:00 PM 1:30 PM - 5:00 PM
Tuesday, June 17	8:00 AM - 1:00 PM
Wednesday, June 18	8:00 AM - 12:00 PM 1:15 PM - 5:00 PM
Thursday, June 19	8:00 AM - 1:00 PM

**OPENING RECEPTION
(Cash Bar)**

**7:00 – 9:00 PM
Pool Area**

Sunday, June 15, 2008

Sunday, June 15, 2008

CSAT Travel Awards Breakfast
(By Invitation Only)

Salon del Mar
7:00 - 8:00 AM

Plenary Session

San Geronimo Ballroom
8:30 - 11:00 AM

- 8:30 *Stephen T. Higgins*
Welcome, CPDD President
- 8:45 *Report from the National Institute on Drug Abuse*
Nora D. Volkow, Director, NIDA
- 9:15 *Presentation of the Distinguished Service Award to Geoffrey K. Mumford*
Introduction by William L. Dewey and Stephen T. Higgins
- 9:20 *Presentation of the Media Award to William Cope Moyers*
Introduction by Marc Kaufman
- 9:40 *Presentation of the J. Michael Morrison Award to Betty Tai and Rita Liu*
Introduction by Martin W. Adler
- 9:45 *Presentation of the Joseph Cochin Young Investigator Award to Hendree Jones*
Introduction by Karol Kaltenbach
- 9:50 *Presentation of the Mentorship Award to Joseph V. Brady*
Introduction by Jack E. Henningfield
- 9:55 *Presentation of the Nathan B. Eddy Award to Billy R. Martin*
Introduction by William L. Dewey
- 10:00 *Nathan B. Eddy Award Lecture by Billy R. Martin:*
The journey from marijuana to the endocannabinoid system
,

Art and Addiction Exhibition

Flamingo
9:00 AM - 6:00 PM

Public Policy Forum

(Brown Bag Lunch)

Auditorium

11:30 AM - 1:00 PM

Chairs: William Dewey and Martin Iguchi

- 11:30 *Introduction*
Martin Iguchi
- 11:40 *Current status on Capitol Hill*
Ed Long
- 12:00 *Friends of NIDA and CPDD Public Policy activities*
William Dewey
- 12:20 *Need for increased public understanding of drug abuse illness*
William Cope Moyers

President's Lecture

San Cristobal

1:15 - 2:15 PM

CAN FOOD BE ADDICTIVE AND WHY?

Kelly D. Brownell, Director, Rudd Center for Food Policy and Obesity, Yale University, New Haven, CT

Symposium I

San Cristobal

2:30 - 4:30 PM

OF VICE AND MEN: SHARED BRAIN VULNERABILITIES FOR DRUG AND NON-DRUG (FOOD, SEX, GAMBLING) REWARDS

Chairs: Anna Rose Childress and Marc Potenza

- 2:30 *Shared brain vulnerabilities in obesity and drug addiction*
Joseph Frascella, NIDA, Bethesda, MD
- 2:55 *Brain activation in obsessive, early romantic infatuation*
Lucy Brown, Albert Einstein College of Medicine, Bronx, NY
- 3:20 *Shared brain, behavioral, and genetic vulnerabilities in pathological gambling and in drug addictions*
Marc Potenza, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT
- 3:45 *Emergence of problematic addiction-relevant behaviors in Parkinsons patients on dopamine replacement therapy*
Dan Weintraub, University of Pennsylvania School of Medicine, Philadelphia, PA
- 4:10 *If it walks like a duck: Theoretical, treatment and nosologic implications of overlapping brain vulnerabilities in the compulsive pursuit of drug and non-drug rewards*
Anna Rose Childress, University of Pennsylvania School of Medicine, Philadelphia, PA

Symposium II

**San Geronimo B
2:30 - 4:30 PM**

COCAINE DEPENDENCE AND SOCIAL DISADVANTAGE: EVIDENCE FROM THE LABORATORY, CLINIC, AND COMMUNITY

Chair: Stephen T. Higgins

- 2:30 *The changing relationship between cocaine use and social class over time*
Howard D. Chilcoat, GlaxoSmithKline, Research Triangle Park, NC
- 2:55 *Social dominance in monkeys: Dopamine D2 receptors and the reinforcing effects of cocaine*
Michael A. Nader, Wake Forest University School of Medicine, Winston-Salem, NC
- 3:20 *Do gestational cocaine exposure and/or socioeconomic status affect child neurocognitive outcome?*
Hallam Hurt, The Children's Hospital of Philadelphia, Philadelphia, PA
- 3:45 *Operant interventions to address the interrelated problems of poverty and cocaine addiction*
Kenneth Silverman, Johns Hopkins University School of Medicine, Baltimore, MD
- 4:10 *Discussant*
Charles R. Schuster, Loyola University-Chicago, Stritch School of Medicine, Maywood, IL

Oral Communications 1

**San Geronimo C
2:30 - 4:30 PM**

HIV/HCV/STD

Chairs: Gayle Baldwin and Leah Floyd

- 2:30 *Cocaine modulates human dendritic cell differentiation and T-cell activation with downstream effects on HIV replication*
G.C. Baldwin, S. Kiertscher, J. Zhuo, A. Harui, D.P. Tashkin and M.D. Roth, Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
- 2:45 *Cocaine use is associated with all-cause mortality among drug users engaged in HIV care*
A.A. Chaudhry¹, R.E. Thompson² and R.D. Moore^{1,2}, ¹Johns Hopkins University School of Medicine, and ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 3:00 *HCV treatment in patients on opioid therapy for narcotic addiction looking at compliance, safety, virological response and effect on drug usage*
I.J. Kronborg¹, M. Weltman², J. Sasadeusz³, G. Dore⁴, D. Barton⁵ and M. Yoshihara⁶, ¹DASWest, Western Health, Footscray, VIC, ²Gastroenterology, Nepean Hospital, Nepean, NSW, ³VIDS, Royal Melbourne Hosp., and ⁵Alfred Hosp., Melbourne, VIC, ⁴Nat'l Centre in HIV Epidemiology and Clinical Research, and ⁶Roche, Sydney, NSW, Australia
- 3:15 *Methamphetamine use as a predictor of a sexually transmitted disease co-infection among HIV positive men who have sex with men*
E.T. Rudy¹, P. Kerndt¹, S. Shoptaw^{2,3}, B. Bolan⁴ and S. Tilekar⁴, ¹Los Angeles County STD Program, ²Family Medicine-University of California-Los Angeles, ³Integrated Substance Abuse Program, University of California-Los Angeles, and ⁴Los Angeles Gay & Lesbian Center, Los Angeles, CA

- 3:30 *Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City*

D.C. Des Jarlais¹, K. Arasteh¹, C. McKnight¹, H. Hagan², D. Perlman¹ and S.R. Friedman²,
¹Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center
and ²National Development and Research Institutes, Inc., New York, NY

- 3:45 *Compound RANTES and CCR2 genetic polymorphisms affect risk of HCV infection among injecting drug users in China*

H. Liu¹, S. Yu², J. Du², H. Chen², C. Fan², C. Yuan², D. Wang², M. Comerford¹, C. McCoy¹
and M. Zhao², ¹University of Miami Miller School of Medicine, Miami, FL and ²Shanghai
Mental Health Center, Shanghai, China

- 4:00 *Substance use and sex trade among South Africans*

L.J. Floyd, C. Salama, A. Lawson and W. Latimer, Johns Hopkins University Bloomberg
School of Public Health, Baltimore, MD

- 4:15 *Injecting equipment sharing among Russian drug-injecting dyads*

V. Gyarmathy¹, N. Li¹, K.E. Tobin¹, I.F. Hoffman², A.P. Kozlov³, H.D. Chilcoat⁴ and
C.A. Latkin¹, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
²U. of North Carolina at Chapel Hill, and ⁴GlaxoSmithKline, Research Triangle Park, NC
³Biomedical Center, St. Petersburg State University, St. Petersburg, Russian Federation

Oral Communications 2

San Geronimo A
2:30- 4:30 PM

OPIOID BEHAVIORAL PHARMACOLOGY

Chairs: Gail Pereira Do Carmo and Drake Morgan

- 2:30 *Effects of pain and analgesia on intracranial self-stimulation in rats*

G. Pereira Do Carmo¹, K. Schrode², W.A. Carlezon³ and S.S. Negus², ¹Department of
Psychology, Marist College, Poughkeepsie, NY, ²Pharmacology & Toxicology, Virginia
Commonwealth University, Richmond, VA and ³Behavioral Genetics Laboratory, McLean
Hospital/Harvard Medical School, Belmont, MA

- 2:45 *Involvement of endogenous β -endorphin in the suppression of the morphine-induced rewarding effect under a neuropathic pain-like state in rodents*

K. Niikura, M. Narita, M. Narita, A. Nakamura, D. Okutsu, K. Kurahashi, Y. Kobayashi,
M. Suzuki and T. Suzuki, Toxicology, Hoshi University, Tokyo, Japan

- 3:00 *Metabotropic glutamate receptor antagonists increase the antinociceptive efficacy of μ -opioid agonists*

B.D. Fischer, L.L. Miller, F.E. Henry, M.J. Picker and L.A. Dykstra, Psychology, University
of North Carolina at Chapel Hill, Chapel Hill, NC

- 3:15 *Involvement of ifenprodil in the addiction memory vs. the spatial learning and memory in rats*

Y. Ma^{1,2}, J.S. Han¹, D.Y. Lee² and C.L. Cui¹, ¹Neurobiology, Neuroscience Research Institute,
Beijing, China and ²Psychiatry, McLean Hospital, Belmont, MA

- 3:30 *Chronic fentanyl administration in aging rats: Body composition, thermoregulation, and behavioral outcomes*

D. Morgan^{1,3}, J. DuPree³, S. DePaolo¹, G. Foremny¹, D. Seo³ and C.S. Carter^{2,3}, ¹Psychiatry,
University of Florida, ²Geriatric Research, Education, Clinical Center, and ³Institute on Aging,
Gainesville, FL

- 3:45 *Interactions between direct- and indirect-acting 5-HT₂ receptor agonists and the discriminative stimulus effects of morphine in rhesus monkeys: Perceptual masking?*
J. Li¹ and C.P. France^{1,2}, ¹Pharmacology, and ²Psychiatry, University of Texas Health Science Center, San Antonio, TX
- 4:00 *Compromised endogenous opioid activity results in habitual behavior*
K. Wassum¹, I.C. Cely¹, B.W. Balleine² and N.T. Maidment¹, ¹Semel Institute and ²Psychology, University of California-Los Angeles, Los Angeles, CA
- 4:15 *Orexin neurons that project to the ventral tegmental area are activated by morphine preference during protracted forced abstinence*
K.A. Richardson, P.T. Knackstedt and G. Aston-Jones, Neurosciences, Medical University of South Carolina, Charleston, SC

Forum

**San Cristobal
4:45 - 5:45 PM**

A ROADMAP TO NIH AND NIDA FUNDING OPPORTUNITIES AND RESEARCH RESOURCES

Chairs: Timothy P. Condon and David Shurtleff

Genetic resources and initiatives at NIH and NIDA
Joni Rutter, NIDA, Bethesda, MD

Taking advantage of the NIH KOMP GENSAT and collaborative cross projects for drug abuse research
Jonathan Pollock, NIDA, Bethesda, MD

Using the NIH-Roadmap and NIDA funding opportunities to advance drug abuse research
Timothy P. Condon, NIDA, Bethesda, MD

ASPET Mixer

**Las Olas
6:00 - 8:00 PM**

Primm-Singleton Travel Awardees Meeting

**Salon del Mar
6:30 - 8:00 PM**

Workshop I

**San Geronimo A
8:00 - 10:00 PM**

ORGANIZING A SPECIAL INTEREST GROUP ON STRESS AND ADDICTION

Chairs: Rajita Sinha and Helen Wu

Panelists: Nicholas E. Goeders, Rajita Sinha, Byron Adinoff, Friedbert Weiss, and Helen Wu

Workshop II

**San Geronimo B
8:00 - 10:00 PM**

DEA'S DRUG AND CHEMICAL EVALUATION SECTION: THE SCIENTISTS BEHIND THE BADGE. THE ROLE OF THE SCIENTIFIC STAFF WITHIN DEA AND RESOURCES FOR CPDD

Chairs: Christine A. Sannerud and Srihari R. Tella

*DEA's Drug and Chemical Evaluation section overview: Who we are and what we do
domestically and internationally*

Christine A. Sannerud, Office of Diversion Control, Drug Enforcement Administration,
Washington, DC

*Gathering the data necessary to support drug control: DEA databases and cooperation with
other agencies*

Srihari R. Tella, Office of Diversion Control, Drug Enforcement Administration,
Washington, DC

Ongoing drug-scheduling actions and Schedule I researcher registrations

Sandy G. Ghosland, Office of Diversion Control, Drug Enforcement Administration,
Washington, DC

Precursor chemical control, analogue determinations, and drug exemptions

Terrence L. Boos, Office of Diversion Control, Drug Enforcement Administration,
Washington, DC

Workshop III

**San Geronimo C
8:00 - 10:00 PM**

FROM AN ACUTE CARE MODEL TO A RECOVERY MANAGED CARE MODEL: WHAT DO WE KNOW AND WHERE DO WE GO FROM HERE?

Chairs: Ken Winters and Anne Helene Skinstad

A summary of the status of existing research on long-term care for substance use disorders

Peter Nathan, College of Public Health, University of Iowa, Iowa City, IA

Recovery support services and client outcomes: Results of two interim evaluations in Texas

Laurel M. Mangrum, University of Texas-Austin, Austin, TX

Recovery management in recovery high schools

Paul Moberg, Population Health Institute, University of Wisconsin School of Medicine and
Public Health, Madison, WI

From a passive to an active recovery environment

Gary Olson, Center for Alcohol and Drug Treatment, Duluth, MN

Building an agenda in research and practice to support recovery in America:

What's the difference?

Michael Flaherty, IRETA, Pittsburgh, PA

Movie: THE PANIC IN NEEDLE PARK featuring Al Pacino **Auditorium 8:00 PM**

Monday, June 16, 2008

Monday, June 16, 2008

POSTER SESSION I (Breakfast)

**Expo Center
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Sunday 1:00 PM
Must be removed by Monday 12:00 NOON**

OPIOIDS: ANIMAL STUDIES

- 1 *Studies on the determination of the pharmacophoric elements of the naturally occurring opioid receptor agonist, mitragynine and related alkaloids from Mitragyna speciosa*
J. Cui¹, J.F. Leon¹, C. Mesangeau¹, B. Peres¹, J.E. Adkins¹, E.B. Furr¹, M. Arribas¹, T.L. Nolan¹, S.J. Cutler¹, W.E. Polgar², L. Toll² and C.R. McCurdy¹, ¹Medicinal Chemistry, University of Mississippi, University, MS and ²Pharmacology, SRI, Inc., Menlo Park, CA
- 2 *Comparison of amphibian and human mu opioid receptors: Differences in receptor internalization and inhibition of cAMP in stable cell lines*
C.W. Stevens, C.M. Brasel and G.W. Sawyer, Pharmacology, OSU-CHS, Tulsa, OK
- 3 *Buprenorphine and naltrexone are partial kappa agonists*
J.M. Bidlack and B.I. Knapp, Pharmacology and Physiology, University of Rochester, Rochester, NY
- 4 *Identification of a "neutral" mu opioid receptor antagonist, LTC-274, for pharmacological analyses*
E.J. Sally, H. Xu, C.M. Dersch, L.T. Chang, L.W. Hsin, T.E. Prisinzano, D. Simpson, K.C. Rice, A.E. Jacobson, J. Zezula, K.J. Cheng and R.B. Rothman, Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD
- 5 *Pre-treatment with PKC and PKA inhibitors prevents the development of morphine tolerance but not physical dependence in mice*
B.H. Gabra¹, F.L. Smith² and W.L. Dewey¹, ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA and ²Pharmaceutical Sciences, Harding University College of Pharmacy, Searcy, AR
- 6 *Role of delta receptor efficacy as a determinant of delta/mu opioid interactions in rhesus monkeys*
S.S. Negus¹ and K.C. Rice², ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA and ²Chemical Biology Research Branch, NIDA/NIAAA, Rockville, MD
- 7 *Anxiolytic behavior induced by delta opioid receptor activation within the central nucleus of the amygdala*
J.F. Randall-Thompson and E.M. Unterwald, Pharmacology, Temple University School of Medicine, Philadelphia, PA
- 8 *SNC80-induced taste aversions in F344 and LEW rat strains*
C.M. Davis¹, K.C. Rice² and A.L. Riley¹, ¹Psychology, American University, Washington, DC, and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD

- 9 *Naloxone as a stimulus in drug discrimination learning*
A.L. Riley¹, G.W. Stevenson², C.M. Davis¹, F. Cañadas¹, T. Ullrich³ and K.C. Rice³,
¹Psychology, American University, Washington, DC, ²Psychology, University of New
England, Biddeford, ME and ³Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD
- 10 *Synaptic localization of hippocampal AMPA receptors is altered upon the extinction of
morphine-dependent conditioned behavior*
S. Billa, N. Sinha and J. Moron Concepcion, Center for Addiction Research, University of
Texas Medical Branch, Galveston, TX
- 11 *Oxycodone-induced conditioned place preference in adolescent and adult mice*
A. Wells, R. Raugei, Y. Zhang, S.D. Schlussman, E.R. Butelman, A. Ho and M.J. Kreek,
The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University,
New York, NY
- 12 *Oxycodone self-administration in adolescent and adult C57BL/6J mice*
Y. Zhang, R. Picetti, E.R. Butelman, A. Ho and M.J. Kreek, The Laboratory of the Biology of
the Addictive Diseases, The Rockefeller University, New York, NY
- 13 *The specific 1h channel blocker ZD7288 potentiates acquisition of morphine CPP and increases
the firing rate of putative dopaminergic neurons in the VTA*
J.M. Mitchell, E.B. Margolis, Y.F. Xia, G.O. Hjelmstad and H.L. Fields, Ernest Gallo Clinic
and Research Center, Neurology, UCSF, San Francisco, CA
- 14 *Usefulness of aripiprazole for reducing morphine-induced nausea and rewarding effect*
T. Suzuki¹, D. Takei¹, M. Shiokawa^{1,2}, Y. Tsurukawa¹, A. Nakamura¹, K. Hashimoto¹,
N. Kuzumaki¹, M. Suzuki¹, T. Inoue² and M. Narita¹, ¹Toxicology, Hoshi University, and
²Pharmacy, St. Luke's International Hospital, Tokyo, Japan
- 15 *Blockade of D1-family dopamine receptors in the dorsolateral striatum attenuates context-
induced reinstatement of heroin seeking*
J.M. Bossert, K.A. Wihbey and Y. Shaham, Behavioral Neuroscience,
IRP/NIDA/NIH/DHHS, Baltimore, MD
- 16 *Individual differences in stress-induced heroin-seeking behavior and neuroendocrine responses
in rats: Involvement of arginine vasopressin and V1b receptor*
Y. Zhou¹, F. Leri², E. Cummins², R. Raugei¹ and M.J. Kreek¹, ¹Rockefeller University,
New York, NY and ²University of Guelph, Guelph, ONT, Canada
- 17 *Effects of herkinorin, a salvinorin analog with μ -opioid effects, in a neuroendocrine biomarker
assay*
E. Butelman¹, S. Rus¹, D.S. Simpson³, K. Tidgewell³, T.E. Prisinzano^{2,3} and M.J. Kreek¹,
¹The Rockefeller University, New York, NY, ²Medicinal Chemistry, University of Kansas,
Lawrence, KS and ³University of Iowa College of Pharmacy, Iowa City, IA
- 18 *The effect of estrogen on cytokine production during inflammatory pain in ovariectomized
female rats*
K.Y. Shivers^{1,2}, N.J. Amador^{1,2}, L. Abrams^{1,2}, D. Hunter^{1,2}, S. Jenab^{1,2} and V. Quinones-
Jenab^{1,2}, ¹Psychology, The Graduate School and University Center, and ²Biopsychology and
Behavioral Neuroscience Subprogram, Hunter College, CUNY, New York, NY
- 19 *Inflammatory pain alters levels of prostaglandin E2 and D2 during the female reproductive
cycle*
N.J. Amador^{1,2}, K.Y. Shivers^{1,2}, D. Hunter^{1,2}, V. Quinones-Jenab^{1,2} and S. Jenab^{1,2},
¹BioPsychology, CUNY Graduate School and University Center, and ²BioPsychology, Hunter
College, New York, NY

- 20 *The NMDA antagonists LY235959 and dextromethorphan enhance morphine's effectiveness in a test of capsaicin-induced hyperalgesia*
F.E. Henry, L. Lomas, M.J. Picker, B.D. Fischer and L.A. Dykstra, Psychology, The University of North Carolina at Chapel Hill, Chapel Hill, NC
- 21 *Opioid-induced antinociception: Alteration by pharmacological and genetic manipulations of the N-methyl-D-aspartate (NMDA) system*
L.A. Dykstra, F.E. Henry and B.D. Fischer, Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 22 *The antinociceptive effect induced by DAMGO in chemokine CCR5 receptor knockout mice*
X. Chen, E.B. Geller and M.W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 23 *Morphine sensitizes to systemic infection with *Acinetobacter baumannii* in a murine model*
J. Breslow^{1,2}, J.J. Meissler^{1,2}, P.B. Spence^{1,2}, J.P. Gaughan⁴, M.W. Adler^{1,3}, M.A. Monroy⁵ and T.K. Eisenstein^{1,2}, ¹Center for Substance Abuse Research, ²Microbiology and Immunology, ³Pharmacology, ⁴Physiology, and ⁵Surgery, Temple University School of Medicine, Philadelphia, PA

HIV/HCV I

- 24 *Increased exposure to an HIV risk-reduction protocol associated with a reduction in substance abuse*
L. Haynes¹, R.E. Carter¹, A.E. Herrin¹ and D.A. Calsyn², ¹Medical University of South Carolina, Charleston, SC and ²University of Washington, Seattle, WA
- 25 *Effect of women's HIV safer sex skills groups on sex-with-drug occasions: NIDA Clinical Trials Network Trial results*
S. Tross^{1,2}, A. Campbell², M. Pavlicova², M. Hu¹, L. Cohen², G. Miele^{1,2} and E. Nunes^{1,2}, ¹HIV Center, NYS Psychiatric Institute, New York, NY and ²Columbia University, NY, NY
- 26 *Changes in HIV and HCV risk-taking behavior and seroprevalence among treatment admissions of opiate users: Possible link with French harm reduction policy from 1994 to 2004*
M. Fatseas¹, C. Denis¹, E. Lavie¹, J. Daulouede² and M. Auriacombe^{1,2}, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen, Bordeaux, and ²Bizia Center, Bayonne, France
- 27 *Puerto Rican injection drug users in Massachusetts and Puerto Rico: HIV, HCV, and other STDs*
L.M. Lopez, L. Zerden, T. Fitzgerald and L. Lundgren, School of Social Work, Boston University, Boston, MA
- 28 *Specific joint hepatology-addiction medicine follow-up of hepatitis C treatment for intravenous drug users (IDU) or ex-IDU: Is there any benefit?*
L. Gourarier¹, A. Gervais², V. Bourseul³, C. Berdah⁴, M. Sananes⁴ and J. Jungman¹, ¹"La Terrasse", Hôpital Maison Blanche, ²Tropical and Infectious Diseases, Hôpital Bichat, AP-HP., ³Réseau de Santé Paris Nord, and ⁴ECIMUD, Hôpital Bichat, AP-HP, Paris, France
- 29 *FibroScan used in street-based outreach for drug users can improve HCV screening, management and treatment: A prospective study*
J. Foucher¹, B. Reiller², V. Jullien², F. Léal³, E. Scotto di Cesare², S. Villars¹, W. Merrouche¹, J.M. Delile² and V. de Lédinghen^{1,4}, ¹Centre d'Investigation de la Fibrose hépatique, Hôpital Haut Leveque, ²Centre Planterose, CEID, ³La Case, Medecins du Monde, and ⁴INSERM U889, Université Victor Segalen, Bordeaux, France

- 30 *Minor fibrosis in patients infected by hepatitis C virus while sharing drug-injection material: A minor problem?*
A. Gervais³, I. Gourarier², M. Pascal¹, A. Gauchet⁴ and A. Hij¹, ¹General Hospital, Saint Dizier, ²La Terrasse, APHP, Paris, ³Hopital Bichat, APHP, Paris, and ⁴Faculte de Psychologie, Grenoble, France
- 31 *The effect of cognitive ability on hepatitis C infection prevalence among injection drug users in Baltimore, Maryland*
C.M. Graham, D.E. Whitaker, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins University, Baltimore, MD
- 32 *Effects of medical/psychiatric comorbidity on HCV treatment eligibility in methadone maintenance*
S.L. Batki^{1,2,3}, K.M. Canfield², E. Smyth², K. Amodio², K. Manser² and R.A. Levine², ¹Psychiatry, University of California, San Francisco, San Francisco, CA, ²Psychiatry, SUNY Upstate Medical University, Syracuse, NY and ³San Francisco VAMC, SF, CA
- 33 *Health-related quality of life after 12 months in treatment with methadone or buprenorphine: Outcome and predictive factors of improvement*
E. Lavie^{1,2}, C. Denis^{1,2}, M. Fatseas^{1,2}, J. Daulouede^{3,2} and M. Auriacombe^{1,2,3}, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux, and ²Addiction Treatment Center, CHCP, CHU, Bordeaux, and ³BIZIA Addiction Center, Bayonne, France
- 34 *Prevalence of chronic health conditions among drug users*
M.E. Mino, S. Deren and S. Kang, Center for Drug Use and HIV Research, National Development and Research Institutes, New York, NY
- 35 *Personality differences among cocaine consumers varies by HIV/HCV status*
C. Morales-Manrique¹, E. Gómez¹, V. Agulló¹, J.C. Valderrama-Zurián¹, M. Castellano², S.R. Friedman³, M. Mateu-Gelabert³, M. Sandoval³, J.C. Perez de los Cobos⁴ and G. Staying Safe Valencia², ¹U. of Valencia, and ²Dirección General de Drogodependencias, Conselleria de Sanitat, Valencia, ⁴Hosp. de la Santa Creu i Sant Pau., Barcelona, Spain, ³NDRI, NY, NY

COCAINE: HUMAN STUDIES I

- 36 *Laboratory model of a cocaine binge*
S.K. Vosburg, C.L. Hart, M. Haney, E. Rubin, N. Vadhan and R.W. Foltin, Substance Abuse, Columbia University/NYS Psychiatric Institute, New York, NY
- 37 *Follow-up drug use of cocaine-dependent humans given cocaine in experimental studies*
C.L. Wallace¹, W.L. Murff¹, R.J. Lamb¹, J. Mojsiak², A. Elkashef² and J.D. Roache¹, ¹University of Texas Health Science Center, San Antonio, TX and ²NIDA, Washington, DC
- 38 *Impact of primary drug of abuse on BMI: Status and at end of treatment*
T. DuBose-O'Hagan, D.J. Brooks, A. Mahony, J. Mariani, W. Raby, E. Nunes, M. Sullivan and F.R. Levin, STARS, Columbia University and NY State Psychiatric Institute, New York, NY
- 39 *Self-reports of interoceptive responses during stress and drug cue-related experiences in cocaine-dependent individuals*
K.L. Bergquist, H.C. Fox and R. Sinha, Psychiatry, Yale University, New Haven, CT
- 40 *Effects of written emotional expression on craving during recovery from cocaine dependence*
K.W. Grasing^{1,2}, D. Mathur¹ and C. DeSouza¹, ¹Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO and ²Division of Clinical Pharmacology, Medicine, University of Kansas School of Medicine, Kansas City, KS

- 41 *Correlates of changing psychological stress over six months among rural stimulant users from Arkansas and Kentucky*
T.F. Garrity¹, J.M. Webster¹, C.G. Leukefeld¹ and B.M. Booth², ¹Behavioral Science, University of Kentucky, Lexington, KY and ²Psychiatry, University of Arkansas, Little Rock, AR
- 42 *Early life trauma and enhanced sensitivity to current life stressors among cocaine-dependent individuals*
S.E. Back, A.E. Waldrop, S.D. Yeatts and K.T. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC
- 43 *Motivations for cocaine use among urban young adults*
B. Wells¹, V. Andersen^{1,2} and J.T. Parsons^{1,3}, ¹The Center for HIV Educational Studies and Training, ²City College of the City University of New York, and ³Psychology, Hunter College of the City University of New York, New York, NY
- 44 *Internalizing and externalizing behavior of children of mothers who misuse drugs versus fathers who misuse drugs*
M.L. Kelley¹, K. Lam² and W. Fals-Stewart², ¹Psychology, Old Dominion University, Norfolk, VA and ²School of Nursing, University of Rochester, Rochester, NY
- 45 *Anxiety sensitivity as a predictor of treatment dropout among inner-city crack/cocaine and heroin users in a residential substance use treatment center*
S.M. Gorka, C.W. Lejuez and S.B. Daughters, Psychology, University of Maryland, College Park, MD
- 46 *Atomoxetine affects responses to psychological and physical stress in humans*
K.P. Hill^{1,2}, J. Poling^{3,4}, T.R. Kosten⁵ and M. Sofuoglu^{3,4}, ¹McLean Hospital, Belmont, and ²Psychiatry, Harvard Medical School, Boston, MA, ³Psychiatry, Yale University, New Haven, and ⁴VA Healthcare System, West Haven, CT and ⁵Psychiatry, Baylor College of Medicine, Houston, TX
- 47 *A safety review of dermatologic conditions in two double-blind placebo-controlled trials: A comparison of modafinil and N-acetylcysteine for cocaine dependence*
R.J. Malcolm¹, K.R. Huebner¹, S.L. Hedden², A. Mountford¹ and K. Hartwell¹, ¹Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC and ²Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 48 *Temperament and Character Inventory dimensions change during a placebo-controlled trial of mirtazapine for patients with cocaine dependence and depression*
L.C. Sanfilippo^{1,2}, W.N. Raby^{1,2} and E.V. Nunes^{1,2}, ¹Columbia University, and ²New York State Psychiatric Institute, New York, NY
- 49 *Anticonvulsive drugs in cocaine dependence: A systematic review and meta-analysis*
M. Farre^{1,3}, Y. Alvarez^{1,3}, F. Fonseca^{2,4}, J. Cami⁴ and M. Torrens^{2,3}, ¹Pharmacology, IMIM-Hospital del Mar, ²Drug Abuse Unit, IAPS-Hospital del Mar, ³Universitat Autònoma de Barcelona, UAB, and ⁴Universitat Pompeu Fabra, UPF, Barcelona, Spain
- 50 *Sequential agonist medication strategies for cocaine dependence: Bayesian analysis*
D.V. Herin¹, C.M. Green¹, N.J. Moukaddam¹, J.M. Schmitz¹ and J. Grabowski², ¹Psychiatry, University of Texas Health Science Center, Houston, TX and ²Psychiatry/Behavioral Science, University of Minnesota and SMDC, Minneapolis/Duluth, MN
- 51 *Cocaine vaccine: 6-month follow-up during drop in antibody levels*
T. Kosten^{1,3}, B. Martell², J. Poling^{2,3} and T. Gardner^{1,3}, ¹Psychiatry, Baylor College of Medicine, and ³Veterans Administration, Houston, TX, ²Psychiatry, Yale University, New Haven, CT

MARIJUANA, CANNABINOIDS

- 52 *Cannabis dimensionality: Dependence, abuse and consumption*
C. Beseler¹, H. Katz¹ and D.S. Hasin^{1,2}, ¹Psychiatry, New York State Psychiatric Institute and ²College of Physicians and Surgeons, Columbia University, NY, NY
- 53 *Clinical features of DSM-IV cannabis abuse in a cross-national context*
F.A. Fiestas¹, M.E. Radovanovic¹, M. Medina-Mora², J. Posada-Villa³, J.C. Anthony¹ and World Mental Health Survey Consortium⁴, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Institute of Psychiatry, Mexico, Mexico, ³Saldarriaga Concha Foundation, Bogota, Colombia and ⁴WHMS Consortium, Boston, MA
- 54 *The reliability of self-report cannabis abuse and dependence criteria: Multisite study of differences between general population and treatment groups*
C.E. Mennes, A. Ben Abdallah and L.B. Cottler, Washington University School of Medicine, Saint Louis, MO
- 55 *Treatment-seeking characteristics of potential participants for substance use disorder clinical trials*
J.J. Mariani, K.A. Murray and F.R. Levin, Psychiatry/Division on Substance Abuse, Columbia University/New York State Psychiatric Institute, New York, NY
- 56 *Drug abuse and HIV risk among IDUs near downtown Kathmandu*
M.B. Poudyal Chhetri, Planning, CIAA, Kathmandu, Nepal
- 57 *Curls and beginners: Use, abuse and representations of cannabis amongst health educators in training*
P. Courty^{1,2}, C. Auclair³, L. Gerbaud^{2,3} and D. Berger², ¹CMP B, CSST SATIS, Clermont Ferrand Cedex 1, ²JE n°;2432 PAEDI, IUFG d'Auvergne, F- 63407 Chamalieres, and ³Epidemiology and Public Health, CHU G.MONTPIED, F-63003 Clermont Ferrand Cedex 1, France
- 58 *Within-session satisfaction and state motivation as predictors of marijuana use at follow-up: An illustrative analysis*
E.R. Grekin² and S.J. Ondersma¹, ¹Psychiatry and OB/GYN, and ²Psychology, Wayne State University, Detroit, MI
- 59 *Reliability and validity of a short form of the Marijuana Craving Questionnaire*
R.J. Evans¹, D.A. Gorelick¹, E.G. Singleton¹, K.H. Levin¹, M.L. Copersino² and S.J. Heishman¹, ¹National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD and ²McLean Hospital, Harvard Medical School, Belmont, MA
- 60 *Cognitive performance in a population-based sample of young cannabis, ecstasy or alcohol users and controls*
C.G. Schütz^{1,2}, F. Indlekofer², M. Piechatzek², M. Daamen¹, C. Glasmacher¹, R. Lieb³, H. Pfister³ and H.U. Wittchen⁴, ¹Psychiatry, Wilhelms-Friedrich-University, Bonn, ²Psychiatry, Munich University, Munich, ³Psychiatry, Max-Planck -Institut, Munich, and ⁴Psychology, TU Dresden, Dresden, Germany
- 61 *Cognitive impairment and treatment retention among cannabis-dependent patients*
D.J. Brooks¹, E. Aharonovich¹ and F.R. Levin^{1,2}, ¹Substance Abuse, NYSPI, and ²Psychiatry, Columbia University, New York, NY
- 62 *Smoked marijuana affects risk taking but not decision making in a lab study of adult marijuana smokers*
E. Aharonovich¹, T. Crowley² and M. Haney¹, ¹Columbia University, New York, NY and ²University of Colorado, Denver, CO

- 63 *Comparison of the effects of marijuana smoked in cigarette paper (joints) versus cigar paper (blunts)*
Z.D. Cooper and M. Haney, Psychiatry, Columbia University, New York, NY
- 64 *Oral THC (dronabinol) effects on sleep parameters in rested and sleep-deprived adults*
D.M. Penetar, G.H. Trksak, W. Tartarini and S.E. Lukas, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA
- 65 *A placebo-controlled trial of buspirone in marijuana-dependent individuals*
A. McRae, R.E. Carter, T.K. Killeen, M.J. Carpenter, S.A. Simpson and K.T. Brady, Medical University of South Carolina, Charleston, SC
- 66 *Relationship between cannabinoid agonist efficacy, tolerance, and cross-tolerance in Δ^9 -tetrahydrocannabinol-treated monkeys*
L. McMahon, Pharmacology, UTHSCSA, San Antonio, TX
- 67 *Effects of THC on reversal learning and extradimensional shifts in rhesus monkeys*
M.A. Taffe, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA
- 68 *Marked differences between cannabinoid receptor agonists revealed by their behavioral effects*
P. Terry^{1,2}, J. Grey² and S. Higgs², ¹Psychology Research Unit, Kingston University, Kingston-upon-Thames and ²School of Psychology, University of Birmingham, Birmingham, UK
- 69 *First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain*
K. Benamar, S. Addou, E.B. Geller and M.W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 70 *Conformational constrained analogs of SR141716: Design, synthesis, computational analysis and biological evaluations*
Y. Zhang, M. Brackeen, J.P. Burgess, A. Gilliam, W.S. Mascarella, K. Page, H.H. Seltzman and B.F. Thomas, Research Triangle Institute, Durham, NC

NICOTINE: ANIMAL STUDIES

- 71 *Role of CB1 receptors on the reinstatement of nicotine seeking in rats*
I.H. Gamal Eddin, Pharmacology, University of Toronto, and Translational Addiction Laboratory, CAMH, Toronto, ON, Canada
- 72 *Effects of varenicline and cytosine on the discriminative stimulus effects of nicotine in rats*
W.A. Corrigall^{1,3}, M.G. LeSage^{1,2}, D. Shelley¹, J.T. Ross¹ and F.I. Carroll⁴, ¹Medicine, Minneapolis Medical Research Foundation, ²Medicine, and ³Psychiatry, University of Minnesota, Minneapolis, MN and ⁴Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC
- 73 *Nicotine, but not varenicline, pretreatment synergistically enhanced amphetamine-stimulated locomotor activity in rats*
M.E. Gnegy and E.M. Jutkiewicz, Pharmacology, University of Michigan, Ann Arbor, MI
- 74 *The nicotinic receptor partial agonist cytosine attenuated some, but not all, behavioral effects of nicotine in rodents*
E.M. Jutkiewicz and J.H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI
- 75 *Effects of the nicotinic acetylcholine receptor antagonist, N,N'-decane-1,10-diyl-bis-3-picolinium diiodide, on nicotine self-administration and food-maintained responding in rats*
T. Wooters¹, J.T. Ross¹, Z. Zhang², P.A. Crooks², L.P. Dwoskin² and M.T. Bardo¹, ¹Psychology, and ²Pharmacy, University of Kentucky, Lexington, KY

- 76 *Bupropion blocks acquisition, but not expression, of nicotine-conditioned taste aversion in CD-1 mice*
A.S. Rauhut^{1,2} and S.K. Mardekian², ¹Psychology, and ²Neuroscience Program, Dickinson College, Carlisle, PA
- 77 *The effects of environmental enrichment on nicotine-induced conditioned hyperactivity and sensitization*
R.A. Coolon, S.T. Pittenger and M.E. Cain, Psychology, Kansas State University, Manhattan, KS
- 78 *Nicotine enhances responding for conditioned and unconditioned reinforcing stimuli under a second-order schedule of food reinforcement in rats*
V.C. Wing and M. Shoaib, Psychobiology Laboratories, Newcastle University, Newcastle, UK
- 79 *Additional support for the reinforcement-enhancing effects of nicotine in rats*
B.R. Raiff and J. Dallery, University of Florida, Gainesville, FL
- 80 *Nicotine effects on the behavioral mechanisms of impulsive choice in rats*
M. Locey and J. Dallery, Psychology, University of Florida, Gainesville, FL
- 81 *Individual differences in delay discounting and nicotine self-administration in rats*
M.M. Sweitzer^{1,2} and E.C. Donny¹, ¹Psychology, and ²Center for Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA
- 82 *Acquisition and maintenance of nicotine self-administration in adolescent male and female rats*
W.J. Lynch, Psychiatry and Neurobehavioral Sciences, University of VA, Charlottesville, VA
- 83 *Enhanced nicotine-taking behavior in a glutamatergic model of schizophrenia in rats*
K. Farid Araki¹, K. Coen¹, U. Busto² and B. Le Foll¹, ¹Translational Addiction Research Laboratory, and ²Clinical Neuroscience Laboratory, Camh, University of Toronto, Toronto, ON, Canada
- 84 *Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats*
S.A. Roiko^{1,2}, A.C. Harris², M.G. LeSage², D.E. Keyler² and P.R. Pentel^{1,2}, ¹Pharmacology, University of Minnesota, and ²Minneapolis Medical Research Foundation, Minneapolis, MN
- 85 *Diminished neurochemical effects of nicotine withdrawal in adolescent versus adult rats*
L.A. Natividad, H.A. Tejeda, O.V. Torres and L.E. O'Dell, Psychology, University of Texas at El Paso, El Paso, TX

PROGRAM DESCRIPTION I

- 86 *Indolizidine 235B¹ potently inhibits nicotine-evoked dopamine release from superfused rat striatal slices*
L.P. Dwoskin¹, M. Pivavarchyk¹, H. Tsuneki², N. Toyooka², Z. Zhang¹ and P.A. Crooks¹, ¹Pharmaceutical Sciences, University of Kentucky, Lexington, KY and ²Clinical Pharmacology, Toyama Medical and Pharmaceutical University, Toyama, Japan
- 87 *Inhibition of nicotine-evoked dopamine release from superfused rat striatal slices by novel quaternary ammonium salts containing an N-5-(3-biphenyl)pentyl-1-yl substituent*
P.A. Crooks, G. Zheng, M. Pivavarchyk and L.P. Dwoskin, Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 88 *Online enhancements of smoking cessation: Peru, 2007*
G.F. Alvarado^{1,2}, O.J. Santiago², C.F. Rios-Bedoya² and J.C. Anthony^{2,1}, ¹Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru and ²Epidemiology, Michigan State University, East Lansing, MI

- 89 *Feasibility of conducting genetics research at community treatment programs*
S.C. Sonne¹, S. Gentilin¹, C.L. DeVane¹, C. Thomas², M. Hatch-Maillette³, A. Saxon⁴,
W. Berrettini⁵ and W. Ling², ¹Medical University of SC, Charleston, SC, ²University of CA,
Los Angeles, CA, ³University of WA, and ⁴VA Puget Sound Health Care System, Seattle, WA
and ⁵University of Pennsylvania, Philadelphia, PA
- 90 *Hepatitis C treatment among methadone-maintained patients: Directly observed therapy
compared with standard-of-care*
R.D. Bruce¹, A. Acosta¹, J. Lim², M. Copenhaver³ and F. Altice¹, ¹Medicine, Yale University
AIDS Program, New Haven ²Medicine, Yale Viral Hepatitis Program, New Haven, and
³University of Connecticut Center for Health, Intervention, and Prevention, Storrs, CT
- 91 *A brief behavioral intervention to enhance medication adherence among HIV-infected injection
drug users*
O. Amaechi¹, I. Lee² and M. Copenhaver³, ¹Allied Health Sciences, and ³Psychology,
University of Connecticut, Storrs, CT ² Psychology, National Chengchi University, Taipei,
Taiwan
- 92 *Access to HIV and hepatitis screening and treatment among ethnic minority drug users*
C.L. Masson¹, D.C. Perlman^{2,3}, N. Pepper¹, C. McKnight² and J.L. Sorensen¹, ¹Psychiatry,
University of California, San Francisco, San Francisco, CA, ²Beth Israel Medical Center, and
³National Development and Research Institutes, Inc., New York, NY
- 93 *Modified directly observed therapy for HIV in substance-abusing minorities*
S.A. Kritz, C. John-Hull, M. Chu, C. Madray, G. Dominguez, C. Bowers, S. Spence,
R. Sumpter, J. Mitchell, B. Louie and L.S. Brown, Jr., Addiction Research and Treatment
Corporation, Brooklyn, NY
- 94 *Successful implementation of an office-based opiate treatment pilot program using
buprenorphine in a marginalized population*
S. Little, D. Hersh and A. Gleghorn, Community Behavioral Health, San Francisco
Department of Public Health, San Francisco, CA
- 95 *Buprenorphine and methadone in a VA narcotic treatment program in New York City: Retention
in treatment and response*
P.P. Casadonte, ¹Mental Health, Veterans Affairs Medical Center, and ²Psychiatry, New York
University School of Medicine, New York, NY
- 96 *Methadone maintenance in Michigan: Five years of data using a contingency management
approach*
G.L. Rhodes, G.K. Tzilos and M.K. Greenwald, Psychiatry and Behavioral Neuroscience,
Wayne State University, Detroit, MI
- 97 *Acceptance-based behavior therapy for methadone detoxification*
A.L. Stotts¹, A. Masuda², K. Wilson³ and J. Schmitz¹, ¹University of Texas Medical School at
Houston, Houston, TX, ²Georgia State University, Atlanta, GA and ³University of Mississippi,
Oxford, MS
- 98 *The Opioid Renewal Clinic: Can urine drug screens predict treatment outcome?*
K. Barth¹, W.C. Becker², N. Wiedemer², R.M. Gallagher^{1,2} and D.W. Oslin^{1,2}, ¹University of
Pennsylvania, and ²Philadelphia VA Medical Center, Philadelphia, PA
- 99 *Survey analysis for implementing an electronic information system to enhance practice at an
opiate treatment program*
M. Lin, S.A. Kritz, C. John-Hull, C. Madray, L.S. Brown, Jr. and B. Louie, Addiction
Research and Treatment Corporation, University of Rhode Island, Brooklyn, NY

- 100 *Collecting daily self-reports of injection drug use via automated telephone interviewing*
B.C. Leigh¹, D.D. Brewer² and E.L. Seddig¹, ¹Alcohol and Drug Abuse Institute, University of Washington, and ²Interdisciplinary Scientific Research, Seattle, WA
- 101 *Technology transfer in a community treatment program: Evidence-based practices from the training room into the therapy room*
D.R. Hall, K. Shuster, C. Street, T. Odell, K. Raymond, G. Soto, C. Chapman, M. Barker and S. Reiner, Psychiatry, Virginia Commonwealth University, Richmond, VA
- 102 *An assessment of substance abuse training and technical assistance needs in frontier states: Implications for the adoption of evidence-based practices*
N.A. Roget¹, J.A. Hartje¹, E. Gifford¹, W.L. Woods¹, J. Brosh¹ and A.H. Skinstad², ¹CASAT, University of Nevada, Reno, Reno, NV and ²School of Public Health, University of Iowa, Iowa City, IA
- 103 *Implementation of a technology-based, quality improvement system at outpatient substance abuse treatment programs: A qualitative analysis*
B. McClure¹, A. Kulaga¹, J. Rotrosen¹, P. Crits-Christoph², S. Ring-Kurtz², C. Temes² and R. Forman³, ¹Psychiatry, NYU School of Medicine, New York, NY, ²University of Pennsylvania, Philadelphia, PA and ³Alkermes, Inc., Boston, MA
- 104 *Outcomes of a Native American cultural educational program for non-native counselors*
D. Mackey², F. Zavadil², A.H. Skinstad¹, C. Peters¹ and K.M. Summers¹, ¹Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA and ²University of South Dakota, Vermillion, SD
- 105 *Developing a data resource center for international substance abuse researchers*
H. Wong, S. Libretto, R. Oser and M. Barahona, Public Health Research, Danya International, Inc., Silver Spring, MD
- 106 *A new approach to the community reduction of cannabis use: The Australian National Cannabis Prevention and Information Centre*
J. Copeland, National Cannabis Prevention and Information Centre, University of NSW, Sydney, NSW, Australia
- 107 *Developing a Computerized Assisted Training protocol for community-based therapists: Contingency Management with adolescents and their families*
A.J. Sheidow, J.E. Chapman and S.W. Henggeler, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 108 *The development of a survey instrument for the problem gambling workforce*
A.B. Wallis, A.H. Skinstad, M.O. Goransson, C.H. Peters and K.M. Summers, Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA
- 109 *Internet survey of prescription opioid abuse among college-aged individuals*
T. Cassidy, K. Lioy, J. Dickinson, A. Licari, S.H. Budman, S. Lord and S.F. Butler, Inflexxion, Inc, Newton, MA
- 110 *Project Lazarus: Prescription opioid overdose prevention and responsible pain management*
N. Dasgupta^{1,2}, F.W. Brason III^{3,5}, S. Albert^{3,4} and J. Graham³, ¹Epidemiology, University of NC School of Public Health, Chapel Hill, ²NC Harm Reduction Coalition, Jamestown, and ³Northwest Community Care Network, ⁴Wilkes County Health Department, and ⁵Wilkes Community Health Council, Healthy Carolinians, North Wilkesboro, NC

- 111 *Improvement of pain assessment and pain management in patients on opioid maintenance therapy: A new French clinical research program*

N.A. Authier^{1,2}, C. Auclair³, C. Le Blanc¹, P. Viguié¹, A. Boyé¹, A. Harrand¹, C. Dubray², A. Eschalier², P. Llorca¹ and P. Courty¹, ¹Pôle de Psychiatrie - CMP B, CHU G Monpied, ²CIC 501, CHU, and ³Dept Santé Publique, CHU, Clermont Ferrand, France

POLYDRUG ABUSE

- 112 *The effects of daily treatment with citicoline on polydrug abuse in cocaine-dependent volunteers*
S.C. Licata¹, D. Penetar¹, J. Rodolico¹, C. Palmer¹, J. Berko¹, T. Geaghan¹, A. Looby¹, E. Peters¹, E. Ryan¹, P. Renshaw² and S. Lukas¹, ¹Behavioral Psychopharmacology Research Laboratory, and ²Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA
- 113 *The association between executive functioning and readiness to change drug use behavior among injection and non-injection drug users in Baltimore, MD*
S.G. Severtson, S. von Thomsen, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 114 *Drug problems, sex trading, and sex-related attitudes among women entering substance abuse treatment*
D.L. Homish, K.H. Dermen, J.R. Koutsky and D.K. Augustino, Research Institute on Addictions, The State University of New York at Buffalo, Buffalo, NY
- 115 *The association of state programs with individual risk of drug use disorder*
M.H. Yang, M.J. Larson and A.M. Stoddard, New England Research Institutes, Watertown, MA
- 116 *Reliability and validity of the BASIS-24 in drug-dependent patients*
L. Madden^{1,2}, R. Freeman¹, K. Burne¹, C. Doebrick^{1,2}, S. Farnum¹ and S. Ball^{1,2}, ¹The APT Foundation, and ²Psychiatry, Yale School of Medicine, New Haven, CT
- 117 *Latent class growth trajectories of neuropsychological dysfunction in drug users*
S.L. Hedden, S.G. Severtson and W.W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD
- 118 *Hospitalization for substance use disorder in a psychiatric emergency service*
D.C. Martínez, J.M. Gines, F. Fonseca, C. Garnier, D. Berge, M.A. Malagon, R. Cortizo and A. Bulbena, Hospital del Mar, Barcelona, Spain
- 119 *Predicting the relative risk of death over a 9-year period taking into account baseline risk, substance abuse treatment history and duration of abstinence*
C.K. Scott¹ and M.L. Dennis², ¹Chestnut Health Systems, Chicago, IL and ²Chestnut Health Systems, Bloomington, IL
- 120 *Overdose within 12 months of treatment for substance use disorders*
P.C. Britton^{1,2}, J.D. Wines³ and K.R. Conner^{2,1}, ¹Psychiatry, Canandaigua VA Medical Center, Canandaigua, NY, ²Psychiatry, Center for the Study and Prevention of Suicide-University of Rochester School of Medicine and Dentistry, Rochester, NY and ³Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA
- 121 *Dual substance-abusing parents vs. mother-only substance-abusing parents in treatment: Behavioral functioning of children*
W.K. Lam¹, W. Fals-Stewart¹ and M.L. Kelley², ¹School of Nursing, University of Rochester, Rochester, NY and ²Old Dominion University, Norfolk, VA

- 122 *Parental substance abuse and long-term coping in a sample of adult domestic violence survivors*
S. Griffing¹, R.E. Sage^{2,1}, T. Jospitre¹ and M. Chu^{2,1}, ¹Urban Resource Institute, and ²Addiction Research and Treatment Corporation, Brooklyn, NY
- 123 *The relations among moral conscience, parental support, and substance use in young adults*
J. Wilkinson, G. Carlo and J. Roy, Psychology, University of Nebraska-Lincoln, Lincoln, NE
- 124 *Evaluating a parent workshop to prevent children's access to prescription narcotics on the Internet*
N.S. Patapis, D.S. Festinger, C.L. McDonald, K.L. Dugosh, D.B. Marlowe and P.L. Arabia, Law and Ethics, Treatment Research Institute, Philadelphia, PA
- 125 *Exploring metacognition, relapse, and stress as an integrated outcome measure*
J. Cilente, Psychology and Education, Middlesex County College, Edison, NJ
- 126 *Deconstructing 12-step involvement as predictor of sustained abstinence from polydrug use*
A.B. Laudet¹ and W.L. White², ¹NDRI, New York City, NY and ²Chestnut, Bloomington, IL
- 127 *Contextual differences in substance use among treatment-seeking women*
L.M. Shannon, R. Walker, J.R. Havens, A. Mateyoke-Scrivner and C. Leukefeld, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 128 *Prevalence of violence and substance use among female victims of intimate-partner violence*
P. Wupperman, P. Amble, S. Devine, H. Zonana, S. Ciskowski and C. Easton, Yale University School of Medicine, New Haven, CT
- 129 *Dimensions of change instrument and retention in therapeutic communities: The moderating effect of time*
J. Miles¹, W. Mandell² and S.L. Wenzel¹, ¹Behavioral and Social Sciences, RAND Corporation, Santa Monica, CA and ²Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
- 130 *Will I stay or will I go? Role of early treatment experiences in predicting attrition*
V. Stanick¹, A.B. Laudet¹ and B. Sands², ¹NDRI, and ²Woodhull Medical Center, New York City, NY
- 131 *Three-year outcomes from the Early Re-Intervention Experiment with Recovery Management Checkups*
M.L. Dennis¹ and C.K. Scott², ¹Chestnut Health Systems, Bloomington, IL and ²Chestnut Health Systems, Chicago, IL
- 132 *Treatment history and job-seeking behaviors among Native Americans*
K. Foley², D. Pallas², M.P. Bogenschutz¹, A.A. Forcehimes¹, D. Svikis³ and J.S. Tonigan¹, ¹CASAA, University of New Mexico, Albuquerque, ²The Na'Nizhoozi Center, Gallup, NM and ³Psychology, Virginia Commonwealth University, Richmond, VA
- 133 *Predictors of social stability among drug users and non-drug users in Baltimore City, Maryland*
D. German and C.A. Latkin, Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 134 *Outcomes of substance abuse treatment from the California Outcomes Measurement System*
R. Gonzales, M. Brecht, R. Rawson and J. Hunter, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 135 *Resource utilization by drug users presenting to an emergency department*
B. Khazan¹, A. Sheer¹, J. Hirshon² and D. Gorelick¹, ¹National Institute on Drug Abuse, NIH, and ²University of Maryland School of Medicine, Baltimore, MD

- 136 *Investigating the active ingredients of motivational interviewing*
K.L. Venner¹, S.J. Erickson², M.P. Bogenschutz¹ and J.S. Tonigan¹, ¹CASAA, and ²Psychology, University of New Mexico, Albuquerque, NM
- 137 *A meta-analysis of motivational interviewing to enhance engagement and adherence to substance use treatment*
J.E. Hettema, Psychiatry, University of California San Francisco, San Francisco, CA
- 138 *Preliminary findings from an ecological momentary assessment study with polydrug users at a methadone clinic*
J. Willner-Reid, D.H. Epstein, K.L. Preston, J.L. Lin and M. Vahabzadeh, IRP Treatment Section, NIDA, Baltimore, MD
- 139 *Clinician knowledge of Cognitive Behavioral Therapy strategies: Room for improvement*
M. Larson¹, M. Amodeo², E. Gerstenberger¹ and J.S. LoCastro^{3,4}, ¹New England Research Institutes, Watertown, ²School of Social Work, and ³School of Medicine, Boston University, and ⁴VA Boston Healthcare, Boston, MA
- 140 *Feasibility and utility of a concurrent recovery monitoring system in Delaware State*
A. Brooks¹, D. Carise¹, A. Camilleri¹, M. Love¹, A. Pecorarro¹, K. Tassini¹ and J. Kemp², ¹Treatment Research Institute, Philadelphia, PA and ²Delaware Division of Mental Health and Substance Abuse, New Castle, DE
- 141 *Predictive validity of Nonparametric-Item-Response-Theory-derived ASI scores*
A. Pecora, J.S. Cacciola, K.G. Lynch and A.I. Alterman, University of Pennsylvania School of Medicine and Treatment Research Institute, Mays Landing, NJ
- 142 *Who seeks help for a substance use disorder and who does not in the NESARC?*
C. Grella¹, M. Karno¹, U. Warda¹, N. Niv¹ and A. Moore^{1,2}, ¹Integrated Substance Abuse Programs, and ²Division of Geriatrics, UCLA, Los Angeles, CA
- 143 *Do active addictions contribute to mortality among urban African Americans with poorly controlled blood pressure?*
J.H. Young^{1,2}, K. Weeks^{1,2}, J. Tilburt³ and S. Dy^{1,2}, ¹Medicine, Johns Hopkins University and ²Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD and ³Medicine, Mayo Clinic, Rochester, MN
- 144 *Lifestyle mobility in a cohort of injection drug users*
B. Pieper¹, T.N. Templin¹, R.S. Kirsner² and T.J. Birk¹, ¹College of Nursing, Wayne State University, Detroit, MI and ²Miller School of Medicine, University of Miami, Miami, FL
- 145 *Medical co-occurring disorders in a substance-abusing Medicaid population*
D.A. Tompkins¹, K. Stoller¹, A. Schuster^{2,3}, P. Fagan^{2,1} and R. Brooner¹, ¹Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins Healthcare, LLC, Glen Burnie, and ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 146 *Will patients initiate chronic disease management care for substance dependence?*
T.W. Kim, R. Saitz, D. Cheng, M. Winter and J.H. Samet, Boston University School of Medicine and Public Health, Boston, MA
- 147 *Ethnic disparities in health and health-related behaviors among homeless women*
L. Gelberg¹, E. Austin³ and R.M. Andersen², ¹Family Medicine, David Geffen School of Medicine, UCLA and ²Health Services, University of California-Los Angeles School of Public Health, Los Angeles, CA and ³Sociology, University of Alabama at Birmingham, Birmingham, AL

CRIMINAL JUSTICE

- 148 *A different kind of hustle: A qualitative study of the process of long-term abstinence from heroin use among female ex-offenders*
N.J. Tiburcio, Institute for Treatment Services Research, National Development and Research Institutes, New York, NY
- 149 *Longitudinal changes in attachment, social support, parenting attitudes, and psychological functioning among women drug offenders*
E. Hall, M. Prendergast and U. Warda, Psychiatry, University of California, Los Angeles, Los Angeles, CA
- 150 *Gender differences in chronic medical conditions, psychiatric disorders and substance dependence among U.S. jail inmates*
I.A. Binswanger¹, J.O. Merrill², P.M. Krueger³, M.C. White⁴, R.E. Booth⁵, J.G. Elmore²,
¹Medicine, Aurora, and ⁵Psychiatry, University of Colorado Denver, Denver, CO, ²Medicine, University of Washington, Seattle, WA, ³Public Health, University of Texas, Houston, TX, ⁴Community Health, University of California San Francisco, San Francisco, CA
- 151 *The impact of race and HIV/AIDS discussion strategies on unprotected sex among female drug-abusing criminal offenders*
C.B. Oser, J. Havens, J. Mooney, M. Staton-Tindall, J. Duvall and C. Leukefeld, University of Kentucky, Lexington, KY
- 152 *Juvenile arrest as an indicator of HIV-related sexual risk behaviors and adult criminal involvement in a community sample of substance-using African American women*
C. Welch, C.L. Callahan and L.B. Cottler, Psychiatry, Washington University in St. Louis, St. Louis, MO
- 153 *Differences in rates and length of incarceration for minority vs. non-minority women: A drug diversion study*
M.C. Scott, P. Wupperman and C.J. Easton, Psychiatry, School of Medicine, Yale University, New Haven, CT
- 154 *Differential success rates in racial groups: Results of a clinical trial of smoking cessation among female prisoners*
K.L. Cropsey¹, M.F. Weaver², G.D. Eldridge⁵, G.C. Villalobos², A.M. Best⁴, M.L. Stitzer³,
¹Psychiatry, University of Alabama at Birmingham, Birmingham, AL, ²Internal Medicine, and ⁴Biostatistics, Virginia Commonwealth University, Richmond, VA, ³Psychiatry, Johns Hopkins University, Baltimore, MD and ⁵Psychology, University of Alaska, Anchorage, AK
- 155 *Transitioning from buprenorphine maintenance in jail to the community*
S. Magura^{1,2}, J. Hersherberger³, A. Rosenblum², H. Joseph², N. Santana², L. Marsch², J.D. Lee⁴, C. Shropshire⁵, A. Glick⁵ and J. Liautaud⁵, ¹Western Michigan University, Kalamazoo, MI, ²NDRI, ³DOHMH, ⁴NY University, and ⁵Prison Health Services, New York, NY
- 156 *Acute effects of topiramate on aggressive responding in individuals on parole/probation with a history of substance use disorders*
S.D. Lane^{1,2}, F.G. Moeller^{1,2}, J.L. Gowin², J.L. Steinberg¹ and D.R. Cherek¹, ¹Psychiatry and Behavioral Sciences and ²Graduate School of Biomedical Sciences, University of Texas Health Science Center-Houston, Houston, TX
- 157 *Limited access to Narcotic Replacement Therapy undermines outcomes of treatment diversion*
A. Hawken^{1,2} and D.M. Anglin¹, ¹Integrated Substance Abuse Program, University of California-Los Angeles, Los Angeles, and ²School of Public Policy, Pepperdine University, Malibu, CA

- 158 *Methadone maintenance for prisoners: Findings at 12 months post-release*
M.S. Gordon, T.W. Kinlock and R.P. Schwartz, Social Research Center, Friends Research Institute, Baltimore, MD
- 159 *Impact of interim methadone treatment vs. waiting list on arrests*
R.P. Schwartz¹, J.H. Jaffe¹, D. Highfield¹, M. Wilson¹, S. Kelly¹, A. Ahmed² and K.E. O'Grady³, ¹Friends Research Institute, and ²Morgan State University, Baltimore, MD and ³University of Maryland, College Park, MD
- 160 *Evaluation of California's Proposition 36: An initiative offering treatment to non-violent drug offenders*
D. Urada, E. Evans, A. Hawken, B.T. Conner and D. Longshore, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 161 *Employment intervention for offenders*
D.M. Coviello¹, D.A. Zanis^{1,2}, S.A. Wesnoski¹, S.M. Lopacinski¹ and L.A. Riley¹, ¹Psychiatry/Addictions, University of Pennsylvania, and ²Social Administration, Temple University, Philadelphia, PA
- 162 *Correlates of age of first criminal activity, crime severity, and first heroin use of male prisoners in a randomized clinical trial of methadone maintenance*
T. Kinlock^{1,2}, M. Gordon¹ and R. Schwartz^{1,3}, ¹Friends Research Institute, ²University of Baltimore, and ³Open Society Institute, Baltimore, MD
- 163 *Racial differences in psychosocial functioning among youth in juvenile detention*
C. Henderson^{1,2}, G.A. Dakof², C. Gillikin², H. Li², C.S. Lederman³ and H.A. Liddle², ¹Psychology, Sam Houston State University, Huntsville, TX, ²Center for Treatment Research on Adolescent Drug Abuse, Miller School of Medicine at the University of Miami, and ³Juvenile Division, 11th Judicial Court, Miami, FL
- 164 *Illicit drug prevalence among inmates and juvenile offenders in PUerto Rico*
J.L. Gonzalez-Perez¹, E. Lopez Vargas¹, A. Segarra³, J. Bloom Oquendo² and J. Rodriguez Orengo^{1,2,3}, ¹Doping and Drug Detection Division, and ²Criminalistic Laboratory Division, Institute of Forensic Sciences, and ³School of Medicine, University of PR, San Juan, PR
- 165 *Marijuana abuse in incarcerated adolescents*
R. Lebeau, L. Stein and K. Quina, Cancer Prevention Research Center, URI, Kingston, RI
- 166 *Validity and reliability of the Marijuana Withdrawal Checklist for incarcerated youth*
M. Clair^{1,3}, L. Stein^{2,1,3}, R. Martin¹, R. Lebeau² and M. Gingras³, ¹Center for Alcohol and Addictions Studies, Brown University, Providence, ²University of Rhode Island, Kingston, and ³Rhode Island Training School, Cranston, RI
- 167 *Evaluating a research-based HIV prevention program adapted for use with incarcerated juvenile offenders*
W.J. McCuller¹, D.W. Watson^{1,2}, F.G. Castro⁴ and C. Reiber³, ¹Friends Research Institute, Torrance, ²Integrated Substance Abuse Programs, University of California, Los Angeles, CA, ³Binghamton University, Binghamton, NY and ⁴Psychology, Arizona State U., Tempe, AZ
- 168 *Outcomes of a substance use and HIV prevention program for incarcerated adolescents*
D.W. Watson^{1,5}, W.J. McCuller¹, F.G. Castro², C. Reiber³ and J. Herting⁴, ¹Friends Research Institute, Torrance, and ⁵Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA, ²Psychology, Arizona State University, Tempe, AZ, ³Binghamton University, Binghamton, NY, ⁴School of Nursing, University of Washington, Seattle, WA
- 169 *Long-term health outcomes of adjudicated adolescent offenders*
R. Ramchand and A. Morral, RAND, Arlington, VA

Art and Addiction Exhibition

Flamingo
9:00 AM - 6:00 PM

Symposium III

San Cristobal
10:00 AM - 12:00 PM

**ADDICTION LIABILITY AND PAIN RELIEF MEDICATION:
RAYMOND HOUE MEMORIAL SYMPOSIUM**

Chairs: Charles P. O'Brien and Charles Inturrisi

- 10:00 *The pharmacological basis of analgesic rotation in the treatment of pain*
Charles Inturrisi, Cornell University Medical College, New York, NY
- 10:25 *How analgesic studies have contributed to an understanding of opiate receptors*
Gavril Pasternak, Memorial Sloan Kettering Cancer Center, New York, NY
- 10:50 *Pain measurement in the design of modern analgesic clinical trials*
John Farrar, University of Pennsylvania, Philadelphia, PA
- 11:15 *The impact of Houde's work on analgesic medication development*
William L. Dewey, Virginia Commonwealth University, Richmond, VA
- 11:40 *Discussant*
Charles P. O'Brien, University of Pennsylvania, Philadelphia, PA

Symposium IV

San Geronimo B
10:00 AM - 12:00 PM

**UNDERSTANDING EXTINCTION LEARNING AND
ITS TRANSLATION TO DRUG ADDICTION**

Chairs: Paul Schnur and David Shurtleff

- 10:00 *Neural substrates of drug-seeking after abstinence vs. extinction training in an animal model of relapse*
Ronald E. See, Medical University of South Carolina, Charleston, SC
- 10:25 *Cognitive enhancement as a therapeutic strategy for drug addiction*
Kathleen M. Kantak, Boston University, Boston, MA
- 10:50 *Environments and people: The challenge smoking-related cues pose for extinction-based treatments*
Cynthia A. Conklin, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA
- 11:15 *Extinction-based smoking cessation treatment attenuates event-related brain responses to smoking cues: Results of a preliminary fMRI study*
Joseph McClernon, Duke University Medical Center, Durham, NC
- 11:40 *Discussant*
Gregory Quirk, University of Puerto Rico School of Medicine, San Juan, PR

Oral Communications 3

**San Geronimo C
10:00 AM - 12:00 PM**

CLUB DRUGS: WHAT'S IN?

Chairs: Jillian Broadbear and Wouter Koek

- 10:00 *Psychedelic-like effects of dextromethorphan*
C.J. Reissig¹, L.P. Carter², M.Z. Mintzer¹ and R.R. Griffiths¹, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD and ²Medical Affairs Department, Jazz Pharmaceuticals Inc., Bloomington, IN
- 10:15 *Psychomotor, subjective, and cognitive effects of ketamine and triazolam in healthy volunteers*
L.P. Carter¹, R.R. Griffiths^{2,3} and M.Z. Mintzer², ¹Medical Affairs, Jazz Pharmaceuticals Inc., Bloomington, IN ²Psychiatry and Behavioral Sciences, and ³Neuroscience, Johns Hopkins University, Baltimore, MD
- 10:30 *Self-administration of the gamma-hydroxybutyrate (GHB) prodrug gamma-butyrolactone (GBL) in baboons*
E.M. Weerts, A.K. Goodwin, B.J. Kaminski, R.R. Griffiths and N.A. Ator, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD
- 10:45 *CGP7930, a positive modulator of GABA-B receptors, enhances catalepsy induced by the GABA-B receptor agonist baclofen and by gamma-hydroxybutyrate (GHB)*
W. Koek^{1,2}, K. Cheng³, K.C. Rice³ and C.P. France^{2,1}, ¹Psychiatry, and ²Pharmacology, University of Texas Health Science Campus San Antonio, San Antonio, TX and ³Chemical Biology Research Branch, NIDA, Bethesda, MD
- 11:00 *The acute effects of trifluoromethylphenylpiperazine (TFMPP) administration on the Poffenberger Paradigm of Interhemispheric Transfer Time*
B.R. Russell¹, H. Lee¹ and I.J. Kirk², ¹School of Pharmacy, and ²Research Centre for Cognitive Neuroscience, Psychology, The University of Auckland, Auckland, New Zealand
- 11:15 *Long-term repeated exposure to MDMA in rats: Effects on thermoregulation and neurotoxicity*
E.J. Jaehne, A. Salem and R.J. Irvine, Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia
- 11:30 *Assessing the role of oxytocin in the interoceptive cues of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm*
J.H. Broadbear and K. Beringer, SPPPM, Monash University, Clayton, VIC, Australia
- 11:45 *Comparison of effects produced by methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans under controlled conditions*
C.L. Hart, A.Y. Perez, E.W. Gunderson, M. Haney and R.W. Foltin, Psychiatry, Columbia University, New York, NY

Oral Communications 4

**San Geronimo A
10:00 AM - 12:00 PM**

TREATING FOR TWO: DRUGS AND PREGNANCY

Chairs: Oriana Vesga and Hendree Jones

- 10:00 *Twelve-month prevalence of substance use and substance use disorders in pregnant and postpartum women*
O. Vesga¹, C. Blanco², K. Keyes³, M. Olfson², B. Grant⁴ and D. Hasin^{3, 12}Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, ³Epidemiology, Mailman School of Public Health, Columbia University, NYC, NY and ⁴Laboratory of Epidemiology and Biometry, NIAA, NIH, Bethesda, MD
- 10:15 *Characterizing methadone dose during late pregnancy and postpartum*
S.H. Heil¹², T. Scott¹, S. Sigmon¹² and S. Higgins¹², ¹Psychiatry and ²Psychology, University of Vermont, Burlington, VT
- 10:30 *Methamphetamine use among white pregnant women*
W. Tompkins and W. Clark, SAMHSA, Rockville, MD
- 10:45 *Pregnancy and race/ethnicity as predictors of readiness for drug treatment*
M.M. Mitchell, S.G. Severtson, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins University, Baltimore, MD
- 11:00 *Binge drinking and not heavy regular drinking relates to pregnancy risk due to ineffective contraception*
S. Fabbri, L. Farrell, T. Ly, C.D. Ceperich, J.K. Penberthy, J.E. Wartella and K.S. Ingersoll, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA
- 11:15 *Does tobacco use identify post-partum women at risk for alcohol problems and depression?*
L. Islam¹, L. Keyser-Marcus¹, S. Ondersma² and D.S. Svikis¹, ¹Psychology, Virginia Commonwealth University, Richmond, VA and ²Wayne State University, Detroit, MI
- 11:30 *Smoking in pregnant patients screened for an agonist medication study: Comparisons to other pregnant and/or drug-dependent female patients*
H.E. Jones¹, K. O'Grady¹, K. Kaltenbach², G. Fischer³, S. Heil⁴, P. Martin⁵, S. Stine⁶, M. Coyle⁷, P. Selby¹ and A. Arria¹, ¹Johns Hopkins U., Baltimore, MD, ²Thomas Jefferson U., Philadelphia, PA, ³Medical U. Vienna, Vienna, Austria, ⁴U. of Vermont, Burlington, VT, ⁵Vanderbilt U, Nashville, TN, ⁶Wayne State U., Detroit, MI and ⁷Brown U., Providence, RI
- 11:45 *Nicotine replacement treatment for pregnant smokers*
C. Oncken¹, E. Dornelas^{2,1}, J. Greene^{2,1}, H. Sankey³, A. Glasmann⁴ and H.R. Kranzler¹, ¹University of Connecticut School of Medicine, Farmington, ²Hartford Hospital, Hartford, and ⁴Hospital of Central Connecticut, New Britain, CT and ³Baystate Medical Center, Baystate, MA

**Early Career Investigator Awards
Luncheon**
(By Invitation Only)

**Las Olas
12:00 - 1:30 PM**

Art and Addiction Exhibition

**Flamingo
12:00 - 1:30 PM**

THE NARCOTIC FARM: FACTS AND FICTIONS

Nancy D. Campbell

Symposium V

**San Geronimo A
1:30 - 3:30 PM**

ADULTS MAY BE FROM MARS, BUT ADOLESCENTS ARE FROM VENUS

Chairs: Minda R. Lynch and James Bjork

- 1:30 *Social interactions during adolescence: Giving a boost to drug reward*
Janet L. Neisewander, Arizona State University, Tempe, AZ
- 1:55 *The social and physical environment differentially alters drug reward in adults and adolescents:
Are adolescents more sensitive to the world around them?*
Sari Izenwasser, University of Miami School of Medicine, Miami, FL
- 2:20 *Adolescent phenotypes: Stress and emotional reactivity in the vulnerability to addiction*
Nicole Schramm Sapyta, Duke University Medical Center, Durham, NC
- 2:45 *Adolescent THC exposure: Genetic and neurobiological mechanisms of adult addiction*
Yasmin L. Hurd, Mount Sinai School of Medicine, New York, NY
- 3:10 *Risk and reward in human adolescence: A framework for translation*
James Bjork, NIDA, Bethesda, MD

Oral Communications 5

**San Cristobal
1:30 - 3:30 PM**

PAIN RELIEF, ADDICTION GRIEF: OPIATE ANALGESIC ABUSE

Chairs: Marc Auriacombe and Stacey Sigmon

- 1:30 *Methodological issues in designing a clinical trial for opioid analgesic dependence:
Defining the population*
R.D. Weiss^{1,2}, J.S. Potter^{1,2}, K. Prather¹, S. Provost¹, J. Selzer³ and W. Ling⁴, ¹Alcohol and
Drug Abuse Treatment Program, McLean Hospital, Belmont, and ²Psychiatry, Harvard
Medical School, Boston, MA, ³Psychiatry, Hillside Hospital, Glen Oaks, NY and ⁴Psychiatry,
University of California-Los Angeles School of Medicine, Los Angeles, CA
- 1:45 *A descriptive profile of opioid-dependent patients with chronic pain attending the Columbia
University Buprenorphine Program*
J.M. Manubay^{1,2}, S.K. Vosburg^{1,2}, E. Gunderson^{1,2}, E. Yango¹ and H.D. Kleber^{1,2}, ¹Psychiatry,
Columbia University, and ²NYSPI, New York, NY

- 2:00 *A protocol to use buprenorphine for chronic pain in patients at risk for drug abuse*
A. Rosenblum¹, R. Cruciani², H. Joseph¹, L.F. McNicholas⁴, S. Magura⁵, L. Marsch¹,
S.R. Savage⁶, E.C. Strain³ and R.K. Portenoy², ¹NDRI, and ²Beth Israel Medical Center, NY,
NY, ³Johns Hopkins University, Baltimore, MD, ⁴University of Pennsylvania, Philadelphia,
PA, ⁵Western MI University, Kalamazoo, MI and ⁶Dartmouth Medical School, Hanover, NH
- 2:15 *Discontinuation of chronic opioids for pain: Addiction concerns*
J.O. Merrill¹, C. Banta-Green¹, D. Boudreau², S. Doyle¹ and D. Calsyn¹, ¹University of
Washington and ²Center for Health Studies, Seattle, WA
- 2:30 *Self-perceived pain and physical condition after 1 year in maintenance treatment for opiate
dependence: Comparison between methadone and buprenorphine patients*
M. Auriacombe¹, E. Lavie¹, C. Denis¹, M. Fatseas¹, R. Ali³ and W. Ling², ¹Addiction
Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen, Bordeaux, France, ²ISAP,
University of California-LA, Los Angeles, CA and ³University, Adelaide, NSW, Australia
- 2:45 *Opioid abuse and pain: Does dose matter?*
D.L. Haller^{1,2} and M.C. Acosta^{1,2}, ¹St. Luke's Roosevelt Hospital, and ²Columbia University,
New York, NY
- 3:00 *Treatment outcomes of MMT patients with and without chronic pain*
D.T. Barry¹, M. Beitel¹, B. Garnet², D. Joshi² and R.S. Schottenfeld¹, ¹Yale University and
²The APT Foundation, Inc., New Haven, CT
- 3:15 *Developing a treatment for prescription opioid abuse*
S.C. Sigmon, K. Dunn, S. Heil and S. Higgins, Psychiatry, University of Vermont,
Burlington, VT

Oral Communications 6

San Geronimo C
1:30 - 3:30 PM

DECISION IMPRECISION: COGNITIVE DEFICITS

Chairs: F. Gerard Moeller and Jesse Suh

- 1:30 *Differential effects of cocaine on neurocognitive functioning of the orbitofrontal cortex in
adolescent vs. adult rats*
R.C. Harvey, K.A. Dembro, K. Rajagopalan, M.M. Mutebi and K.M. Kantak, Psychology,
Boston University, Boston, MA
- 1:45 *Escalating dose of methamphetamine induces deficits in response inhibition in non-human
primates*
S. Groman¹, B. Lee², E. Seu¹, E.D. London^{2,3} and J.D. Jentsch³, ¹Psychology ²Psychiatry and
Behavioral Sciences and ³Molecular and Medical Pharmacology, University of California Los
Angeles, Los Angeles, CA
- 2:00 *fMRI of response inhibition in cocaine-dependent subjects and controls: Effect of amphetamine*
F. Moeller¹, J.L. Steinberg¹, S.D. Lane¹, L.A. Kramer², P.A. Narayana² and T.R. Kosten³,
¹Psychiatry and Behavioral Sciences and ²Diagnostic and Interventional Imaging, University
of Texas Health Science Center at Houston, and ³Menninger Department of Psychiatry and
Behavioral Sciences, Baylor College of Medicine, Houston, TX
- 2:15 *A novel Affect-Congruent Go NoGo task demonstrates limbic prepotency in cocaine-dependent
patients*
M. Goldman¹, R. Ehrman², Z. Wang¹, Y. Li¹, J. Hakun¹, W. Jens¹, J. Suh¹, C.P. O'Brien¹,
J. Detre¹ and A.R. Childress¹, ¹University of Pennsylvania, and ²VAMC, Philadelphia, PA

- 2:30 *Are cocaine-dependent patients less able to predict errors—an fMRI study of the stop signal task?*
C. Li, P. Yan, K. Bergquist and R. Sinha, Psychiatry, Yale University, New Haven, CT
- 2:45 *Decision-making in cocaine abusers: Contingencies and gambling task performance*
N.P. Vadhan, M. Haney, C.L. Hart, W.G. van Gorp and R.W. Foltin, Psychiatry, Columbia University/NYSPI, New York, NY
- 3:00 *Poor fronto-limbic connectivity during both "seen" and "unseen" aversive cues in cocaine patients*
J.J. Suh^{1,2}, R. Ehrman^{1,2}, Y. Li^{1,2}, Z. Wang¹, W. Jens¹, J. Hakun¹, M. Goldman¹, C.P. O'Brien^{1,2} and A.R. Childress^{1,2}, ¹University of Pennsylvania and ²VAMC, Philadelphia, PA
- 3:15 *Sensorimotor integration deficits in chronic cocaine users: An fMRI and DTI study*
C.A. Hanlon, M.J. Wesley, A.L. Roth and L.J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC

Symposium VI

San Geronimo B
1:30 - 2:30 PM

SEXUAL ACQUISITION AND TRANSMISSION OF HIV FROM AND AMONG DRUG-USING POPULATIONS

Chairs: Martin Y. Iguchi and Richard Jenkins

- 1:30 *Behavioral and biological indicators of risk for HIV transmission in homeless drug users in Los Angeles*
Steven Shoptaw, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
- 1:45 *Comparison of risks for HIV transmission in rural and urban settings*
Bill Zule, RTI International, Research Triangle Park, NC
- 2:00 *Geographic, recruitment network, and behavioral indices of bridging: Implications for HIV diffusion*
Larry Ouellet, University of Illinois, School of Public Health, Chicago, IL
- 2:15 *Discussant*
Robert Heimer, Epidemiology and Public Health, Yale University, New Haven, CT

Symposium VII

San Geronimo B
2:45 - 3:45 PM

THE TWIN DESIGN: STUDYING GENES AND ENVIRONMENT ON SUBSTANCE USE BEHAVIORS

Chairs: Arpana Agrawal and Michael T. Lynskey

- 2:45 *A longitudinal twin study of vulnerability to substance dependence: The Colorado twins*
Soo Hyun Rhee, University of Colorado, Boulder, CO
- 3:05 *Predictors of cannabis use initiation in Finnish adolescent twins*
Anja C. Huizink, Erasmus Medical Center, Rotterdam, Netherlands
- 3:25 *The role of peer group deviancy in the genetic and environmental pathways to cannabis use in male twins*
Nathan Gillespie, Virginia Commonwealth University, Richmond, VA

Monday, June 16, 2008

**Marian W. Fischman Memorial
Award Lecture**

**San Cristobal
3:45 - 4:45 PM**

*Presentation of the Marian W. Fischman Memorial Award to
Edythe D. London*

Introduction by Jerome H. Jaffe

Lecture: Studying addiction in the age of neuroimaging
Edythe D. London

Pre- and Post-Doc Mixer

**Las Olas
5:00 - 6:30 PM**

Workshop IV

**San Geronimo A
8:00 - 10:00 PM**

**CHALLENGES FOR ABUSE LIABILITY TESTING FROM
DRUG DEVELOPMENT TO FDA APPROVAL**

Chairs: Michael A. Nader and Beatriz Rocha

*Challenges for abuse liability testing of compounds in development for non-CNS indications—
Industry perspective: Case scenario 1*

Beatriz Rocha, Merck & Co., Inc., Rahway, NJ

*Challenges for abuse liability testing of compounds in development for non-CNS indications—
Industry perspective: Case scenario 2*

Mark A. Ammann, Regulatory Affairs United BioSource Corporation

*Challenges for abuse liability testing of compounds in development for non-CNS indications—
FDA perspective*

Silvia N. Calderon, Center for Drug Evaluation and Research, FDA, Rockville, MD

Workshop V

**San Geronimo B
8:00 - 10:00 PM**

ACADEMIC SUCCESS AND TENURE IN TIGHT TIMES

Chairs: Kristen Huntley, Nadine Rogers, Eliane Lazar-Wesley and
Mark Swieter

*Panelists: William L. Dewey, Linda Dykstra, Carl Latkin, Charles O'Brien, Kathy Sander-
Phillips, and Sharon Walsh*

Workshop VI

**San Geronimo C
8:00 - 10:00 PM**

ADOLESCENT SUBSTANCE ABUSE TREATMENT: CURRENT FINDINGS AND IMPLICATIONS FOR JUVENILE JUSTICE SETTINGS

Chairs: Lyn Stein and Michael Dennis

Empirical support for adolescent substance abuse treatments: A meta-analytic study
Charles Turner, Oregon Research Institute, Eugene, OR

Partner-specific HIV risk reduction in substance-using juvenile delinquents
Cynthia Rosengard, The Warren Alpert Medical School of Brown University, Providence, RI

Multidimensional family therapy for adolescents in the justice system
Howard Liddle, University of Miami Miller School of Medicine, Miami, FL

Treatment outcomes in drug court studies, including evidence for juvenile drug courts
Douglas B. Marlowe, TRI, University of Pennsylvania, Philadelphia, PA

Implications of presentations, followed by the Society for Adolescent Substance Abuse Treatment Effectiveness (SASATE) Business Meeting
Michael L. Dennis, Chestnut Health System, Bloomington, IL

Workshop VII

**San Cristobal
8:00 - 10:00 PM**

A STEP-BY-STEP GUIDE TO ANALYSIS OF EPIDEMIOLOGICAL FIELD SURVEY DATA ON MINORITY HEALTH DISPARITIES AND MALE- FEMALE DIFFERENCES IN NIDA-RELATED OUTCOMES

Chairs: James Anthony and Silvia S. Martins

It's about the basics: Estimating differences and sub-group variation; 95% CI; P-Values
James Anthony, College of Human Medicine, Michigan State University, East Lansing, MI

It's about the basics: Using a generalized linear model to control covariates
Silvia S. Martins, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

It's about time: The basic life-table, plus event history analysis
Fernando Wagner, School of Public Health and Policy, Morgan State University, Baltimore, MD

It's about Eta: Bias detection via IRT and MIMIC
Mirjana Radovanovic, Michigan State University, East Lansing, MI

It's about online analysis: Buyer beware, you get what you pay for!
German Alvarado, Universidad Peruana Cayetano Heredia, Lima, Peru

It's about hot spots: Sizing up epidemiological clusters of drug use
Carlos Rios-Bedoya, College of Human Medicine, Michigan State University, East Lansing, MI

Monday, June 16, 2008

**NIDA INTERNATIONAL RESEARCH
POSTERS**

**Peacock Alley
8:00 - 10:00 PM**

Chair: Steven W. Gust

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Tuesday, June 17, 2008

Tuesday, June 17, 2008

POSTER SESSION II (Breakfast)

**Expo Center
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Monday 1:00 PM
Must be removed by Tuesday 12:00 NOON**

HALLUCINOGENS

- 1 *Serotonin vs. hallucinogen actions at the 5-HT_{2A} receptor: A determining role for beta-arrestins in vivo*
C.L. Schmid, K.M. Raehal and L.M. Bohn, Pharmacology and Psychiatry, The Ohio State University, Columbus, OH
- 2 *Novel PCP analogs with high inhibitory potency at $\alpha 7$ nAChRs*
G. Abdrakhmanova¹, F.I. Carroll², B. Blough², M. Thiruvazhi², R.B. Rothman³, M.I. Damaj¹ and B.R. Martin¹, ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, ²Research Triangle Institute, Research Triangle Park, NC and ³National Institute of Drug Abuse, Baltimore, MD
- 3 *The role of NMDAR 2A and 2B in PCP-induced neurotoxicity and development of locomotor sensitization*
N. Anastasio and K.M. Johnson, UTMB Galveston, Galveston, TX
- 4 *The street drugs 2C-I and 2C-T-2 share discriminative stimulus effects with abused hallucinogens*
M.B. Gatch, T. Carbonaro, M. Rutledge, C. Elsken and M.J. Forster, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 5 *Cross-substitution between LSD and commonly co-abused drugs*
T. Carbonaro and M.B. Gatch, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX
- 6 *Linguistic analysis of psilocybin session narratives*
M.W. Johnson and R.R. Griffiths, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD
- 7 *Psilocybin occasions mystical-type experiences: Dose effects*
R.R. Griffiths¹, M.W. Johnson², W.A. Richards², U.D. McCann² and B.D. Richards², ¹Psychiatry and Neuroscience and ²Psychiatry, Johns Hopkins, Baltimore, MD
- 8 *Use of a hallucinogenic sacrament by American members of the Santo Daime Church: Evidence of safety*
J.H. Halpern¹, A.R. Sherwood² and A.J. Rutenber³, ¹Alcohol and Drug Abuse Research Center, McLean Hospital/HMS, Belmont, MA, ²Center for Neuropsychological Services, University of New Mexico School of Medicine, Albuquerque, NM and ³University of Colorado Health Science Center, Denver, CO

SEDATIVE-HYPNOTICS, INHALANTS

- 9 *Youth's inhalant drug use in Bogotá, Colombia*
Y. Neumark and C. Lopez, School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel
- 10 *Anxiety and depressive symptoms among crack and inhalant users in Southern Brazil*
C. Zubaran, K. Foresti-Zubaran, M. Thorell and P. Franceschini, Biomedical Sciences, University of Caxias do Sul, Caxias do Sul, Brazil
- 11 *Factors predicting the onset and discontinuity of prescribed benzodiazepine long-term use*
S. Fang¹, C. Chen¹, K. Lin¹, I. Chang¹, E. Wu² and C. Chang³, ¹National Health Research Institute, and ²Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan and ³Chang Gung Memorial Hospital, Taoyuan County, Taiwan
- 12 *Tolerance develops differentially to the sedative effects of alprazolam following chronic treatment in rhesus monkeys*
A. Duke, D. Platt and J. Rowlett, Harvard Medical School/New England Primate Research Center, Southborough, MA
- 13 *Flumazenil selectively attenuates the discriminative stimulus effects of benzodiazepines, and not pregnanolone, in rats discriminating pregnanolone*
L.R. Gerak, Pharmacology, University of Texas Health Science Center, San Antonio, TX
- 14 *Discriminative stimulus effects of toluene vapor: Effect of exposure duration and route of administration*
K.L. Shelton, Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
- 15 *Development of a dynamic exposure system allowing for self-administration of abused inhalants in mice*
S. Irtenkauf and S. Bowen, Psychology, Wayne State University, Detroit, MI
- 16 *Increased sensitivity in adolescent versus adult rats to the locomotor activating effects of toluene*
S. Bowen and J. Batis, Psychology, Wayne State University, Detroit, MI
- 17 *Alterations in skeletal development following gestational toluene exposure*
A. Stefanski¹, S. Irtenkauf¹, J. Hannigan^{1,2} and S. Bowen^{1,2}, ¹Psychology, and ²Obstetrics and Gynecology, Wayne State University, Detroit, MI

PHARMACOKINETICS

- 18 *Identification of the enzymes metabolizing buprenorphine in preterm human placentas*
V. Fokina, O. Zharikova, T.N. Nanovskaya, G. Hankins and M.S. Ahmed, OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX
- 19 *Pharmacodynamic and pharmacokinetic evaluations of immediate release morphine in combination with ethanol in healthy subjects*
B. Setnik¹, M. Miguelez¹, G. Leowen², A. Negro-Vilar² and E. Sellers¹, ¹Research Consulting, DecisionLine Clinical Research Corporation, Toronto, ON, Canada and ²Ligand Pharmaceuticals Inc., San Diego, CA
- 20 *Relative abuse potential of ALO-01, extended-release morphine sulfate plus sequestered naltrexone*
J.B. Jones¹, F. Johnson¹, G. Wagner¹, J. Stauffer¹ and E. Sellers², ¹Alpharma Pharmaceuticals LLC, Piscataway, NJ and ²DecisionLine CRC, Toronto, ON, Canada
- 21 *Local blockade of cocaine actions in brain by local gene transfer of cocaine hydrolase*
S. Brimijoin and Y. Gao, Molecular Pharmacology, Mayo Clinic, Rochester, MN

- 22 *Blood levels and dopamine transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET*
K.M. Wilcox¹, D.F. Wong^{1,2}, Y. Zhou², M. Alexander², A. Rahmim² and M.R. Weed¹,
¹Psychiatry and Behavioral Sciences, and ²Radiology, Johns Hopkins University School of Medicine, Baltimore, MD
- 23 *Abuse potential of a slow-onset, long-duration methylphenidate analog with selectivity for the dopamine transporter*
M. Froimowitz^{1,2}, Y. Gu², L.A. Dakin², C.J. Kelley², X. Li³, J. Li³, Z.X. Xi³ and E.L. Gardner³,
¹DNAPrint Pharmaceuticals, Sarasota, FL, ²Massachusetts College of Pharmacy and Health Sciences, Boston, MA and ³Neuropsychopharmacology Section, Intramural Research Program, NIDA, Baltimore, MD
- 24 *Enhanced immunogenicity of bivalent nicotine vaccine*
D. Keyler^{1,2}, S.A. Roiko², C.A. Ross¹, M.P. Murtaugh² and P.R. Pentel^{1,2}, ¹Minneapolis Medical Research Foundation, and ²University of Minnesota, Minneapolis, MN

COCAINE: ANIMAL STUDIES

- 25 *Improving conjugate vaccines against cocaine and methamphetamine*
B.M. Kinsey^{2,1}, F.M. Orson^{2,1}, Y. Wu¹, R.A. Singh¹, W. Huang^{3,2} and T.A. Kosten^{3,2}, ¹Internal Medicine, and ³Psychiatry, Baylor College of Medicine, Houston, ²Medical Service, Veterans Affairs Medical Center, Houston, TX
- 26 *Prolonged durations of protection of thermal stabilizing cocaine esterase mutants against cocaine-induced toxicity in mice*
M.C. Ko^{1,2}, D. Narasimhan¹, J.H. Woods¹ and R.K. Sunahara¹, ¹Pharmacology, University of Michigan, Ann Arbor, MI and ²Psychology, National Cheng-Chi University, Taipei City, Taiwan
- 27 *Novel substituted piperazines with high affinity and selectivity for sigma receptors attenuate cocaine-induced behaviors in mice: Role for sigma-1 and sigma-2 subtypes*
N. Kaushal¹, J. Shaikh¹, C. Croom¹, C. Mesangeau¹, S. Narayanan¹, J.H. Poupaert², C.R. McCurdy¹ and R.R. Matsumoto¹, ¹University of Mississippi, University, MS and ²Universite Catholique de Louvain, Brussels, Belgium
- 28 *Predictive pharmacophore models for novel sigma-1 and sigma-2 ligands*
T.L. Nolan¹, N. Singh¹, C. Mesangeau¹, S. Narayanan¹, J. Shaikh², R.R. Matsumoto² and C.R. McCurdy¹, ¹Medicinal Chemistry, and ²Pharmacology, University of Mississippi, University, MS
- 29 *Regulation of serotonin 5-HT_{2C} receptor (5-HT_{2CR}) in models of addiction: Measurement of 5-HT_{2CR} protein expression at cortical synaptic membranes*
M.F. Lanfranco, J. Moron-Concepcion and K.A. Cunningham, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- 30 *Molecular mechanisms underlying the conditioned association made to a single injection of cocaine*
A.M. dela Cruz, J. Moron-Concepcion and K.A. Cunningham, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- 31 *Effects of acute cocaine on ERK and DARPP-32 phosphorylation pathways in the caudate-putamen of Fischer rats*
W. Sun¹, L. Zhou², R. Hazim¹, V. Quinones-Jenab¹ and S. Jenab¹, ¹Psychology, and ²Biological Sciences, Hunter College and Graduate Center of CUNY, New York, NY

- 32 *Nucleus accumbens shell and core involvement in drug context-induced cocaine-seeking behavior in rats*
R.A. Fuchs, D.R. Ramirez, G.H. Bell, Z. Su and J.L. Eaddy, Psychology, University of North Carolina, Chapel Hill, NC
- 33 *Cocaine-induced increases in limbic and basal ganglia met-enkephalin content are mediated by a dopaminergic mechanism*
M.E. Alburges and G.R. Hanson, Pharmacology and Toxicology, University of Utah, Salt Lake City, UT
- 34 *Effect of amygdala inactivation on conditioned hyperactivity and sensitization in high-responder and low-responder rats*
M.J. Gill, R.A. Coolon and M.E. Cain, Kansas State University, Manhattan, KS
- 35 *Tolerance to decreases in pigeon locomotion following repeated cocaine administration*
M.T. Weaver, G.M. Sizemore and M.N. Branch, Psychology, University of Florida, Gainesville, FL
- 36 *Effects of chronic cocaine in the presence of an operant contingency in Long-Evans rats: Tolerance to lever pressing and locomotion and no sensitization*
J.A. Marusich, M.N. Branch and J. Dallery, University of Florida, Gainesville, FL
- 37 *Chronic exercise decreases the reinforcing efficacy of cocaine*
M.A. Smith, K.T. Schmidt, J.C. Iordanou and M.L. Mustroph, Psychology and Program in Neuroscience, Davidson College, Davidson, NC
- 38 *Estrogen interacts with mu opioid peptides to modulate behavioral sensitization to cocaine in female rats*
A.C. Segarra¹, G. Diaz¹, P. Hernandez¹, G. Santiago¹, M. Febo² and C. Ferris², ¹Physiology, U. of Puerto Rico, San Juan, PR and ²Psychology, Northeastern University, Boston, MA
- 39 *Progesterone attenuates acute locomotor responses but does not alter cocaine-induced behavioral sensitization in female rats*
S.E. Diaz^{1,2}, G. Seidman², I. Tulloch^{1,2}, S. Jenab^{2,1} and V. Quinones-Jenab^{2,1}, ¹Psychology, Graduate Center of New York, CUNY, and ²Psychology, Hunter College, New York, NY
- 40 *Progesterone treatment of the escalation of i.v. cocaine self-administration in rats differing in vulnerability*
J.L. Pawlik, J.J. Anker and M.E. Carroll, Psychiatry, University of Minnesota, Minneapolis, MN
- 41 *Effects of the vasopressin V1b blockade on cocaine self-administration*
R. Picetti and M.J. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 42 *Chronic unpredictable stress alters cocaine conditioned place preference in CBI knockout mice but not their wildtype littermates*
L.L. Miller¹, F. Henry¹, B.D. Fischer¹, S.J. Ward² and L.A. Dykstra¹, ¹Psychology, University of North Carolina, Chapel Hill, NC and ²Pharmaceutical Sciences, Temple University, Philadelphia, PA
- 43 *Prenatal and neonatal exposure to bisphenol-A affects the central dopaminergic systems in mice: Implications of the functional changes in dopamine D3 receptors*
K. Mizuo^{1,2}, M. Narita¹, K. Miyagawa¹, M. Miyatake¹, Y. Tsurukawa¹, K. Takeda² and T. Suzuki¹, ¹Toxicology, Hoshi University of Pharmacy and Pharmaceutical Sciences, Tokyo, and ²Research Center for Health Science of Nanoparticles, Tokyo University of Science, Chiba, Japan

PERINATAL SUBSTANCE ABUSE

- 44 *Prenatal cocaine exposure alters default mode and emotional network brain activity: Functional and resting state MRI evidence*
P. Santhanam¹, Z. Li¹, X. Hu¹, S. Hamann³, M.E. Lynch² and C.D. Coles², ¹Biomedical Engineering, ²Psychiatry and Behavioral Sciences, and ³Psychology, Emory University, Atlanta, GA
- 45 *Prenatal cocaine exposure and infant stress reactivity*
R.D. Eiden¹, Y. Veira¹, D. Granger² and P. Schuetze³, ¹Research Institute on Addictions, University at Buffalo, SUNY, Buffalo, NY ²Biobehavioral Health, Pennsylvania State University, University Park, PA and ³Psychology, Buffalo State College, Buffalo, NY
- 46 *Effects of prenatal cocaine exposure on toddlers' emotional arousal and regulation: Implications for behavior problems across a three-year follow-up*
T.M. Chaplin¹, L.C. Mayes², R. Sinha¹ and T. Fahy³, ¹Psychiatry, and ²Yale Child Study Center, Yale University, and ³Social Sciences, Gateway Community College, New Haven, CT
- 47 *The effects of prenatal cocaine exposure and lead on language at age 10*
S. Minnes, B. Lewis, E. Short, S. Satayathum and L. Singer, Case Western Reserve University, Cleveland, OH
- 48 *Prenatal cocaine exposure, childhood maltreatment, and adolescent marijuana use*
C. Larkby¹, S.L. Leech², M.D. Cornelius¹ and G.A. Richardson¹, ¹Psychiatry, University of Pittsburgh School of Medicine, and ²Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA
- 49 *MET for pregnant substance-abusing women (NIDA CTN 0013): Does baseline motivation moderate efficacy?*
S.J. Ondersma¹, T. Winhusen² and Y. Wang³, ¹Psychiatry and Ob/Gyn, and ³Family Medicine, Wayne State University, Detroit, MI, ²Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH
- 50 *Therapist effects in the treatment of pregnant substance abusers: Clinical Trials Network #13*
S.J. Erickson¹, J.S. Tonigan² and M.P. Bogenschutz², ¹Psychology, and ²CASAA, University of New Mexico, Albuquerque, NM
- 51 *Technological innovations in adapting an evidenced-based HIV intervention for pregnant African American women in substance abuse treatment*
W. Wechsberg, RTI International, Durham, NC and University of North Carolina School of Public Health, Chapel Hill, NC
- 52 *Licit substance use, depression and trauma in pregnant women at high and low risk for prenatal illicit drug*
C. Smith, A. Alvanzo, K. Reid-Quinones, D. Langhorst and D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA
- 53 *Pregnant women in methadone maintenance: Treatment engagement and illicit drug use*
L.M. Sander and L.H. Lundahl, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI
- 54 *Characterics of opioid-dependent pregnant women who accept or refuse participation in a clinical trial*
S. Stine¹, S. Heil², A. Arria³, K. O'Grady³, K. Kaltenbach⁴, G. Fischer⁵, P. Martin⁶, M. Coyle⁷, P. Selby⁸ and H. Jones³, ¹Wayne State U., MI ²University of VT, VT ³Johns Hopkins U., MD ⁴Thomas Jefferson U., PA ⁵Med. U. Vienna, Austria, ⁶Vanderbilt U., TN ⁷Brown U., RI, and U of Toronto, Canada

- 55 *Infant mortality among drug-dependent women*
L. Burns and R.P. Mattick, NDARC, UNSW, Sydney, NSW, Australia
- 56 *Maternal methadone dosing schedule and fetal neurobehavior*
L.M. Jansson¹, J.A. DiPietro², M. Velez¹, A. Elko¹, H. Knauer¹ and K.T. Kivlighan²,
¹Pediatrics, Johns Hopkins School of Medicine, and ²Population and Family Health Sciences,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 57 *Examination of withdrawal symptoms in methadone- or buprenorphine-exposed neonates*
T. Linares Scott¹, S.H. Heil¹, S.T. Higgins¹, S.C. Sigmon¹ and H.E. Jones², ¹University of
Vermont, Burlington, VT and ²Johns Hopkins University, Baltimore, MD
- 58 *An examination of physiological regulation in cocaine-exposed infants across the first 7 months of life*
P. Schuetze^{1,2,3}, E.P. Edwards² and R.D. Eiden^{2,3}, ¹Psychology, Buffalo State College,
²Research Institute on Addictions, University at Buffalo, and ³Pediatrics, University at
Buffalo, Buffalo, NY
- 59 *Brief, universal intervention for child maltreatment prevention among high-risk parents: Effects on substance use, mental health, and intimate partner violence*
A. Loree², S.J. Ondersma¹, J.R. Beatty³, G. Tzilos³, S.K. Chase³ and C.R. Schuster⁴,
¹Psychiatry and Ob/Gyn, ²Psychiatry, and ³Psychology, Wayne State University, Detroit, MI
and ⁴Neuroscience Institute, Loyola University, Chicago, IL

OPIOIDS: HUMAN STUDIES I

- 60 *Codeine effects in sleepy versus alert healthy normal subjects*
T. Roehrs^{1,2}, E. Harris¹, M. Hyde¹, M. Greenwald² and T. Roth^{1,2}, ¹Sleep Disorders and
Research Center, Henry Ford Hospital, and ²Psychiatry and Behavioral Neuroscience, Wayne
State University, Detroit, MI
- 61 *Assessment of the level of physical dependence and blockade efficacy produced by tramadol*
R.K. Lanier, M.Z. Mintzer, M.R. Lofwall, G.E. Bigelow and E.C. Strain, Psychiatry and
Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD
- 62 *Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers*
M.Z. Mintzer¹, G.E. Bigelow¹, R.K. Lanier¹, M.R. Lofwall² and E.C. Strain¹, ¹Johns Hopkins
University School of Medicine, Baltimore, MD and ²University of Kentucky College of
Medicine, Lexington, KY
- 63 *Within-subject comparison of the psychopharmacological profile of hydrocodone/acetaminophen and oxycodone/acetaminophen in healthy volunteers*
J.P. Zacny and S. Gutierrez, Anesthesia and Critical Care, University of Chicago, Chicago, IL
- 64 *A preliminary examination of tolerance to oxycodone in humans*
W.J. Kowalczyk, S.L. Stephens, M.A. Sullivan, S.K. Vosburg, S.M. Evans, R.W. Foltin and
S.D. Comer, SURC, New York State Psychiatric Institute, Columbia University,
New York, NY
- 65 *Effects of cold pressor pain on cortisol stress response and abuse liability of intranasal Oxycontin® in non-dependent prescription opioid abusers*
M. Lofwall^{1,2}, P.A. Nuzzo², J.P. Tuttle¹ and S.L. Walsh^{2,1}, ¹Psychiatry, and ²Behavioral
Science, University of Kentucky, Lexington, KY

- 66 *Validation of assessments for abuse liability trials*
M. Sokolowska¹, B. Setnik¹, J. Jones², F. Johnson², M. Romach¹ and E. Sellers^{1,3},
¹DecisionLine Clinical Research Corporation, Toronto, ON, Canada, ²Alpharma
Pharmaceuticals LLC, Piscataway, NJ and ³University of Toronto, Toronto, ON, Canada
- 67 *An exploratory profile of illicit prescription opiate users by route of administration*
E. McNees¹, M. Staton-Tindall¹, C. Leukefeld¹, R. Walker¹ and J. Rees², ¹University of
Kentucky, Lexington, and ²Kentucky Department of Corrections, Frankfort, KY
- 68 *Modeling transitions in behavior during naltrexone-based interventions for opioid dependence*
K.M. Carpenter^{1,2}, H. Jiang^{2,1}, M.A. Sullivan^{2,1}, A. Bisaga^{2,1}, W.N. Raby^{2,1}, A.C. Brooks³ and
E.V. Nunes^{2,1}, ¹Columbia University, and ²Division on Substance Abuse, New York State
Psychiatric Institute, New York, NY and ³Treatment Research Institute, Philadelphia, PA
- 69 *Behavioral naltrexone therapy for heroin dependence: A randomized controlled trial*
M.A. Sullivan, K.M. Carpenter, Y. Elkus, S.J. Anen, E. Leimsider and E.V. Nunes, Columbia
University, New York State Psychiatric Institute, New York, NY
- 70 *Reinforcement-based treatment: A randomized clinical trial*
M. Tuten, H. Jones and M. Stitzer, Johns Hopkins University, Baltimore, MD
- 71 *Employment-based reinforcement of acceptance of depot naltrexone injections in opioid-
dependent adults*
J.J. Everly, A. Umbricht, M. Fingerhood, G. Bigelow and K. Silverman, Johns Hopkins
University School of Medicine, Baltimore, MD
- 72 *A stress-coping profile of opioid-dependent individuals entering naltrexone treatment*
S.M. Hyman, K.A. Hong, D. Comegys, Z. Dabre and R. Sinha, Psychiatry, Yale University
School of Medicine, Substance Abuse Treatment Unit, New Haven, CT
- 73 *A double-blind, placebo-controlled trial of long-acting implantable formulation of naltrexone
for heroin dependence: Results of interim analysis*
E. Krupitsky², E. Zvartau², V. Egorova², D. Masalov², M. Tsoi², A. Burakov², N. Bushara²,
T. Romanova², E. Verbitskaya², T. Slavina², A. Grinenko² and G.E. Woody¹, ¹Psychiatry,
University of Pennsylvania, Philadelphia, PA and ²Pharmacology, St. Petersburg State Pavlov
Medical University, St. Petersburg, Russian Federation
- 74 *Buprenorphine medication contingency efficacious in promoting abstinence from opioids and
cocaine*
M.P. Chopra¹, R.D. Landes¹, M. Mancino¹, C. Cargile¹, L. Jackson¹, K.M. Gatchalian¹,
A. Buchhalter⁴, L. Marsch^{2,3} and W.K. Bickel¹, ¹Psychiatry, University of Arkansas for
Medical Sciences, Little Rock, AR, ²National Development and Research Institutes, and ³St.
Luke's-Roosevelt Hospital Center, New York, NY and ⁴Pinney Associates, Bethesda, MD
- 75 *"Feeling normal again": Patient perspectives on buprenorphine treatment*
J.E. Egan, J. Gass, J. Netherland and L. Weiss, New York Academy of Medicine,
New York, NY
- 76 *Sexual risk and physician screening practices in office-based buprenorphine*
L.E. Sullivan¹, D.A. Fiellin¹, B.A. Moore² and R.S. Schottenfeld², ¹Internal Medicine, and
²Psychiatry, Yale University, New Haven, CT
- 77 *Automated clinical history database for office management of the individual buprenorphine*
J. Listerud^{1,2}, L. McNicholas^{1,2}, D. Oslin^{1,2}, C. Burke² and J. McKay^{1,2}, ¹Psychiatry, University
of Pennsylvania, and ²Psychiatry, VAMC, Philadelphia, PA

- 78 *Treatment considerations of physicians prescribing buprenorphine*
T.J. Grosheider¹, J. Luther^{1,2}, R. Ramgopal² and A.J. Gordon^{1,2}, ¹University of Pittsburgh, and ²VA Pittsburgh Healthcare System, Pittsburgh, PA
- 79 *Factors associated to buprenorphine treatment adoption by Puerto Rican physicians in private practice*
G. Caraballo and C.E. Albizu, Graduate School of Public Health, University of Puerto Rico, San Juan, PR
- 80 *Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering*
C. Steinmiller and M. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 81 *Semi-quantitative buprenorphine testing in an ongoing study with prescription opioid abusers*
K.E. Dunn, S.C. Sigmon, S.H. Heil and S.T. Higgins, University of Vermont, Burlington, VT
- 82 *Primary care buprenorphine treatment among persons released from jail*
J.D. Lee^{1,2}, E. Grossman^{1,2}, D. DiRocco^{1,2}, H. Joseph³, A. Rosenblum³, S. Magura^{3,4} and M.N. Gourevitch^{1,2}, ¹New York University School of Medicine, ²Bellevue Hospital Center, and ³NDRI, Inc., New York, NY and ⁴Western Michigan University, Kalamazoo, MI
- 83 *Predictors of successful treatment outcomes in a 30-day buprenorphine detoxification*
S. King¹, E.C. Katz^{2,1}, B. Brown^{1,3}, R. Schwartz¹, D. Gandhi⁴ and W. Barksdale⁴, ¹Friends Research Institute, Baltimore, MD, ²Towson University, Towson, MD, ³University of N. Carolina, Wilmington, NC and ⁴University of Maryland, Baltimore, MD
- 84 *Examination of a brief adjunctive interoceptive-based intervention for heroin users with high anxiety sensitivity*
J.M. Richards, M.T. Tull, S. Gorka, M.J. McDermott, S.B. Daughters and C.W. Lejuez, Psychology, Center for Addictions, Personality, and Emotion Research [CAPER], University of Maryland, College Park, MD
- 85 *Katrina and Rita: Two years later*
J.C. Maxwell¹ and D. Podus², ¹University of Texas Austin, Austin, TX and ²University of California-Los Angeles, Los Angeles, CA

EPIDEMIOLOGY, ETHNIC DIFFERENCES

- 86 *Scientific collaboration between the United States and the European union in substance abuse (2002-2006)*
R. Aleixandre-Benavent¹, J.C. Valderrama¹, G. González¹, A. Alonso¹, V. Agulló¹, N. Llorens¹, F. Bueno² and J.C. Pérez de los Cobos³, ¹IHCD López Piñero, and ²Plan Municipal Drogodependencias, Ayuntamiento de Valencia, València, and ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- 87 *Polydrug use and implications for longitudinal research: Ten-year trajectories for heroin, cocaine, and methamphetamine users*
M. Brecht, D. Huang, E. Evans and Y. Hser, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 88 *Family attention and coca paste use in northern Chile, 1999 and 2005*
L.H. Caris¹ and J.C. Anthony², ¹Medicine Faculty, University of Chile, Santiago, Chile and ²Epidemiology, Michigan State University, East Lansing, MI
- 89 *Demographic characteristics of cocaine-related decedents in Gainesville, FL*
N.A. Graham¹, L. Merlo¹, S. Win¹, C. Hammond¹, M. Burt^{1,2}, W. Hamilton², B. Goldberger¹ and M. Gold¹, ¹Psychiatry and Pathology, University of Florida, and ²District Eight, Medical Examiners Office, Gainesville, FL

- 90 *The relationship of substance abuse to dependence in the U.S. general population*
D. Hasin¹ and T. Harford², ¹Columbia University, College of Physicians and Surgeons, New York City, NY and ²Boston University, Boston, MA
- 91 *Substance use in patients with STDs: Results from a national survey*
J.M. Tetrault, D.A. Fiellin and L.E. Sullivan, Yale University School of Medicine, New Haven, CT
- 92 *Natural history of opioid addiction: The relationship between time using opioids, patterns of use, and problem severity in clients in treatment*
S.H. Budman and S.F. Butler, Inflexxion, Inc, Newton, MA
- 93 *Age-related drug use patterns in Central Ukraine*
O. Zezyulin¹, J.E. Schumacher², K. Dumchev², P. Slobodyanyuk² and L. Moroz³, ¹Vinnitsa Regional Narcological Dispensary, Vinnitsya, Ukraine, ²University of Alabama at Birmingham, Birmingham, AL and ³Vinnitsya National Pirogov Medical University, Vinnitsya, Ukraine
- 94 *Correlates of substance use and related problems in Nigeria and Uganda: Findings from general population surveys*
I.S. Obot, M.B. Hossain and K. Sydnor, Morgan State University, Baltimore, MD
- 95 *Characteristics of a sample female injection drug users in Malaysia*
V.B. Kasinather¹, M.C. Chawarski², R.S. Schottenfeld² and M. Mazlan³, ¹Centre for Drug Research, University Sains Malaysia, Penang, and ³SARC, Muar, Malaysia and ²Yale University School of Medicine, New Haven, CT
- 96 *Substance use in inner city minority MSM and WSW*
S.R. Chappin^{1,3}, J.P. Sanchez² and S. Tross³, ¹Psychiatry, New York University, New York, ²Emergency Medicine, Jacobi Medical Center, Bronx, and ³Psychiatry, Beth Israel, New York, NY
- 97 *Psychosocial correlates of sex trade among drug-abusing women by race/ethnicity*
A.L. Lawson, L.J. Floyd, C.H. Salama and W.W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 98 *Intra-ethnic differences on the lifetime risk for alcohol, cannabis, and cocaine use among Latinos*
C.F. Ríos-Bedoya, Family Medicine, Michigan State University, East Lansing, MI
- 99 *Using racial admixture to delineate genetic and environmental risk factors of illicit drug use and dependence*
R.K. Price¹, N. Risk¹, G. Widner¹ and J. Sakai², ¹Psychiatry, Washington University School of Medicine, St. Louis, MO and ²Psychiatry, University of Colorado School of Medicine, Denver, CO
- 100 *Classism, racism, and expectations of drug use prevalence among low-income African Americans in the National Survey on Drug Use and Health*
L. Windsor, ¹Special Populations Office, National Development and Research Institutes, Inc., New York, NY and ²School of Social Work, The University of Texas at Austin, Austin, TX
- 101 *Describing differences between never smokers, current smokers, and former smokers in a low SES community sample*
P. Sheikhattari^{1,2,3}, H. Klein^{1,2}, S. Zhu⁴ and F.A. Wagner^{1,2,3}, ¹Center for the Study and Prevention of Drug Use, ²Center for Health Disparities Solutions, and ³School of Community Health and Policy, Morgan State University, and ⁴School of Medicine, University of Maryland, Baltimore, MD

- 102 *Racial differences in the effect of family formation on smoking cessation by middle age among women*
A. Thompson, ¹Columbia University, and ²National Development and Research Institute, New York, NY
- 103 *Predicting changes in smoking: Individual, partner and relationship influences*
G.G. Homish^{1,2}, K.E. Leonard^{2,3} and J.R. Cornelius⁴, ¹Health Behavior, ²Research Institute on Addictions, and ³Psychiatry, The State University of New York at Buffalo, Buffalo, NY and ⁴Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 104 *Association of prior tobacco dependence with recent posttraumatic stress disorder in a general population sample: Peru, 2007*
V.O. Cruz^{1,2}, C. Cachay² and J. Saavedra², ¹Epidemiology, Michigan State University, East Lansing, MI and ²Office of Epidemiology, Peruvian National Institute of Mental Health, Lima, Peru

PSYCHIATRIC COMORBIDITY I

- 105 *Validation and comparison of screening tools for mental disorders in substance abusers*
B.R. Rush¹, S. Castel², B. Brands³ and T. Toneatto¹, ¹Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, Toronto, ²Whitby Mental Health Centre, Oshawa, and ³Health Canada, Ottawa, ON, Canada
- 106 *Personality disorder diagnoses and psychotherapy outcome in a residential therapeutic community*
S. Ball^{1,2}, L. Maccarelli^{2,1}, D. LaPaglia² and M. Ostrowski², ¹The APT Foundation, and ²Psychiatry, Yale School of Medicine, New Haven, CT
- 107 *Psychiatric diagnosis, inner resources, and their relations to patients' outcome in methadone maintenance treatment*
Y. Abramsohn, D. Potik, E. Peles, S. Schreiber and M. Adelson, Adelson Clinic, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
- 108 *Appropriately identifying mental health services needs among minority substance abuse clients*
C.N. Martin, A.A. Mericle and D. Carise, Treatment Research Institute, Philadelphia, PA
- 109 *Comorbidity among drug users presenting to an emergency department*
A.J. Sheer¹, J. Hirshon² and D. Gorelick¹, ¹NIDA, NIH, and ²University of Maryland School of Medicine, Baltimore, MD
- 110 *Referenced-EEG guided pharmacotherapy of dual diagnosis patients*
M.J. Schiller¹, J.H. Shaffer² and J.E. Milner², ¹University of California, San Francisco, San Francisco, and ²Rancho L'Abri, Dulzura, CA
- 111 *ASPD and distress tolerance: The role of psychopathic traits in a substance use treatment-seeking sample*
M.N. Sargeant, S.B. Daughters, R. Schuster, S. Gorka and C.W. Lejuez, Psychology, University of Maryland, College Park, College Park, MD
- 112 *Stress, health-related quality of life and DSM-IV substance abuse and dependence in young, low-income women*
H. Wu, C. Holzer, J.J. Grady and A.B. Berenson, University of Texas Medical Branch, Galveston, TX
- 113 *Treatment outcomes for women and men offenders with comorbid mental disorders*
D. Jiang¹, Y.Y. Hser² and D. Huang², ¹Shanghai Mental Health Center, Shanghai, China and ²ISAP, Los Angeles, CA

- 114 *Social and mental health correlates of female inmates in the Puerto Rico prison system with lifetime drug use disorder and likely post traumatic stress disorder*
A. Hernandez and C.E. Albizu-Garcia, Center for Evaluation and Sociomedical Research, UPR-Medical Sciences Campus, San Juan, PR
- 115 *Trauma, health problems and depression in drug-dependent women*
S. Meshberg-Cohen, D. Nilson, C. Smith and D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA
- 116 *Co-morbid psychiatric and substance use disorders among African American women at high risk for HIV*
H.L. Surratt and J.A. Inciardi, Center for Drug & Alcohol Studies, University of Delaware, Coral Gables, FL
- 117 *HIV risk behaviors and PTSD: Secondary findings from a NIDA Clinical Trials Network randomized controlled trial of women in community-based substance abuse treatment*
D. Hien¹, T. Killeen², A. Campbell¹ and E. Nunes³, ¹Columbia University School of Social Work, Columbia University, New York, NY ²Psychiatry, Medical University of South Carolina, Charleston, SC and ³Columbia University and New York State Psychiatry Institute, New York, NY
- 118 *Client's drug treatment satisfaction: Posttraumatic stress disorder and perceived health*
J. Astone-Twerell¹, K. Morgen², T. Hernitche¹, J. Montbach³, T. Varela⁴ and E. Friedman⁴, ¹Research Division, Samaritan Village, Inc., Briarwood, ³Palladia Inc., Bronx, and ⁴Project Samaritan Inc., Bronx, NY ²and Psychology, Monmouth University, Monmouth, NJ
- 119 *A randomized controlled trial of an integrated treatment for substance use and PTSD incorporating exposure therapy: Preliminary findings*
K.L. Mills¹, M. Teesson¹, S. Back⁴, A. Baker², S. Hopwood³, K. Brady⁴ and C. Sannibale¹, ¹National Drug and Alcohol Research Centre, U. of New South Wales, Sydney, ²Centre for Mental Health Studies, U. of Newcastle, Newcastle, ³Centre for Traumatic Stress, Westmead Hospital, Sydney, NSW, Australia and ⁴Psychiatry, Medical U. of SC, Charleston, SC
- 120 *Substance use disorders, chronic pain, and specific depressive symptoms predict suicidality in individuals with major depression*
J.S. Potter¹, L.B. Potter², K. Prather¹ and R.D. Weiss¹, ¹McLean Hospital, Belmont, MA and ²Education Development Center, Newton, MA
- 121 *Trust in social network and risk of suicidality among drug users with depressive symptoms*
P. Chatterjee, S.G. Severtson and C. Latkin, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 122 *Recent marijuana, ecstasy and methamphetamine use not associated with depressive symptoms in a community-based urban population*
I. Kuo¹, M. Magnus¹, A.L. Rawls¹, J.A. Peterson¹, K.D. Shelley¹, T. West-Ojo², S. Hader², F. Hamilton³ and A.E. Greenberg¹, ¹Epidemiology and Biostatistics, George Washington University School of Public Health, ²HIV/AIDS Administration, District of Columbia Department of Health, and ³Family and Medical Counseling Services, Inc., Washington, DC

HIV/HCV II

- 123 *Development of a novel behavioral activation intervention for depressed, HIV positive, African American substance users-ACT HEALTHY*
J. Magidson, R. Schuster and S.B. Daughters, Psychology, University of Maryland, College Park, College Park, MD
- 124 *Adherence during an HIV vaccine clinical trial: High risk drug-using women*
J. Becher, S. Chhatre, M. Eisenberg, D. Fiore, D. Dunbar, I. Frank, G. Woody and D. Metzger, University of Pennsylvania, Philadelphia, PA
- 125 *Methamphetamine-related immune system changes in methamphetamine-dependent participants*
J. Zhuo², K. Whittaker², R. De La Garza¹, T.F. Newton¹ and G.C. Baldwin², ¹Psychiatry, and ²Medicine-Hematology & Oncology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
- 126 *Differential incidence of HIV and syphilis between male and female drug users in southwest China*
C. Hao^{1,2}, G.M. Qin³, H.Z. Qian⁴, Y.H. Ruan¹, J.L. Zhu¹, L. Yin¹, K.L. Chen⁵, S. Liang³, H. Xing¹, K.X. Hong¹ and Y.M. Shao¹, ¹China CDC, Beijing, ²The Chinese University of Hong Kong, Hong Kong, ³Sichuan CDC, Chengdu, and ⁵Xichang Center for STD and Leprosy Control, Xichang, China and ⁴Vanderbilt University School of Medicine, Nashville, TN
- 127 *Longitudinal trajectories of HIV risk behaviors among methamphetamine users*
D. Murphy, M. Brecht, D. Herbeck, E. Evans, L. Li and M. Hillhouse, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 128 *A comparison of two intervention modalities to reduce HIV risk behavior among chronic drug users*
C.B. McCoy¹, V. DeGruttola² and M. Comerford¹, ¹Epidemiology and Public Health, University of Miami, Miami, FL and ²Harvard University, Cambridge, MA
- 129 *Use of a peer leader intervention model to reduce needle-related risk behaviors among drug injectors in Ukraine*
R.E. Booth¹, W.K. Lehman¹, C. Latkin², J.T. Brewster¹, L. Sinitsyna^{3,4} and S. Dvoryak⁴, ¹Psychiatry, University of Colorado Denver Health Sciences Center, Denver, CO, ²Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Counterpart International, and ⁴Ukrainian Institute on Public Policy, Kyiv, Ukraine
- 130 *WHO collaborative study on substitution therapy of opioid dependence and HIV/AIDS*
R. Ali and W. WHO Opioid Substitution Therapy Study Group, WHO Collaborating Centre for Research in the Treatment of Drug and Alcohol Problems, University of Adelaide, Adelaide, SA, Australia
- 131 *Mixed drug use influences HIV risk in Ukrainian IDUs*
K. Dumchev¹, J.E. Schumacher², O. Zezyulin¹, P. Slobodyanyuk¹ and L. Moroz³, ¹Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine, ²University of Alabama at Birmingham, Birmingham, AL and ³Vinnitsya National Pirogov Medical University, Vinnitsya, Ukraine
- 132 *Risk behaviors of HIV + and HIV - out-of-treatment IDUs in Malaysia*
M.C. Chawarski¹, M. Mazlan², B. Vicknasingam³ and R. Schottenfeld¹, ¹Psychiatry, Yale University School of Medicine, New Haven, CT ²Substance Abuse Research Centre, Muar, Malaysia and ³Centre for Drug Research, University Sains Malaysia, Penang, Malaysia

- 133 *A comparison of social networks and injection risk behaviors among injection drug users in St. Petersburg, Russia and the Ukraine*
C. Latkin¹, A. Gyarmathy¹, R. Booth³ and A. Kozlov², ¹HBS, Johns Hopkins University, Baltimore, MD, ²Biomedical Institute, St. Petersburg, Russian Federation and ³Psychiatry, School of Medicine, Denver, CO
- 134 *Concurrency of sexual and injection risk among new heroin injectors*
L.A. Goldsamt¹ and M.C. Clatts², ¹IIRYAR, NDRI, New York, NY and ²School of Public Health, University of Puerto Rico, San Juan, PR
- 135 *Feasibility of expanded services for pharmacy IDU syringe customers*
N.D. Crawford^{1,2}, K. Standish¹, D. Vlahov¹ and C.M. Fuller^{1,2}, ¹Center for Urban Epidemiologic Studies, New York Academy of Medicine, and ²Mailman School of Public Health, Columbia University, New York, NY
- 136 *Developmental epidemiology and prevention of drug disorders and HIV sexual risk behavior*
A.M. Windham¹, S. Kellam¹, J. Poduska¹, C.H. Brown² and N. Ialongo³, ¹American Institutes for Research, Baltimore, MD, ²University of South Florida, Tampa, FL and ³Johns Hopkins University, Baltimore, MD
- 137 *Teaching condom use skills: Practice is superior to observation*
D.A. Calsyn¹, M. Godinez², S.R. Doyle¹, M.A. Hatch-Maillette¹, S.J. Cousins³ and T. Chen⁴, ¹University of Washington, Seattle, WA, ²University of New Mexico, Albuquerque, NM, ³Matrix Institute on Addictions, Rancho Cucamonga, CA and ⁴University of California San Francisco, San Francisco, CA
- 138 *Predictors of condom use among drug-abusing women involved in sex trade in Baltimore, MD*
C.H. Salama, A. Nandi, A. Lawson, L. Floyd and W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 139 *Drug use, sex, and women's risky relationships*
C.G. Leukefeld¹, J. Havens¹, C. Oser¹, M. Staton-Tindall¹, H. Knudsen¹, J. Palmer¹, J. Inciardi², H. Surratt³ and L. Frisman⁴, ¹University of KY, Lexington, KY, ²University of Delaware, Coral Gables, FL, ³Brown University, Providence, RI and ⁴University of Connecticut, Hartford, CT
- 140 *Sex trade behavior among injection and non-injection drug users in Baltimore, MD*
B.E. Mancha, D.E. Whitaker and W.W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 141 *HIV risk among treatment-seeking marijuana, cocaine and opioid users*
B.R. Bryan^{1,2}, D.J. Brooks^{1,2}, J.J. Mariani^{1,2} and F.R. Levin^{1,2}, ¹Division on Substance Abuse, Columbia University, and ²New York State Psychiatric Institute, New York, NY
- 142 *Alcohol and substance use among persons engaged in HIV prevention in a community mental health center*
M.B. Blank, D.S. Metzger, S. Eachus, J. Tennille, T. Ten Have, P. Solomon and M.M. Eisenberg, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 143 *Methods for estimating dynamical risk factors for HIV spread on sexual and drug-injecting networks*
G. Bobashev, R.J. Morris, E. Costenbader and W. Zule, RTI International, Durham, NC
- 144 *Sexual risk factors: Rates and reliability among ecstasy users*
E. Shacham and L.B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO

- 145 *A comparison of HIV prevalence among MSM and MSMW within a sample of drug users in Los Angeles*
C. Hucks-Ortiz¹, J. Wang¹, S. Larkins¹, P. Gorbach² and S. Shoptaw¹, ¹Family Medicine, University of California-Los Angeles and ²Epidemiology, University of California-Los Angeles School of Public Health, Los Angeles, CA
- 146 *Factors associated with stimulant use during sex in a low-income sample of men who have sex with men*
A. Ober^{1,2}, S. Shoptaw³, J. Wang³ and P. Gorbach⁴, ¹Social Welfare, University of California-Los Angeles School of Public Affairs, Los Angeles, ²RAND Corporation, Santa Monica, ³Family Medicine, David Geffen School of Medicine and ⁴Epidemiology, University of California-Los Angeles School of Public Health, Los Angeles, CA
- 147 *Women who have sex with women: HIV risk behaviors and perceived HIV risk*
J. Mooney¹, J. Havens¹, C. Oser¹, J. Duvall¹, M. Staton-Tindall¹, C. Leukefeld¹, J. Inciardi², J. Clarke³ and L. Frisman⁴, ¹University of Kentucky, Lexington, KY, ²University of Delaware, Newark, DE, ³Brown University, Providence, RI and ⁴University of Connecticut, Storrs, CT

SUBSTANCE ABUSE IN ADOLESCENTS I

- 148 *Gender differences in HIV risk behaviors among adolescents in substance abuse treatment*
Y. Chan¹, L.L. Passetti¹, J. Lloyd², B.R. Garner¹ and M.L. Dennis¹, ¹Chestnut Health Systems, Bloomington, IL and ²School of Social Administration, Temple University, Philadelphia, PA
- 149 *Gender differences in risky behaviors among inpatient adolescents*
A. Clark, N. Johnson, C. Merritt and D. Deas, Psychiatry, Medical University of South Carolina, Charleston, SC
- 150 *Perceived harmfulness of drugs and its association with drug use: Young men and women in Bogotá, Colombia see and do things differently*
C. Lopez and Y. Neumark, School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel
- 151 *Risk behaviors and risk trajectories among young injection drug users*
S.E. Lankenau^{1,2}, K. Wagner², J. Jackson Bloom², B. Sanders^{1,2} and D. Hathazi², ¹Pediatrics, University of Southern California, and ²Saban Research Institute, Childrens Hospital Los Angeles, Los Angeles, CA
- 152 *Availability of HIV-related services in adolescent substance abuse treatment programs*
H. Knudsen, Behavioral Science, University of Kentucky, Lexington, KY
- 153 *Relationship between HIV risk behaviors and suicide risk among youth in substance abuse treatment*
J.J. Lloyd¹, M.L. Dennis², M. Ives², J. Blanchette² and Y.F. Chan², ¹School of Social Administration, Temple University, Philadelphia, PA and ²Chestnut Health Systems, Bloomington, IL
- 154 *The intranasal heroin epidemic among Latino adolescents in Texas: They're calling it "cheese"*
C.F. Tirado¹, J.C. Maxwell² and B.A. Adinoff¹, ¹Psychiatry, UT-Southwestern, Dallas, TX and ²UT-Austin, Austin, TX
- 155 *Prevalence of muscle-building substances among students*
V. Agulló¹, S. Tomás², E. Gómez¹, M.J. Torrijos², A. Vidal², C. Morales¹, R. Aleixandre¹, J.C. Valderrama¹ and J.C. Pérez de los Cobos³, ¹IHCD López Piñero, and ²Fundació per a l'Estudi, Prevenció i Assistència Drogues, FEPAD, València, and ³Hospital Santa Creu i Sant Pau, Barcelona, Spain

- 156 *Efficacy of an online substance use prevention program for early adolescents*
S.E. Lord¹, D. D'Amante¹, K. Clements² and K. Trudeau¹, ¹Inflexxion, Newton, MA and ²Department of Public Health, Boston, MA
- 157 *Adolescent substance use and condom use in first and recent sexual encounters*
B. Beadnell², D.M. Morrison², M.J. Hoppe² and B.C. Leigh¹, ¹Alcohol and Drug Abuse Institute, and ²School of Social Work, University of Washington, Seattle, WA
- 158 *Substance use and sexually transmitted infection among young adults in the United States*
M.R. Khan, National Development and Research Institutes, New York, NY
- 159 *Family health and neighborhood satisfaction as a context for motivated learning among urban African American adolescents at risk for drug use*
D. Whitaker, G.S. Severtson and W. Latimer, Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD
- 160 *The relationship between emotional abuse, disinhibition, and substance use and risk-taking behavior in a community sample of young adolescents*
F.L. Wang, E.K. Reynolds, M.S. Duplinsky, M. Bornovalova, L. MacPherson and C.W. Lejuez, University of Maryland, College Park, College Park, MD
- 161 *Sexual maturation, peer delinquency, and drug use in daughters of substance use disorder fathers from childhood to adolescence*
A.C. Mezzich, L. Kirisci, M. Vanyukov, G. Kirillova and T. Ridenour, Pharmacy, University of Pittsburgh, Pittsburgh, PA
- 162 *Does childhood abuse history impact outcomes among homeless youth receiving substance abuse treatment?*
N. Slesnick, S. Bartle-Haring, A. Khurana and D. Bantchevska, The Ohio State University, Columbus, OH
- 163 *Psychobiological correlates of childhood neglect and parental care perception in cocaine addicts*
G. Gerra^{1,2,3}, C. Leonardi², M.A. Raggi², A. Busse¹, J. Tomás-Rosselló¹, E. Saen-Miranda¹, S. Berterame¹, C. Donini⁴, ¹Global Challenges Sect., UNODC, Vienna, Austria, ²Dipendenza, ASL Roma C, Rome, ³Scienze Farmaceutiche, U. degli Studi di Bologna, Rome, ⁴Genetica Biologia dei Microrganismi Antropologia Evoluzione, U. degli Studi di Parma, Parma, Italy
- 164 *Adolescent patients with conduct and substance problems and adolescent controls: Examining perpetrator type and physical and sexual abuse*
E.F. Upwood, S.K. Mikulich-Gilbertson and T.J. Crowley, Division of Substance Dependence, Psychiatry, University of Colorado School of Medicine, Denver, CO
- 165 *Adolescent patients with serious substance and conduct problems and siblings: Directives for retained DNA*
M.E. Coors¹, K.M. Raymond², S.K. Mikulich-Gilbertson², S.K. Stover² and T.J. Crowley², ¹Center for Bioethics, University of Colorado at Denver School of Medicine, and ²Division of Substance Dependence, Psychiatry, University of Colorado at Denver, Denver, CO
- 166 *Adolescents with attention deficit disorder and co-occurring substance use disorders: Referral sources and recruitment in a multi-site clinical trial*
G. Bailey³, W. Jaffee¹, R. Weiss¹, M. Lohman² and P. Riggs², ¹ADATP, Harvard Medical School, McLean Hospital, Belmont, MA, ²Psychiatry, University of Colorado School of Medicine, Denver, CO and ³Stanley Street Treatment and Resources, Fall River, MA
- 167 *One-year post-treatment follow-up in adolescents treated for depression and substance abuse*
P. Riggs, S.K. Mikulich-Gilbertson, M. Lohman, C. Klein, R. Davies and S. Stover, Psychiatry, University of Colorado School of Medicine, Denver, CO

- 168 *The effectiveness of an integrated CBT intervention for co-occurring depression and substance misuse in young people*
L. Hides¹, D.I. Lubman¹, S. Carroll¹, L. Catania¹, N. Allen¹, F. Kay-Lambkin² and A. Baker²,
¹ORYGEN Research Centre, Psychiatry, University of Melbourne, Melbourne, VIC, and
²Centre for Mental Health Studies, University of Newcastle, Newcastle, NSW, Australia
- 169 *Self-efficacy mediates the relationship between depression and length of abstinence after treatment in youth but not adults*
D. Ramo^{1,2} and S.A. Brown^{3,4}, ¹Psychiatry, UCSF, San Francisco, ²SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, ³Psychology & Psychiatry, UCSD, and
⁴VASDHS, La Jolla, CA
- 170 *Brief intervention for drug-abusing adolescents*
K. Winters, ¹Psychiatry, University of Minnesota, Minneapolis, MN and ²Treatment Research Institute, Philadelphia, PA
- 171 *Effective thresholds of adolescent self-help meeting attendance and their predictors*
L. Passetti, M.L. Dennis, R. Funk, S.H. Godley and M.D. Godley, Chestnut Health Systems, Bloomington, IL
- 172 *Findings from the Strengthening Communities for Youth initiative: A cluster analysis of services received, their correlates, and how they are associated with outcomes*
M.K. White, M.L. Dennis and M. Ives, Chestnut Health Systems, Bloomington, IL
- 173 *Exposure to A-CRA treatment procedures as a mediator of the relationship between adolescent substance abuse treatment retention and outcome*
B. Garner, S.H. Godley, R. Funk, M. Dennis and M.D. Godley, Chestnut Health Systems, Bloomington, IL
- 174 *Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults*
M.P. Bogenschutz^{1,2}, R. Kushner^{1,2}, J.S. Tonigan² and G.E. Woody³, ¹Psychiatry, and
²CASAA, University of New Mexico, Albuquerque, NM and ³TRI, University of Pennsylvania, Philadelphia, PA
- 175 *Impact of therapeutic alliance on treatment outcome in opioid-dependent adolescents and young adults treated with buprenorphine*
A.A. Forcehimes¹, M.P. Bogenschutz¹, J.S. Tonigan¹ and G.E. Woody², ¹CASAA, University of New Mexico, Albuquerque, NM and ²University of Pennsylvania, Philadelphia, PA
- 176 *Changes in 12-step cognitions and practices among treatment-seeking adolescents*
J.S. Tonigan, A.A. Forcehimes and M.P. Bogenschutz, CASAA, University of New Mexico, Albuquerque, NM

Art and Addiction Exhibition

**Flamingo
9:00 AM - 6:00 PM**

Symposium VIII

**San Geronimo A
10:00 AM - 12:00 PM**

THE CONSEQUENCES OF CHRONIC CANNABIS ABUSE: FROM NEUROCHEMISTRY TO TREATMENT

Chair: Philip Terry

- 10:00 *Cognitive and neural consequences of chronic cannabinoid exposure: Evidence from animal studies*
Paul Mallet, Wilfrid Laurier University, Waterloo, Ontario, Canada
- 10:25 *The effects of chronic cannabis use on cognition, and the brain changes associated with altered psychological function*
Deborah Yurgelun-Todd, McLean Hospital, Belmont, MA
- 10:50 *Long-term cannabis use and the risk of psychosis and other mental health problems*
Louisa Degenhardt, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
- 11:15 *The impacts of long-term cannabis use on the everyday lives of recreational users*
Philip Terry, Kingston University, Surrey, UK
- 11:40 *Cannabis use, addiction, and treatment*
Alan J. Budney, University of Arkansas, Center for Addiction Research, Little Rock, AR

Symposium IX

**San Geronimo B
10:00 - 11:00 AM**

NEONATAL RESPONSES TO MATERNAL SUBSTANCE USE

Chairs: Karol Kaltenbach and Loretta Finnegan

- 10:00 *Neonatal abstinence resulting from in-utero exposure to opioids/opiates: Assessment and determination of treatment*
Karol Kaltenbach, Thomas Jefferson University, Philadelphia, PA
- 10:20 *Effects of in-utero cocaine exposure on growth and neurobehavior of the neonate*
Emmalee Bandstra, University of Miami School of Medicine, Miller School of Medicine, Miami, FL
- 10:40 *Adverse effects on gestational and neonatal outcomes: Contributions from depression and antidepressant drugs*
Katherine Wisner, Western Psychiatric Institute and Clinic, Pittsburgh, PA

Oral Communications 7

**San Geronimo B
11:15 AM - 12:15 PM**

ALL BOTTLED UP: TREATMENTS FOR ALCOHOL DEPENDENCE AND PSYCHIATRIC COMORBIDITY

Chairs: Kyle Kampman and Ihsan Salloum

- 11:15 *Initiating acamprosate within versus post-detoxification in the treatment of alcohol dependence*
K.M. Kampman, H.M. Pettinati, K.G. Lynch, C. Dackis, T. Sharkoski, K. Kirchner, H. Xie
and C.P. O'Brien, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 11:30 *Safety of atomoxetine in ADHD patients with or without comorbid alcohol abuse and
dependence*
L. Adler¹, T. Wilens², S. Zhang³, T. Durell³, D. Walker³, L. Schuh³ and P. Trzepacz³,
¹New York University School of Medicine, New York City, NY, ²Harvard Medical School,
Boston, MA and ³Eli Lilly and Company, Indianapolis, IN
- 11:45 *Does alcohol use precipitate depression among patients with co-occurring bipolar and
substance use disorders?*
W. Jaffee¹, M. Griffin¹, R. Gallop², C. Meade¹, F. Graff⁴, R. Bender³ R. Weiss¹, ¹ADATP,
Harvard Medical School, McLean Hosp., Belmont, MA, ²Math and Statistics, West Chester U.
of PA, West Chester, and ³Psychology, Temple University, Philadelphia, PA, and ⁴Grad.
School of Applied and Professional Psychology, Rutgers University, New Brunswick, NJ
- 12:00 *Advantage of an integrated individual psychotherapy over treatment-as-usual for comorbid
bipolar and addictive disorders: Results from a randomized pilot study*
I.M. Salloum¹, A.B. Douaihy², T.M. Kelly², J.R. Cornelius² and L. Kirisci³, ¹Psychiatry,
University of Miami Leonard M. Miller School of Medicine, Miami, FL, ²Psychiatry,
University of Pittsburgh School of Medicine, and ³Pharmacy, University of Pittsburgh,
Pittsburgh, PA

Symposium X

**San Geronimo C
10:00 - 11:00 AM**

FUNCTIONAL AND CLINICAL RELEVANCE OF OPIOID RECEPTOR HETERODIMERS

Chair: Philip S. Portoghese

- 10:00 *Opioid receptor heterooligomers: Distinct pharmacological signaling units*
Susan R. George, University of Toronto, Toronto, ON, Canada
- 10:20 *Behavioral studies in rodents on analgesics that mediate their effects via heterodimeric opioid
receptors*
Sandra Roerig, Louisiana State University Health Sciences Center, Shreveport, LA
- 10:40 *Identification of clinically employed analgesics whose pharmacology is mediated through
putative heterodimeric opioid receptors*
Ajay Yekkirala, University of Minnesota, Minneapolis, MN

Oral Communications 8

San Geronimo C
11:15 AM - 12:15 PM

BONDING WITH CHEMISTRY

Chairs: Herbert Seltzman and Fred Nyberg

- 11:15 *Atropisomers as conformational probes of the human hCB1 cannabinoid receptor*
H.H. Seltzman, M.F. Brackeen, D.J. Watkins, J.P. Burgess, A.F. Gilliam, Y. Zhang, B.F. Thomas, T.L. Langston and H.A. Navarro, Center for Organic and Medicinal Chemistry, RTI International, Research Triangle Park, NC
- 11:30 *Molecular modeling-guided elucidation of dopamine transporter ligand binding sites: Development of an in silico "cocaine antagonist" screening tool*
C.K. Surratt¹, M. Indarte¹, J.D. Madura², Y. Liu¹ and Y. Huang¹, ¹Pharmaceutical Sciences, and ²Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA
- 11:45 *Discovery of a selective sigma-2 receptor ligand and the potential involvement of sigma-2 receptors in cocaine toxicity*
C.R. McCurdy^{1,2}, C. Mesangeau¹, S. Narayanan¹, J. Shaikh², N. Kaushal², R.R. Matsumoto² and J.H. Poupaert³, ¹Medicinal Chemistry, and ²Pharmacology, University of Mississippi, University, MS and ³Catholic University of Louvain, Brussels, Belgium
- 12:00 *The Substance P system as a target in the development of peptidomimetics acting as drugs for treatment of opioid addiction*
F.J. Nyberg, Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

Oral Communications 9

San Cristobal
10:00 AM - 12:00 PM

SEX DIFFERENCES WITH COCAINE

Chairs: Steve Kohut and Michael Mancino

- 10:00 *Sex and rearing condition affect generalization to direct and indirect dopamine agonists in adult rats discriminating cocaine*
S.J. Kohut¹, K.C. Rice² and A.L. Riley¹, ¹American University, Washington, DC, and ²NIDDK, Bethesda, MD
- 10:15 *Sex differences in non-reinforced responding for cocaine*
T.A. Kosten and X.Y. Zhang, Psychiatry, Baylor College of Medicine, Houston, TX
- 10:30 *Age and sex alter sensitivity to cocaine-conditioned reward in rats*
E. Zakharova, I. Kichko, G. Leoni and S. Izenwasser, Psychiatry, University of Miami Miller School of Medicine, Miami, FL
- 10:45 *Differential effect of estrous cycle on cocaine-primed reinstatement to food- and cocaine-seeking*
K.A. Kerstetter, V.R. Aguilar, A.B. Parrish and T.E. Kippin, Psychology, UCSB, Goleta, CA
- 11:00 *Neural correlates of stress-induced and cue-induced craving: Effects of gender and cocaine dependence*
M.N. Potenza¹, K.A. Hong¹, C.M. Lacadie², R.K. Fulbright², C.R. Li¹, K.L. Bergquist¹ and R. Sinha¹, ¹Psychiatry, and ²Diagnostic Radiology, Yale School of Medicine, New Haven, CT

- 11:15 *HPA axis responding in cocaine-dependent males and females*
M. Moran-Santa Maria, A.L. McRae, S.E. Back, A.E. Waldrop, S.M. DeSantis,
H.P. Upadhyaya, M.E. Saladin and K.T. Brady, Psychiatry and Behavioral Neurosciences,
Medical University of South Carolina, Charleston, SC
- 11:30 *Early and later abstinence in cocaine pharmacotherapy trials: Importance of gender in
predicting treatment outcome*
J.G. Plebani, K.M. Kampman, K.G. Lynch, H.M. Pettinati and C.P. O'Brien, Psychiatry,
University of Pennsylvania, Philadelphia, PA
- 11:45 *Gender differences in response to disulfiram treatment for cocaine dependence in methadone-
stabilized opioid- and cocaine-dependent individuals*
M.J. Mancino, Z. Feldman and A. Oliveto, Psychiatry, University of Arkansas for Medical
Sciences, Little Rock, AR

Late-Breaking Research News

San Cristobal
12:15 - 1:30 PM

Chair: Sari Izenwasser

Art and Addiction Exhibition

Flamingo
1:15 - 2:45 PM

THE NARCOTIC FARM: FACTS AND FICTIONS

Nancy D. Campbell

Grant-Writing Workshop (Pre-Registrants Only)

Las Olas
1:15 - 5:00 PM

Workshop VIII

San Geronimo A
8:00 - 10:00 PM

14TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chairs: Stacey Sigmon and Kelly Dunn

Workshop IX

**San Geronimo B
8:00 - 10:00 PM**

WHAT'S NEW AT NIDA AND NIH: A PEEK INTO THE BLACK BOX

Chairs: Nadine Rogers, Eliane Lazar-Wesley, Kristen Huntley and Mark Swieter

Workshop X

**San Geronimo C
8:00 - 10:00 PM**

INNOVATIVE TECHNOLOGY TRANSFER AND INFORMATION DISSEMINATION STRATEGIES: RESULTS FROM FIVE ATTC-SPONSORED INITIATIVES

Chairs: Anne Helene Skinstad and Paula K. Horvatic

The Native American cultural education program for non-native counselors: An innovative project that examines the impact of training on counselors and their Native American clients

Duane H. Mackey, University of South Dakota, Vermillion, SD

The United Nations project: Utilizing the TOT model and continuing consultation to promote the adoption of EBP's internationally

Thomas Freese, Pacific Southwest ATTC, University of California Los Angeles, Los Angeles, CA

Where's the neuroscience in our undergraduate and graduate programs? A survey of addiction educators across the United States

Nancy A. Roget, University of Nevada-Reno, Reno, NV

Training tips and lessons learned from the toolbox training programs: Promoting the adoptions of EBPs in Iowa's community-based treatment provider system

Anne-Helene Skinstad, Prairelands ATTC, Iowa City, IA

Implementing motivational interviewing utilizing clinical supervisors in community treatment agencies: A review of performance implementation/integration, resources and associated costs

Paula K. Horvatic, Mid-Atlantic ATTC, Virginia Commonwealth University, Richmond, VA

Workshop XI

**San Cristobal
8:00 - 10:00 P.M.**

CLINICAL TRIALS OF DRUG ABUSE PHARMACOTHERAPIES: TOOLS AND STRATEGIES TO ENSURE COMPLIANCE WITH CURRENT REGULATIONS

Chairs: Robert L. Walsh and Ivan D. Montoya

What's coming down the pike from the FDA?

Robert Walsh, NIDA, Bethesda, MD

How to comply with NIH policies for grants involving clinical trials

Ivan D. Montoya, NIDA, Bethesda, MD

Investigator's strategies to cope with clinical trial requirements

Frances Levin, Columbia University, New York, NY

Regulatory pitfalls observed in pharmacotherapy grant applications and how to avoid them

Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

A Web-based tool for collecting and reporting serious adverse events

Robert L. Walsh and Ivan D. Montoya, NIDA, Bethesda, MD

Discussion

Movie

**Auditorium
8:00 PM**

DAYS OF WINE AND ROSES

featuring Jack Lemmon and Lee Remick

Wednesday, June 18, 2008

Wednesday, June 18, 2008

POSTER SESSION III

**Expo Center
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Tuesday 1:00 PM
Must be removed by Wednesday 12:00 NOON**

GENETICS

- 1 *Prospective study of genetics informed consent rates for local study and also sharing with a national repository*
B. Ray¹, C. Jackson¹, R. Raugai¹, E. Ducate¹, D. Melia¹, P. Casadonte^{2,3}, J. Rotrosen^{2,3}, S. Linzy⁴, M. Adelson^{1,4} and M.J. Kreek¹, ¹Biology of Addictive Diseases, Rockefeller University, ²VA Medical Center, NY Harbor Healthcare Sys, and ³NYU Sch. of Med., NY, NY and ⁴Adelson Clinic for Drug Abuse, Treatment and Research, Las Vegas, NV
- 2 *Genetic variations affecting susceptibility to develop heroin addiction*
O. Levran¹, D. Londono², K. O'Hara¹, D.A. Nielsen¹, E. Peles³, J. Rotrosen^{4,5}, P. Casadonte^{4,5}, S. Linzy⁶, M. Randesi¹, J. Ott², M. Adelson^{6,3} M. Kreek¹, ¹Biol. of Addictive Dis., and ²Stat. Gen. Labs, Rockefeller U., ⁴VA NY Harbor Healthcare System, and ⁵Sch. Med., NYU, NY, NY, ^{3,6}Adelson Clinic, Sourasky Med. Ctr, Tel Aviv, Israel and Las Vegas, NV
- 3 *Pharmacogenomic study of opioid addicts non-responders to methadone treatment: Preliminary results*
F. Fonseca¹, A. Pastor², K. Langohr², R. Martín-Santos^{1,2}, M. Farre^{2,4}, R. de la Torre^{2,3} and M. Torrens^{1,5}, ¹Drug Addiction Unit, IAPS and, ²Pharmacology Unit, IMIM-Hospital del Mar, ³Experimental and Health Sciences, Pompeu Fabra U., ⁴Pharmacology and Psychiatry, Universitat Autònoma de Barcelona, ⁵Universitat Autònoma de Barcelona, Barcelona, Spain
- 4 *A haplotype implicated in cocaine dependence susceptibility is associated with reduced PDYN expression in human brain*
V. Yuferov¹, F. Ji¹, S. Morgello², A. Ho¹, J. Ott¹ and M.J. Kreek¹, ¹The Rockefeller University, and ²Mount Sinai Medical Center, New York, NY
- 5 *Citalopram and 5HT TC102: A Bayesian analysis*
C.E. Green³, F.G. Moeller¹, J.M. Schmitz¹ and D. Guo², ¹Psychiatry, ²Internal Medicine, and ³Pediatrics, University of Texas, Houston, TX
- 6 *Sexual dimorphism in the effects of Homer1a deletion upon the behavioral response to acute, but not repeated, cocaine*
A.W. Ary¹, M.C. Datko¹, P.F. Worley² and K.K. Szumlinski¹, ¹Psychology, University of California at Santa Barbara, Santa Barbara, CA and ²Neurosciences, The Johns Hopkins University School of Medicine, Baltimore, MD
- 7 *Effect of matrix metalloproteinase 9 gene expression on methamphetamine neurotoxicity*
Y. Liu¹, S. Brown², J. Shaikh², J.A. Fishback² and R.R. Matsumoto^{1,2}, ¹University of Oklahoma HSC, Oklahoma City, OK and ²University of Mississippi, University, MS

- 8 *Genetic vulnerability in alcohol intake relates to accumbens Homer expression and alcohol-induced neurochemical sensitization*

Z. Kapasova¹, S.P. Goulding², I. Obara² and K.K. Szumlinski², ¹Behavioral Neuroscience, Oregon Health and Science University, Portland, OR and ²Psychology, University of California at Santa Barbara, Santa Barbara, CA

- 9 *Altered pharmacokinetics of delta-9-tetrahydrocannabinol in CF-1 mice deficient in mdr1a P-glycoprotein*

A. Benyamina¹, L. Bonhomme-Faivre², M. Reynaud¹, R. Farinotti³ and C. Abbara², ¹Psychiatry, and ²Pharmacology, Paul Brousse Hospital, Villejuif, and ³Faculty of Pharmacy, University of Paris XI, Chatenay-Malabry, France

- 10 *Detection of significant association of ANKK1 and of a functional polymorphism with nicotine dependence in African American population*

M.D. Li¹, W. Huang¹, J.Z. Ma² and T.J. Payne³, ¹Psychiatry and Neurobehavioral Sciences, and ²Public Health Sciences, University of Virginia, Charlottesville, VA and ³ACT Center, University of Mississippi Medical Center, Jackson, MS

IMAGING

- 11 *Imaging of GABA-A benzodiazepine receptor availability in men and women smokers and nonsmokers: Relationship with subsyndromal anxiety and depression*

J. Batis¹, I. Esterlis¹, K.P. Cosgrove¹, F. Bois¹, S. Stiklus¹, T.A. Kloczynski¹, E. Perry¹, G.D. Tamagnan², J.P. Seibyl², S. Krishnan-Sarin¹, S. O'Malley¹ and J.K. Staley¹, ¹Psychiatry, Yale School of Medicine, West Haven, CT and ²Molecular Neuroimaging, New Haven, CT

- 12 *Arterial spin labeling imaging study of IV nicotine administration: Evidence of neurovascular decoupling?*

D. Olson, M. Rohan, N. Goletiani, E. Habecker, D. Keith, P. Renshaw and N. Mello, Brain Imaging Center and Alcohol and Drug Abuse Research Center, McLean Hospital/Harvard Medical School, Belmont, MA

- 13 *The correlation between cue-induced craving for Internet video game play and brain activation*

D. Han^{1,2}, M.A. Daniels¹, N. Bolo¹, L. Arenella³, I. Lyoo^{4,1} and P.F. Renshaw¹, ¹Brain Imaging Center, McLean Hospital, Belmont, and ³Natural Science, Bentley College, Waltham, MA, ²Chung Ang University Hospital, Seoul, and ⁴Psychiatry, Seoul National University Hospital, Seoul, South Korea

- 14 *Brain activation in preadolescent with low vs. high risk for subsequent substance abuse*

I. Ivanov, S. Clerkin, K. Schulz, J. Fan, J. Halperin and J. Newcorn, Mt. Sinai School of Medicine, New York, NY

- 15 *Addictive behavior is associated with changes in putamen dopaminergic function*

C.E. Wilcox³, M.N. Braskie¹, J.T. Kluth¹, J. Mitchell², H.L. Fields^{2,1} and W.J. Jagust^{1,3}, ¹UC Berkeley, Berkeley, ²EGCRC, Emeryville, and ³UCSF, San Francisco, CA

- 16 *Volumetric analysis of the striatum in methamphetamine abusers in early abstinence*

B. Lee¹, M. Tobias¹, S. Chakrapani¹, A.V. Bokarius¹, J. O'Neil¹, J. Monterosso¹, R.A. Poldrack^{2,4} and E.D. London^{1,3,4}, ¹Psychiatry and Biobehavioral Sciences, ²Psychology, ³Molecular and Medical, Pharmacology, and ⁴Brain Research Institute, University of California, Los Angeles, CA

- 17 *Proton MRSI of the human brain in early abstinence from methamphetamine*

J. O'Neill¹, M. Tobias², A. Bejjani², S. Tafazoli², B. Lee², M. Walker² and E.D. London², ¹Child Psychiatry, and ²Laboratory of Molecular Neuroimaging, University of California-Los Angeles Semel Institute for Neurosciences, Los Angeles, CA

- 18 *The influences of dopamine receptor D4 polymorphism on the brain structures and activity in methamphetamine-dependent subjects*
J. Hwang¹, D.H. Han², I. Lyoo¹ and P.F. Renshaw², ¹Psychiatry, Seoul National University Hospital, Seoul, South Korea and ²Brain Imaging Center, Mclean Hospital, Belmont, MA
- 19 *Brain activation in a cognitive control task correlates with outcome measures after cognitive behavioral treatment in cocaine-dependent individuals*
J. Brewer, P. Worhunsky, K.M. Carroll, B.J. Rounsaville and M.N. Potenza, Psychiatry, Yale University School of Medicine, New Haven, CT
- 20 *Prefrontal cortical changes in gray matter associated with cocaine addiction*
A. Straub, G. Pagnoni and C. Kilts, Emory University, Atlanta, GA
- 21 *Cocaine abstainers have greater gray and white matter densities than current cocaine users*
D.L. Dufault, C.A. Hanlon, M.J. Wesley and L.J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC
- 22 *Prolonged exposure to cocaine self-administration in rhesus monkeys induces a significant decrease in functional activity in the prefrontal cortex*
T.J. Beveridge, H.R. Smith, M.A. Nader and L.J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC
- 23 *The effects of prolonged exposure to cocaine self-administration on functional activity in monkey striatum*
H.R. Smith, T.J. Beveridge, M.A. Nader and L.J. Porrino, Wake Forest University Health Sciences, Winston-Salem, NC
- 24 *Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy*
S.A. Perrine, M.S. Michaels, E.M. Hyde, F. Ghoddoussi, M.E. Tancer and M.P. Galloway, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI

AMPHETAMINES: HUMAN STUDIES

- 25 *Behavioral and cardiovascular effects of intranasal d-amphetamine in humans*
J.A. Lile, T.R. Phillips, S. Babalonis, D.P. Wermeling, J.E. Joseph, C.R. Corbly, J. Clark, C.A. Martin and T.H. Kelly, University of Kentucky, Lexington, KY
- 26 *Differential effects of repeated intranasal methamphetamine administration*
M.G. Kirkpatrick^{1,2}, A.Y. Perez^{1,2}, E. Gunderson^{1,2}, R.W. Foltin^{1,2} and C.L. Hart^{1,2}, ¹College of Physicians and Surgeons of Columbia University, and ²The New York State Psychiatric Institute, New York, NY
- 27 *Effects of repeated intranasal methamphetamine on sleep*
A.Y. Perez, M.G. Kirkpatrick, E.W. Gunderson, R.W. Foltin and C.L. Hart, Psychiatry, Columbia University, New York, NY
- 28 *The effects of inhaled l-methamphetamine on athletic performance while riding a stationary bicycle*
F. Dufka², G. Galloway¹, M. Baggott¹ and J. Mendelson¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA and ²French American International School, San Francisco, CA
- 29 *Discriminative-stimulus effects of methamphetamine, d-amphetamine, methylphenidate and triazolam in humans*
R. Sevak¹, W.W. Stoops¹, L.R. Hays² and C.R. Rush^{1,2,3}, ¹Behavioral Science, ²Psychiatry, and ³Psychology, University of Kentucky, Lexington, KY

- 30 *d-Amphetamine modifies the discriminative-stimulus effects of methamphetamine in humans*
A.R. Vansickel^{1,2}, W.W. Stoops¹, P.E. Glaser³ and C.R. Rush^{1,2,3}, ¹Behavioral Science, ²Psychology, and ³Psychiatry, University of Kentucky, Lexington, KY
- 31 *Factors associated with cognitive dysfunction among methamphetamine users*
K.G. Heinzerling, S. Shoptaw, A. Swanson and E. Rotheram-Fuller, Family Medicine, University of California-Los Angeles, Los Angeles, CA
- 32 *Developing and testing of a novel virtual reality device in methamphetamine-dependent humans*
C. Culbertson¹, I. Zaharovits², R. De La Garza, II¹ and T. Newton¹, ¹Psychiatry and Biobehavioral Sciences, and ²Experimental Technology Center, University of California, Los Angeles, CA
- 33 *An examination of drug craving over time in abstinent methamphetamine users*
G. Galloway¹, E.G. Singleton², R.M. Dickerhoof¹, M.J. Baggott¹ and J.E. Mendelson¹, ¹Research Institute, California Pacific Medical Center, San Francisco, CA and ²The MayaTech Corporation, Silver Spring, MD
- 34 *Modafinil attenuates subjective effects of methamphetamine in methamphetamine-dependent research subjects*
R. De La Garza, T.F. Newton, T.S. Zorick and E.D. London, Psychiatry, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
- 35 *Open label modafinil for methamphetamine dependence: Safety and tolerability*
J.D. McGaugh, M. Mancino, W. Gentry, M. Chopra, C. Cargile and A. Oliveto, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR
- 36 *Changes in addiction severity in an open trial of long-acting injectable risperidone for methamphetamine dependence*
A.J. Saxon^{1,2}, C.W. Meredith^{1,2}, C. Jaffe², M. Cherrier^{2,1}, J. Robinson¹, E. Yanasak¹, A. Kennedy¹, L. Ferguson^{1,2}, C.A. Malte¹ and A. Tapp^{1,2}, ¹Mental Health, VA Puget Sound Health Care System, and ²Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA
- 37 *A controlled trial of flumazenil, gabapentin and hydroxyzine in treatment of methamphetamine dependence*
H.C. Urschel¹, L.L. Hanselka² and M. Baron³, ¹Urschel Recovery Science Institute, ²Research Across America, and ³University of Texas at Dallas, Dallas, TX
- 38 *Naltrexone for the treatment of amphetamine dependence: A randomized placebo-controlled trial*
N. Jayaram-Lindstrom¹, A. Hammarberg¹, O. Beck² and J. Franck¹, ¹Clinical Neuroscience, and ²Clinical Chemistry, Karolinska Institutet, Stockholm, Sweden
- 39 *Impact of change in incentives on retention and outcomes in a controlled trial of a medication regimen for treating methamphetamine dependence*
L.L. Hanselka¹, H.C. Urschel² and M. Baron³, ¹Research Across America, ²Urschel Recovery Science Institute, and ³University of Texas at Dallas, Dallas, TX
- 40 *Assessing paranoia in methamphetamine users: The Methamphetamine Experience Questionnaire*
M.H. Leamon¹, K. Flower², R.E. Salo¹, T.E. Nordahl¹, H.R. Kranzler³ and G.P. Galloway², ¹University of California, Davis, and ²California Pacific Medical Center, San Francisco, CA, and ³University of Connecticut, Farmington, CT
- 41 *Women methamphetamine users' narratives of maternal blame*
A.H. Brown and R.A. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

- 42 *Sexual behaviors among female methamphetamine users*
S.J. Cousins, A. Brown, J. Brummer, R. Gonzales, V. Pearce and R. Rawson, ISAP, University of California-Los Angeles, Los Angeles, CA
- 43 *Relationship between trauma histories and sexual behaviors among methamphetamine users*
J. Brummer, A. Brown, S. Cousins, R. Gonzales, V. Pearce and R. Rawson, ISAP, University of California-Los Angeles, Los Angeles, CA
- 44 *Stimulant treatment programs in New South Wales, Australia*
A. Dunlop^{1,3}, A. Wodak², T. Adam², A. Baker³, B. Tulloch¹ and R. McKetin⁴, ¹Drug & Alcohol Clinical Ser, Hunter New England Area Health Ser. Newcastle East, ²Drug & Alcohol Ser, St. Vincents Hospital, Sydney, ³Mental Health Studies, U. of Newcastle, and ⁴National Drug & Alcohol Research Centre, U. of New South Wales, Sydney, NSW, Australia

TREATMENT

- 45 *Relational discord at conclusion of treatment predicts future substance use for partnered patients*
W.H. Denton¹, P.A. Nakonezny¹, B.H. Adinoff¹ and K.M. Carroll², ¹University of Texas Southwestern Medical Center, Dallas, TX and ²Yale University School of Medicine, New Haven, CT
- 46 *Recovery-oriented systems of care: An examination of recovery support service types and client outcomes*
L. Mangrum, Addiction Research Institute, University of Texas, Austin, TX
- 47 *Patient and staff satisfaction in outpatient substance abuse treatment programs*
A. Kulaga¹, B. McClure¹, J. Rotrosen¹, P. Crits-Christoph², S. Ring-Kurtz², C. Temes² and R. Forman³, ¹Psychiatry, NYU School of Medicine, New York, NY, ²University of Pennsylvania, Philadelphia, PA and ³Alkermes, Inc., Boston, MA
- 48 *MMTP staff attitudes toward provision of medical and harm reduction services*
S. Deren¹, S.Y. Kang¹, M. Mino¹ and R. Seewald², ¹Center for Drug Use and HIV Research, NDRI, and ²Office of MMTP Administration, Beth Israel Medical Center, New York, NY
- 49 *Feedback and performance-based incentives for counselors: Response to a brief intervention for improving group attendance*
R. Vandrey and M.L. Stitzer, Johns Hopkins University, Baltimore, MD
- 50 *Preliminary description of South African substance abuse counseling workforce, their training background, and experience*
S. Rataemane¹, D.W. Watson^{2,4}, L. Rataemane³, R. Rawson² and W.J. McCuller⁴, ¹University of Limpopo, Pretoria, and ³Mental Health and Addiction Centre, Pretoria, South Africa and ²Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, and ⁴Friends Research Institute, Torrance, CA
- 51 *What do addiction clinicians untrained in Cognitive Behavioral Therapy (CBT) report about their use of and interest in CBT practices?*
M. Amodeo¹, J. Muroff¹, M.J. Larson² and E. Gerstenberger², ¹Boston University, Boston, MA and ²New England Research Institutes, Inc., Watertown, MA
- 52 *The addiction treatment roundtable*
S. Kellogg¹ and A. Tatarsky², ¹Psychology, New York University, and ²Harm Reduction Psychotherapy and Training Associates, New York, NY

- 53 *Drug treatment and data management: An analysis of information technology infrastructure*
J.P. Wisdom¹, J.H. Ford², D.L. Mackey³ and M.E. Wise², ¹Columbia University, New York, NY, ²University of Wisconsin, Madison, WI and ³Oregon Health and Science University, Portland, OR
- 54 *Measuring dissemination of evidenced-based practices: The creation and validation of the Survey of Practiced Research Efforts to Aid in Dissemination*
A.O. Wente, J.E. Hettema and J.L. Sorensen, Psychiatry, University of California, San Francisco, San Francisco, CA
- 55 *Construct and predictive validity of the URICA*
C. Field¹, B.A. Adinoff², T.R. Harris³, S.A. Ball⁴ and K.M. Carroll⁴, ¹Health Promotion and Behavioral Sciences, UT School of Public Health, ²Psychiatry, UT Southwestern Medical Center at Dallas and VA North Texas Healthcare System, ³Biostatistics, UT School of Public Health, Dallas, TX and ⁴Psychiatry, Yale University School of Medicine, New Haven, CT

SUBSTANCE ABUSE IN ADOLESCENTS II

- 56 *Examining the severity of alcohol use problems associated with DSM-IV abuse and dependence diagnostic categories using Item Response Theory*
H.L. Gelhorn¹, C. Hartman¹, J. Sakai¹, M. Stallings^{2,3}, S. Young², S.H. Rhee^{2,3}, R. Corley², J. Hewitt^{2,3}, C. Hopfer¹ and T.J. Crowley¹, ¹Psychiatry, University of Colorado School of Medicine, Denver, and ²Institute for Behavioral Genetics, and ³Psychology, University of Colorado, Boulder, Boulder, CO
- 57 *A latent class analysis of substance use patterns and mental health problems among youth in mental health treatment*
K.S. Riehm, R. Stephens, M. Schurig and B. Manteuffel, Macro International Inc., Atlanta, GA
- 58 *Expectancy, subjective response and alcohol involvement in childhood*
C. Chen¹, C.L. Storr², S.L. Huang¹, C.Y. Liu³ and W.J. Chen⁴, ¹Division of Mental Health and Substance Abuse Research, NHRI, Taipei, Taiwan, ²Mental Health, Johns Hopkins University, Baltimore, MD, ³Nursing, National Taipei College of Nursing, and ⁴Institute of Epidemiology, National Taiwan University, Taipei, Taiwan
- 59 *Trends in adolescent substance use, abuse, dependence, and treatment need between 1998 and 2005 in Kentucky*
M. Webster^{1,2}, D.B. Clark² and T.F. Garrity¹, ¹Behavioral Science, and ²Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 60 *Cross-cultural sex differences in adolescent substance use: Germany and the United States*
T.C. Link, Sociology, University of Kentucky, Lexington, KY
- 61 *Examination of ethnicity differences in risk-taking behavior within a community sample of youth*
E.K. Reynolds, F.L. Wang, L. MacPherson, M.S. Duplinsky and C.W. Lejuez, Center for Addictions, Personality, and Emotion Research, University of Maryland, College Park, MD
- 62 *Predicting sexual debut*
P. Cavazos-Rehg, M. Krauss, E. Spitznagel, L. Cottler and L. Bierut, Washington University School of Medicine, St. Louis, MO
- 63 *Impulsivity and delay discounting in drug-using and non-drug using adolescents*
S.K. Moore¹, L.A. Marsch¹, W.K. Bickel², G.J. Badger³ and A.J. Budney², ¹National Development and Research Institutes, NY, NY, ²University of Arkansas for Medical Sciences, Little Rock, AR, and ³Medical Biostatistics, University of Vermont, Burlington, VT

- 64 *Marijuana use, impulsivity, coping and gender in adolescents*
T.S. Schepis, A.E. Smith, D.A. Cavallo, A. McFetridge, T. Liss and S. Krishnan-Sarin,
Psychiatry, Yale University School of Medicine, New Haven, CT
- 65 *Adolescent coping and self-efficacy to resist marijuana use in the presence of negative emotion*
A.E. Smith, D.A. Cavallo, T. Schepis, A. McFetridge, T. Liss and S. Krishnan-Sarin,
Psychiatry, Yale University School of Medicine, New Haven, CT
- 66 *Parent monitoring at age 11 and subsequent onset of cannabis use: Results from a prospective study in two socially disparate communities*
K.M. Bohnert and N. Breslau, Epidemiology, Michigan State University, East Lansing, MI
- 67 *Nobody asked me: Substance use screening and HIV risk among high school students in Trinidad and Tobago*
M. Pantin, School of Public Health, Columbia University/NDRI/MHRA, Brooklyn, NY
- 68 *Tobacco and drug use across the transition from high school to college*
A.P. Anokhin, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 69 *Incidence and persistence of cannabis dependence among college students*
A. Arria¹, K.M. Caldeira¹, K.B. Vincent¹, K.E. O'Grady² and E.D. Wish¹, ¹Center for Substance Abuse Research, and ²Psychology, University of Maryland, College Park, MD
- 70 *Withdrawn*
- 71 *Neighborhood conditions and the first chance to try cannabis*
Y.G. Flores-Ortega, J.C. Anthony and the PACARDO research consortium, Epidemiology, Michigan State University, East Lansing, MI
- 72 *Predictors of early marijuana use and sex in the offspring of teenage mothers*
N.M. De Genna and M. Cornelius, Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 73 *Subjective reactions to cannabis remain associated with heaviness of use and cannabis abuse/dependence in adolescents/young adults after controlling for covariates*
J.D. Grant¹, J.F. Scherrer^{1,2}, A.E. Duncan¹, J.R. Haber³, T. Jacob³ and K.K. Bucholz¹,
¹Psychiatry, Washington University School of Medicine, and ²St. Louis VAMC, St. Louis, MO and ³Palo Alto VAHCS, Menlo Park, CA
- 74 *Efficacy of brief image-based interventions for emerging adults*
C.C. Werch^{1,3}, H. Bian¹, M. Moore², S. Ames³, C. DiClemente⁴, D. Thombs¹, S. Porkorny¹ and A. Mendez¹, ¹University of Florida, ²University of North Florida, and ³Mayo Clinic, Jacksonville, FL and ⁴University of Maryland, Baltimore County, Baltimore, MD
- 75 *Trajectories of adolescent cannabis use to problematic use in young adulthood*
W. Swift¹, C. Coffey², J.B. Carlin², L. Degenhardt¹ and G.C. Patton², ¹National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia and ²Murdoch Children's Research Institute, Melbourne, VIC, Australia
- 76 *Contingency management for community treatment-seeking adolescents with marijuana use disorders*
T.K. Killeen, H. Upadhyaya, A. Mcrae, A. Waldrop, C. Brown and K. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 77 *Disruptive behavior disorders influence response to contingency management among adolescent marijuana abusers*
J. VanScoyoc, C. Stanger, A. Budney and J. Thostenson, Center for Addiction Research, University of Arkansas, Little Rock, AR

- 78 *Interest in marijuana quit programs among adolescents seeking tobacco cessation treatment: Gender and ethnic differences*
E.T. Moolchan, C.C. Collins, C.S. Parzynski, S.J. Heishman and M.K. Leff, TTATRC, NIDA IRP, Baltimore, MD
- 79 *Multidimensional family therapy for severely impaired, dually diagnosed youth: A randomized controlled trial comparing outpatient and residential treatment*
H.A. Liddle¹, C.E. Henderson^{2,1}, G.A. Dakof¹, C.L. Rowe¹ and P.E. Greenbaum³, ¹Center for Treatment Research on Adolescent Drug Abuse, Miller School of Medicine at the University of Miami, Miami, FL, ²Psychology, Sam Houston State University, Huntsville, TX and ³Florida Mental Health Institute, University of South Florida, Tampa, FL
- 80 *Academic performance trajectories in college students: Relationships with alcohol and marijuana use, depression, anxiety, and behavioral dysregulation*
K. O'Grady¹, A. Arria², K. Caldeira², K. Vincent² and E. Wish², ¹Psychology, and ²Center for Substance Abuse Research, University of Maryland, College Park, MD
- 81 *Use of quantitative THC/creatinine ratio to refine urinalysis results in teen drug abuse studies*
R. Davies, S. Mikulich-Gilbertson, S. Stover and P. Riggs, Psychiatry, University of Colorado Denver School of Medicine, Denver, CO
- 82 *Double-blind fluoxetine in comorbid MDD-AUD adolescents*
J.R. Cornelius¹, O.G. Bukstein¹, I.M. Salloum², D.S. Wood¹ and D.B. Clark¹, ¹Psychiatry, University of Pittsburgh, Pittsburgh, PA and ²Psychiatry, University of Miami, Miami, FL

ALCOHOL

- 83 *Plasma, serum, and whole-blood ethanol concentrations: Effects of storage conditions and collection tubes*
J.F. McNeil, D.M. Penetar, E.T. Ryan and S.E. Lukas, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA
- 84 *Alpha-5/GABA(A) receptor mechanisms and the reinforcing effects of ethanol in monkeys*
D. Ruedi-Bettschen¹, S. Harper-Castle¹, T. Clayton², S. Rallapalli², J.M. Cook² and D.M. Platt¹, ¹New England Primate Research Center, Harvard Medical School, Southborough, MA and ²U. of Wisconsin, Milwaukee, WI
- 85 *Effects of naltrexone on the oral self-administration of ethanol+milk or milk alone in rats trained under a two-lever "choice" procedure*
C.A. Paronis, J. Bergman and N.S. Shaller, McLean Hospital, Harvard Medical School, Belmont, MA
- 86 *Extended-release naltrexone injectable suspension for treatment of alcohol dependence in urban primary care: A feasibility study, preliminary analysis*
E. Grossman, J.D. Lee, D. DiRocco, J. Rotrosen, L. Chuang, K. Hanley, D. Stevens and M.N. Gourevitch, New York University School of Medicine, New York, NY
- 87 *Ondansetron with olanzapine for the treatment of alcohol dependence: Preliminary clinical trial*
B.A. Johnson and N. Ait-Daoud, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA
- 88 *Use of dietary supplements by regular and non-regular female users of tobacco, alcohol, and caffeine*
L.B. Phipps, N. Karjane, L. Anderson, D. Stovall, D. Miles and D.S. Svikis, Institute for Women's Health, AWHARE Program, Virginia Commonwealth University, Richmond, VA
- 89 *Alcohol alters stance stability longer than subjective effects in healthy volunteers*
S.E. Lukas, D.M. Penetar and E.T. Ryan, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA

- 90 *Alcohol affects anxiety but not fear*
C.A. Moberg and J.J. Curtin, Psychology, University of Wisconsin, Madison, WI
- 91 *Are samples of subjects in clinical trials of pharmacotherapies for alcohol dependence representative of the general population of alcohol-dependent individuals?*
A.C. Andorn and H.D. Chilcoat, Research and Development, GlaxoSmithKline, Durham, NC
- 92 *Measurement properties of the WHOQOL-BREF in alcoholics using the Rasch model*
F.H. Kessler, N.S. Rocha, S. Faller, D. Benzano and F. Pechansky, Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 93 *The Neuropsychological Assessment Battery - Screening Module: Utility at treatment entry*
K. Grohman and E. Edwards, The Research Institute on Addictions, University at Buffalo, Buffalo, NY
- 94 *SBIRT outcomes in Houston: Initial report on a hospital-district program*
R.T. Spence¹, T. Bohman¹, K. Von Sternberg¹, M.M. Velasquez¹, V. Waters², K. McQueen², L. Wallisch¹, A. Yeung¹, A. Pittman¹ and M. Cook¹, ¹University of Texas, Austin, TX and ²Baylor College of Medicine, Houston, TX
- 95 *Expectancies of alcohol consumption among alcohol-dependent patients: Validation of the French version of the VAV questionnaire*
S. Balester Mouret, E. Languerand and P. Batel, UTAMA, APHP, Clichy, France
- 96 *Early outcomes of a 1-session intervention to prevent alcohol-exposed pregnancy in preconception women*
S. Ceperich, K. Ingersoll, M. Karakashian, J.K. Penberthy, L. Farrell, S. Fabbri, T. Ly, A. Kracen and C. Detrick, University of Virginia, Charlottesville, VA
- 97 *Mechanisms of a motivational interviewing intervention that reduced drinking and improved contraception*
K.S. Ingersoll¹, C.C. Wagner², S.D. Ceperich¹, K. von Sternberg⁴, M.B. Sobell³, M.M. Velasquez⁴, L.C. Sobell³, S. Agrawal¹ and A.C. Fansler¹, ¹Psychiatry, U. of Virginia, Charlottesville, and ²Rehabilitation Counseling, VCU, Richmond, VA, ³Psychology, Nova Southeastern U., Ft. Lauderdale, FL, and ⁴Social Work, U. of Texas, Austin, TX
- 98 *Treatment engagement as a mediator of outcome in the women's Recovery Group Study*
S.F. Greenfield^{1,2}, M.F. Lincoln¹, R. Popuch¹, L. Kuper¹, A. Cummings¹ and R. Gallop³, ¹Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, and ²Psychiatry, Harvard Medical School, Boston, MA, and ³Mathematics, Applied Statistics Program, West Chester University, West Chester, PA
- 99 *Hepatitis C among heavy alcohol consumers: Does it require treatment?*
E. Peyret², M. Pascal¹, A. Gauchet⁴, L. Gourarier³ and A. Hij¹, ¹General Hospital, Saint Dizier, ²APHP, and ³LA Terrasse, APHP, Paris, and ⁴Faculte DE Psychologie, Grenoble, France
- 100 *Interest of Fibroscan in the cohort of alcohol consumers with cirrhosis*
P. Melin¹, A. Gauchet² and A. Hij¹, ¹Internal Medicine, General Hospital, Saint Dizier, and ²Universite de Psychologie, Grenoble, France
- 101 *Understanding the latent structure of alcohol and cannabis problems in a community sample: A taxometric exploration*
T. Slade¹, M. Teesson¹ and A. Baillie², ¹National Drug and Alcohol Research Centre, University of New South Wales, and ²Psychology, Macquarie University, Sydney, NSW, Australia

- 102 *Risk factors associated with drinking and driving in Brazil*
F. Pechansky¹, L. Von Diemen¹, R. DeBoni¹, D. Bumaguin¹, I. Pinsky², M. Zaleski³,
R. Caetano⁴ and R. Laranjeira², ¹Psychiatry, Center for Drug and Alcohol Res, Federal U. of
Rio Grande do Sul, Porto Alegre, and ²Psychiatry, U. of São Paulo, São Paulo, ³Psychiatry, U.
of Santa Catarina, Florianopolis, Brazil and ⁴Epidemiology, U. of Texas SPH, Dallas, TX
- 103 *Gender and the alcohol-violence association in two cities of Peru*
M. Piazza, School of Public Health, Universidad Peruana Cayetano Heredia, Barranco, Peru
- 104 *Oppression among poor drug-using African American women in New York: Implications for
practice and policy*
E. Benoit, L. Windsor and E. Dunlap, Special Populations Office, National Development and
Research Institutes, Inc., New York, NY
- 105 *Religiosity and substance use in a community sample of adults*
C. Walker, T.A. Wills, M. Ainette and C. Isasi, Epidemiology and Population Health, Albert
Einstein College of Medicine, Bronx, NY

NICOTINE: HUMAN STUDIES

- 106 *A pilot study of topiramate for smoking cessation*
A. Hulbert^{1,2}, K. Drexler^{1,2}, J. Casarella², S. Salles², M. Vaughn^{1,2} and T. Carter², ¹Psychiatry
and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA and ²Addiction
Medicine, Veterans Affairs Medical Center, Decatur, GA
- 107 *The effects of acute varenicline administration on eating and smoking behavior*
W.W. Stoops¹, A.R. Vansickel^{1,2} and C.R. Rush^{1,2,3}, ¹Behavioral Science, ²Psychology, and
³Psychiatry, University of Kentucky, Lexington, KY
- 108 *N-Acetylcysteine for smoking reduction: A pilot study*
S. LaRowe^{1,2}, P.N. Mardikian¹, H. Upadhyaya¹, M. Corley¹ and R.J. Malcolm¹, ¹Psychiatry
and Behavioral Sciences, Medical University of South Carolina, and ²Mental Health Service
Line, Ralph H. Johnson VAMC, Charleston, SC
- 109 *A control trial of the feasibility of remote real-time monitoring of smoking*
P.A. Nuzzo¹, J. Dallery², S. McQueary¹, C.A. Martin¹, T.H. Kelly¹ and C.J. Wong¹,
¹Behavioral Science and Psychiatry, University of Kentucky, Lexington, KY and ²Psychology,
University of Florida, Gainesville, FL
- 110 *A single dose of nicotine enhances reward responsiveness in non-smokers: Implications for
development of dependence*
A.E. Evins, Psychiatry, Massachusetts General Hospital, Boston, MA
- 111 *Subliminal processing of smoking and affective stimuli in tobacco dependence*
A.M. Leventhal¹, A.J. Waters², B.G. Breitmeyer³, E.K. Miller⁴, E. Tapia³ and Y. Li⁴, ¹Center
for Alcohol and Addiction Studies, Brown U., Providence, RI, ²Medical and Clinical
Psychology, Uniformed Services U. of the Health Sciences, Bethesda, MD, ³Psychology, U. of
Houston, and ⁴The University of Texas-M.D. Anderson Cancer Center, Houston, TX
- 112 *Current tobacco use and other health risk behaviors in a primary care sample of women*
A. Alvanzo, D. Langhorst and D. Svikis, Virginia Commonwealth University, Richmond, VA
- 113 *An experimental investigation of a self-control mechanism underlying the detrimental effects of
dieting on concurrent smoking cessation*
D. Shmueli and J.J. Prochaska, Psychiatry, UCSF, San Francisco, CA

- 114 *Standard versus stringent CO cutoffs: Implications for smoking cessation outcomes*
D.O. Jackson¹, K.L. Cropsey², M.F. Weaver³, G.C. Villalobos³ and M.L. Stitzer⁴, ¹Psychology, and ²Psychiatry, University of Alabama at Birmingham, Birmingham, AL, ³Internal Medicine, Virginia Commonwealth University, Richmond, VA and ⁴Psychiatry, Johns Hopkins University, Baltimore, MD
- 115 *Effectiveness of a community pharmacist-based smoking cessation intervention: The STOP Study Phase IV*
B. Sproule^{1,2}, M.J. Costello¹, R. Dragonetti¹, L. Zawertailo^{1,2} and P. Selby^{1,2}, ¹Centre for Addiction and Mental Health, and ²University of Toronto, Toronto, ON, Canada
- 116 *Smokers know what they want, but do they know what they need?*
S. Hussain, L. Zawertailo, R. Dragonetti and P. Selby, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 117 *A meta-analysis of the use of Motivational Interviewing for smoking cessation*
C. Heckman, B.L. Egleston and M. Hofmann, Population Science, Fox Chase Cancer Center, Philadelphia, PA
- 118 *Internet-based contingency management for smoking cessation*
C.J. Wong¹, C.A. Martin¹, J. Dallery², T. Helmbrecht¹, G. Guenther¹, P.A. Nuzzo¹, M. Grabinski³ and T.H. Kelly¹, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Florida, Gainesville, FL and ³Red5Group, New York, NY
- 119 *An organizational change intervention to address smoking in drug abuse treatment*
J.R. Guydish¹, B. Tajima¹, D. Ziedonis² and L. Zammarelli³, ¹University of California, San Francisco, San Francisco, CA, ²University of Massachusetts Medical School, Worcester, MA and ³Willamette Family Inc., Eugene, OR
- 120 *Does participation in clinical trials research affect clinical practices related to smoking?*
B. Tajima, J.R. Guydish, K. Delucchi and E. Passalacqua, University of California, San Francisco, San Francisco, CA
- 121 *Lung cancer in the family: A teachable moment*
C.A. Martin¹, V. Luftman¹, T. Helmbrecht¹, G. Guenther¹, S. Arnold² and T. Mullett³, ¹Psychiatry, ²Internal Medicine, and ³Surgery, University of Kentucky, Lexington, KY
- 122 *Assessing stigma toward nicotine-dependent clients among social workers*
B.K. Ahmedani¹, S.P. Kubiak¹ and J. Anthony², ¹School of Social Work, and ²Epidemiology, Michigan State University, East Lansing, MI
- 123 *Smoking cessation and self-efficacy in methadone-maintained individuals: Brief computer-delivered motivation, with and without concomitant contingency management*
H. Durdle¹, S.J. Ondersma² and D.M. Ledgerwood², ¹Psychology, University of Windsor, Windsor, ON, Canada and ²Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 124 *Prize reinforcement for smoking cessation in methadone patients: Preliminary analysis*
D.M. Ledgerwood and M.K. Greenwald, Psychiatry, Wayne State School of Medicine, Detroit, MI
- 125 *Cigarette smoking among opioid-dependent clients in a therapeutic community*
J. Chun, N. Haug, J.R. Guydish, J. Sorensen and K. Delucchi, University of California, San Francisco, San Francisco, CA

PRESCRIPTION DRUG ABUSE

- 126 *Training medical residents to recognize and manage prescription opioid abuse among chronic pain patients*
E.W. Gunderson^{1,2}, P. Coffin¹, S. Polydorou¹, N. Chang¹ and F.R. Levin^{1,2}, ¹Columbia University, and ²NYS Psychiatric Institute, New York, NY
- 127 *Gender differences in prescription opioid use and misuse among chronic pain patients in an outpatient pain management clinic*
R. Payne, Medical University of South Carolina, Charleston, SC
- 128 *Opioid misuse, abuse, and dependence: Prevalence, measurement and factor structure among chronic pain patients in a large HMO*
C.J. Banta-Green¹, J.O. Merrill¹, S. Doyle¹, D.M. Boudreau² and D. Calsyn¹, ¹University of Washington, and ²Center for Health Studies, Seattle, WA
- 129 *Association between chronic pain and prescription drug abuse—cross-sectional analysis of a VA cohort*
W. Becker, R. Gallagher, J. Ross and D. Oslin, VISN 4 MIRECC, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
- 130 *Epidemiological trends in prescription drug misuse and abuse*
H.A. Spiller¹, D.J. Lorenz², J.E. Bailey³ and R.C. Dart^{3,4}, ¹KY Regional Poison Center, and ²U. of Louisville, Louisville, KY, ³Rocky Mountain Poison and Drug Center, Denver, CO and ⁴U. of Colorado Health Sciences Center, Denver, CO
- 131 *Prescription forgery of OxyContin® tablets in the USA*
J.D. Haddox and M.Y. Smith, Risk Management & Health Policy, Purdue Pharma L.P., Stamford, CT
- 132 *Detection of prescription opioid abuse/diversion using Research Abuse Diversion and Addiction-Related Surveillance (RADARS®) System data*
E.J. Campagna¹, J.E. Bailey¹ and R.C. Dart^{1,2}, ¹Denver Health-Rocky Mountain Poison and Drug Center, and ²University of Colorado Health Sciences Center, Denver, CO
- 133 *Demographic variables associated with prescription opioid-abuse and diversion detected by the RADARS® System*
A.E. Zosel^{1,2}, E. Campagna¹, J. Bailey¹ and R. Dart^{1,2}, ¹Rocky Mountain Poison & Drug Center, Denver Health, and ²University of Colorado Health Sciences Center, Denver, CO
- 134 *Spatial analysis of RADARS® System data to identify geographic hot spots of prescription opioid-abuse*
A.M. Montoya¹, S.L. Heltshe¹ and R.C. Dart^{1,2}, ¹Rocky Mountain Poison and Drug Center-Denver Health, and ²University of Colorado Health Sciences Center, Denver, CO
- 135 *Empirical validation of spatial cluster detection for monitoring local patterns of prescription opioid abuse*
S.F. Butler¹ and J.S. Brownstein², ¹Inflexxion, Inc, Newton, MA and ²Epidemico, LLC, Boston, MA
- 136 *Diversion of medically prescribed stimulants and analgesics by college students*
L. Garnier¹, A. Arria¹, K.M. Caldeira¹, K.B. Vincent¹, K.E. O'Grady² and E.D. Wish¹, ¹Center for Substance Abuse Research, and ²Psychology, University of Maryland, College Park, MD
- 137 *Drug abuse problems among medical and nonmedical users of prescription opioids*
C.J. Boyd and S.E. McCabe, UM Substance Abuse Research Center, University of Michigan, Ann Arbor, MI

- 138 *Non-medical use of pharmaceutical opioids among MDMA users in Ohio*
R. Daniulaityte, R. Carlson, R. Falck and J. Wang, Wright State University, Dayton, OH
- 139 *Heavy opioid and benzodiazepine abusers in Miami's club scene: Overlapping groups with drug-specific health markers*
S.P. Kurtz, J. Inciardi, H. Surratt and J. Kish, Center for Drug and Alcohol Studies, University of Delaware, Coral Gables, FL
- 140 *Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: A preliminary analysis among college students*
D.R. Sepulveda^{1,2}, L.M. Thomas^{1,2}, S.E. McCabe^{3,4}, J.A. Cranford³, C.J. Boyd^{3,4} and C.J. Teter^{1,2,3}, ¹Pharmacy, Northeastern U., Boston, and ²Alcohol & Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, ³Substance Abuse Research Center, and ⁴Institute for Research on Women and Gender, U. of Michigan, Ann Arbor, MI
- 141 *Diversion of prescribed stimulant medication for ADHD and its association with specific stimulant formulations: A preliminary analysis among college students*
L.M. Thomas^{1,2}, D.R. Sepulveda^{1,2}, S.E. McCabe^{3,4}, J.A. Cranford³, C.J. Boyd^{3,4} and C.J. Teter^{1,2,3}, ¹School of Pharmacy, Northeastern U., Boston, and ²Alcohol & Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, ³Substance Abuse Research Center, and ⁴Institute for Research on Women and Gender, U. of Michigan, Ann Arbor, MI

LITERATURE REVIEW

- 142 *Routes of nonmedical use/abuse of Oxycontin® (oxycodone HCl controlled-release tablets)*
M.Y. Smith, Risk Management & Health Policy, Purdue Pharma LP, Stamford, CT
- 143 *Impact of methadone and buprenorphine on mortality rate. A systematic review*
C. Denis, N. Roscop, E. Lavie, M. Fatseas and M. Auriacombe, Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France
- 144 *Fentanyl-related deaths: Abuse and off-label use of licit and illicit sources of fentanyl*
R.V. Fant, S.H. Schnoll, A.C. Buchman and J.E. Henningfield, Clinical Pharmacology and Risk Management, Pinney Associates, Bethesda, MD
- 145 *Adult women's alcohol abuse: Barriers to detection in primary healthcare settings*
V. Osborne, ¹Social Work, and ²Psychiatric Epidemiology, Washington University in St. Louis, St. Louis, MO
- 146 *Herpes simplex virus type 2 infection in drug and alcohol users in low- and middle-income countries*
A.M. Newberry¹, L. Sherbin Coffin¹, H. Hagan², D.C. Des Jarlais^{1,2,3} and D.C. Perlman^{1,2,3}, ¹Division of Infectious Diseases, Medicine, and ²Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, and ³Center for Drug Use and HIV Research, National Development and Research Institutes, Inc, New York, NY
- 147 *Drug use and syphilis in low- and middle-income countries: A systematic review*
L.S. Coffin¹, A. Newberry¹, H. Hagan², D.C. Des Jarlais^{1,2,3} and D. Perlman^{1,2,3}, ¹Medicine, and ²Baron Edmund de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, and ³Center for Drug Use & HIV Research, NDRI, Inc, New York, NY
- 148 *The relationship between stress, coping, substance abuse and HIV-risk behaviors among African American women*
L. Ruglass, Social Intervention Group, Columbia University, New York, NY

THEORETICAL/COMMENTARY

- 149 *Common principles imbedded in effective adolescent HIV prevention*
D. Flannery¹, M.J. Rotheram-Borus¹, B.L. Ingram² and A. Elkavich¹, ¹Semel Institute for Neuroscience and Behavior, Center for Community Health, University of California, and ²Graduate School of Education and Psychology, Pepperdine University, Los Angeles, CA
- 150 *HIV/AIDS among injecting drug users in Indonesia: The role of drug treatment*
A. Nurhidayat, G.E. Woody and D.S. Metzger, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 151 *Systems dynamic modeling as an approach to understanding the abuse and diversion of opioid analgesic products: Implications for risk management systems*
J.P. Fitzgerald, M.Y. Smith, A.T. Kline and J.D. Haddox, Risk Management, Purdue Pharma L.P., Stamford, CT
- 152 *Withdrawn*
- 153 *Accuracy of media reports concerning the abuse and diversion of OxyContin® (oxycodone HCl controlled-release) tablets*
A.T. Kline, M.A. Philbrook, M.Y. Smith and J.D. Haddox, Risk Management & Health Policy, Purdue Pharma LP, Stamford, CT
- 154 *Monitoring of federal surveys as a risk minimization action plan component: Applications and limitations*
S.H. Schnoll, R.V. Fant, M.E. Ertischek, A.C. Buchman and J.E. Henningfield, Risk Management Services, Pinney Associates, Bethesda, MD
- 155 *Implosion of the criminal justice system and reformulation of illicit drug markets in New Orleans following Hurricane Katrina*
B.D. Johnson and E. Dunlap, Special Populations Research, National Development and Research Institutes, New York, NY
- 156 *Key components of a critical race theory approach to the study of drug abuse disparities*
C.L. Ford, Epidemiology, Columbia University, New York, NY
- 157 *WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence*
N. Clark and V. Poznyak, Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland
- 158 *Past, present and predictions in the history of cocaine dependence treatments*
T. Llosa, Coca Medica, Lima, Peru
- 159 *Allá en Nueva York todo es mejor: A study on the movement of injecting drug users from Puerto Rico to the United States*
R. Torruella, ¹Social-Personality Psych., CUNY, and ²Behavioral Science Training, NDRI, New York, NY
- 160 *Application of principal stratification to control for institutionalization at follow-up in studies of substance abuse treatment programs*
B. Griffin, D.F. McCaffrey and A.R. Morral, RAND Corporation, Arlington, VA
- 161 *Public health system structure and activities as barriers to prenatal care for pregnant women who use drugs and alcohol*
S.C. Roberts, ¹DrPH Program, University California, Berkeley School of Public Health, Berkeley, CA and ²Alcohol Research Group, Emeryville, CA

- 162 *Barriers to the implementation of an integrated co-occurring disorders treatment model*
A.M. Williams¹, M.L. Smith², F. Lorenzi¹ and T.G. Durham¹, ¹The Danya Institute, Inc., Silver Spring, MD and ²District of Columbia, Department of Mental Health, Washington, DC
- 163 *Substance use disorder treatment in an era of integrated behavioral health care*
E. Lopez and H.W. Clark, SAMHSA, U.S. Department of Health and Human Services, Rockville, MD
- 164 *An alternative framework for measuring the economic cost of drug abuse*
R. Pacula¹, J. Ringel¹, S. Paddock¹, J. Arkes², C. Eibner¹, B. Kilmer¹, T. Bentley¹ and M. Suttrop¹, ¹Drug Policy Research Center, RAND Corporation, Santa Monica, CA and ²Naval Postgraduate School, Monterey, CA
- 165 *The business case for process improvement: Linking treatment access and retention to financial performance among substance abuse providers*
A. Quanbeck¹, L. Madden², J. Ford¹, J. McConnell³, D. Gustafson¹, E. Edmundson³ and D. McCarty³, ¹University of Wisconsin, Madison, WI, ²APT Foundation, New Haven, CT and ³Oregon Health Sciences University, Portland, OR
- 166 *Analytic approach for counselor training project with a successive cohort design*
C. Barrick and G. Homish, RIA, University at Buffalo, Buffalo, NY
- 167 *The effect of educational background and individual learning styles on substance abuse clinician training*
L. Slawiak and C. Barrick, RIA, University at Buffalo, Buffalo, NY
- 168 *Turning k on its head: Comments on use of an ED50 in delay discounting*
J.H. Yoon¹ and S.T. Higgins^{1,2}, ¹Psychiatry, and ²Psychology, University of Vermont, Burlington, VT
- 169 *Executive functioning and the treatment of drug addiction: A commentary*
A.M. Horton¹ and C.R. Reynolds², ¹Neuropsychology Laboratory, Psych Associates of Maryland, Towson, MD and ²Educational Psychology, Texas A&M University, College Station, TX
- 170 *Cannabis potency and contamination: Views of key experts*
P. Gates¹, W. Swift¹, J.A. McLaren¹, P. Dillon¹ and S. Allsop², ¹National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, and ²National Drug Research Institute, Curtin University, Perth, WA, Australia
- 171 *Using microsimulation modeling to capture heterogeneity in marijuana use*
S. Paddock¹, J. Arkes², T. Bentley¹, J. Caulkins³, C. Eibner¹, B. Kilmer¹, J. Ringel¹, M. Suttrop¹ and R. Pacula¹, ¹Drug Policy Research Center, RAND Corporation, Santa Monica, and ²Naval Postgraduate School, Monterey, CA and ³Carnegie Mellon University, Pittsburgh, PA

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS

Symposium XI

**San Cristobal
10:00 AM - 12:00 PM**

TRAFFICKING SIGNALS AND ADDICTIVE PROCESSES

Chairs: Kathryn A. Cunningham and Toni S. Shippenberg

- 10:00 *Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors*
Toni S. Shippenberg, NIDA, Intramural Research Program, Baltimore, MD
- 10:25 *Repeated exposure of methamphetamine or morphine differentially regulates AMPA receptor trafficking in limbic brain regions*
T. Celeste Napier, Rush University Medical Center, Chicago, IL
- 10:50 *Morphine-induced neuroplasticity at hippocampal synapses*
Jose Moron-Concepcion, University of Texas Medical Branch, Center for Addiction Research, Galveston, TX
- 11:15 *Plasticity of AMPA receptor transmission during cocaine withdrawal*
Marina E. Wolf, Chicago Medical School, Rosalind Franklin University, North Chicago, IL
- 11:40 *Discussant*
Kathryn A. Cunningham, University of Texas Medical Branch, Center for Addiction Research, Galveston, TX

Symposium XII

**San Geronimo A
10:00 AM - 12:00 PM**

ADVANCES IN THE DEVELOPMENT OF MEDICATIONS FOR COMORBID ADHD AND SUBSTANCE USE DISORDERS

Chairs: Petra Jacobs and Frances R. Levin

- 10:00 *Substance use and abuse in the MTA study sample*
Brooke S. Molina, University of Pittsburgh, Pittsburgh, PA
- 10:25 *Smoking cessation in adolescents with ADHD*
Himanshu P. Upadhyaya, Medical University of South Carolina, Charleston, SC
- 10:50 *Pharmacotherapies for ADHD in adolescents with SUD*
Paula Riggs, University of Colorado at Denver, Denver, CO
- 11:15 *Medication to treat adults with comorbid ADHD and SUD*
Frances R. Levin, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY
- 11:40 *Development of treatments for comorbid ADHD and SUD - Future directions*
Timothy E. Wilens, Harvard Medical School, Boston, MA

Oral Communications 10

San Geronimo B
10:00 AM - 12:00 PM

RAISING THE BAR: STIMULANT EFFECTS ON BEHAVIOR

Chairs: Paul Czoty and Summee Wee

- 10:00 *Bupropion differentially impacts responding for appetitive stimuli*
C.M. Reichel¹, J.E. Murray¹, A.W. Walker¹, K.M. Grant² and R.A. Bevins¹, ¹Psychology, University of Nebraska-Lincoln, Lincoln, NE and ²University of Nebraska Medical Center, Omaha, NE
- 10:15 *Some behavioral effects of modafinil in monkeys*
J. Bergman¹, J. Frasca¹, N. Shaller¹ and T.E. Prisinzano², ¹Psychiatry, Harvard Medical School/McLean Hospital, Belmont, MA and ²Medicinal Chemistry, University of Kansas, Lawrence, KS
- 10:30 *Effects of acute social stressors and enrichment on the reinforcing strength of cocaine in socially housed male monkeys*
P.W. Czoty¹, M. Icenhower¹, N.R. Garrett¹, J.E. Campbell¹, R.W. Gould¹ and M.A. Nader^{1,2}, ¹Physiology and Pharmacology, and ²Radiology, Wake Forest University School of Medicine, Winston-Salem, NC
- 10:45 *History of escalation of cocaine intake with extended access facilitates subsequent escalation of cocaine intake after prolonged drug withdrawal in rats*
S. Wee and G.F. Koob, The Scripps Research Institute, La Jolla, CA
- 11:00 *Cocaine esterase prevents ongoing intravenous cocaine self-administration in rats*
G.T. Collins¹, R.L. Brim¹, D. Narasimhan¹, R.K. Sunahara¹, C.G. Zhan² and J.H. Woods¹, ¹University of Michigan Medical School, Ann Arbor, MI and ²University of Kentucky, Lexington, KY
- 11:15 *Stress-induced potentiation of cued reinstatement of cocaine-seeking in an animal model of relapse*
D. Buffalari and R.E. See, Medical University of South Carolina, Charleston, SC
- 11:30 *Relationship between extinction responding and cue-induced reinstatement in cocaine self-administration in "low-anxiety" and "high-anxiety" rats*
B. Nic Dhonnchadha, S.J. Stutz and K.A. Cunningham, Center for Addiction Research, UTMB, Galveston, TX
- 11:45 *Comorbidity between mood and substance dependence disorders; behavioral phenotyping in laboratory rats*
F. Leri, S. Djazayeri, C. Allen, A.M. Levy and M. Sticht, Psychology, University of Guelph, Guelph, ON, Canada

Oral Communications 11

San Geronimo C
10:00 AM - 12:00 PM

DRUG INTERACTIONS

Chairs: Margaret Haney and William Fantegrossi

- 10:00 *Pharmacodynamic interactions of alprazolam in methadone and buprenorphine-naloxone patients*
S. Nielsen^{1,2,4}, N. Lintzeris^{3,4}, N.K. Lee¹, A.J. Bond⁴ and D.A. Taylor², ¹Turning Point Alcohol and Drug Centre, Fitzroy, ²Monash University, Melbourne, and ³Sydney South West Area Health Service, Sydney, VIC, Australia and ⁴Kings College, London, UK
- 10:15 *Smoking in methadone maintenance patients: Nicotine and methadone relationships*
A. Elkader^{1,2}, B. Sproule^{1,2}, B. Brands^{1,2} and P. Selby^{1,2}, ¹Centre for Addiction and Mental Health, and ²University of Toronto, Toronto, ON, Canada
- 10:30 *Naltrexone increases marijuana intoxication in humans*
M. Haney and Z.D. Cooper, Psychiatry, Columbia University, New York, NY
- 10:45 *Do cannabis users require less opioids to treat pain?*
M.C. Acosta^{1,2} and D.L. Haller^{1,2}, ¹St. Luke's-Roosevelt Hospital, and ²Columbia University, New York, NY
- 11:00 *Cocaine effects during d-amphetamine maintenance*
C.R. Rush^{1,2,3}, W.W. Stoops¹, P.E. Glaser² and L.R. Hays², ¹Behavioral Science, ²Psychiatry, and ³Psychology, University of Kentucky, Lexington, KY
- 11:15 *Adolescent nicotine exposure alters the aversive effects of cocaine in adult rats*
M. Hutchison and A.L. Riley, American University, Washington, DC
- 11:30 *The effects of CXCL12 on cocaine within the mesolimbic dopamine pathway*
J. Trecki^{1,3}, S.M. Rawls^{2,3} and E.M. Unterwald^{1,3}, ¹Pharmacology, Temple University School of Medicine, ²Pharmaceutical Sciences, Temple University School of Pharmacy, and ³Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 11:45 *Interaction of serotonin 5-HT_{2A} and 5-HT_{2C} receptors in DOI-elicited head twitch behavior in mice*
W.E. Fantegrossi^{1,2,3}, J. Simoneau² and J.H. Woods³, ¹Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, ²Division of Neuroscience, Yerkes National Primate Research Center, Atlanta, GA and ³Pharmacology, University of Michigan, Ann Arbor, MI

Workshop

Conference 8/9
12:00 - 1:30 PM

JOURNAL REVIEW LUNCHEON
(Pre-Registrants Only)

Symposium XIII

**San Cristobal
1:30 - 3:30 PM**

OPIOID ANALGESICS: PROTECTING THEIR USE AND PREVENTING ABUSE

Chairs: Sharon L. Walsh and Sidney H. Schnoll

- 1:30 *Abuse-resistant opioid formulations: Current status*
William K. Schmidt, NorthStar Consulting, LLC, Limerick NeuroSciences, Inc., Davis, CA
- 1:55 *Opioid analgesic abuse in patients with chronic non-cancer pain: Project Pain*
Deborah L. Haller, St. Luke's-Roosevelt Hospital Center Behavioral Science Research Unit, New York, NY
- 2:20 *Aberrant drug-taking behaviors in pain management: What do we know?*
Steve Passik, Memorial Sloan Kettering Cancer Center, New York, NY
- 2:45 *Abuse and diversion of prescription pain medications: Policy and clinical imperatives*
Aaron Gilson, University of Wisconsin-Madison, WHO Collaborating Center, Madison, WI
- 3:10 *Discussant*
Sidney Schnoll, Pinney Associates, Inc., Bethesda, MD

Oral Communications 12

**San Geronimo A
1:30 - 3:30 PM**

ALL MIXED UP: POLYDRUG ABUSE

Chairs: Kristen Anderson and Mary Waldron

- 1:30 *Polydrug use among club-going young adults*
C. Grov^{1,2}, B.C. Kelly^{1,3}, S.A. Golub⁴ and J.T. Parsons^{1,5}, ¹CHEST, ²NDRI, ⁴Queens College, and ⁵Hunter College, New York, NY and ³Purdue, West Lafayette, IN
- 1:45 *Treatment of attention-deficit hyperactivity disorder and subsequent cigarette smoking and substance use disorders in adolescent girls*
T.E. Wilens¹, J. Adamson¹, M.C. Monuteaux¹, S.V. Faraone², M. Schillinger¹, D. Westerberg¹ and J. Biederman¹, ¹Pediatric Psychopharmacology Research, Massachusetts General Hospital, Boston, MA and ²SUNY Upstate Medical University, Syracuse, NY
- 2:00 *Sexual risk behaviors and use of methamphetamines and other drugs among incarcerated female adolescents with an STD diagnosis*
J. Steinberg¹, M. Boudov¹, P. Kerndt¹, C. Grella² and C. Kadrnka³, ¹Sexually Transmitted Disease Program, Los Angeles County Department of Public Health, ²Integrated Substance Abuse Programs, University of California-Los Angeles, and ³Juvenile Court Health Services, Los Angeles County Department of Health Services, Los Angeles, CA
- 2:15 *10-year use patterns after adolescent SUD treatment: Impact on relationship status in adulthood*
K.G. Anderson¹ and S.A. Brown^{2,3}, ¹Psychology, Reed College, Portland, OR ²Psychology and Psychiatry, University of California, San Diego, La Jolla, CA and ³VA San Diego Healthcare System, San Diego, CA

- 2:30 *Cannabis and other illicit drug use predict delayed reproduction in men and women*
M. Waldron¹, A.C. Heath¹, M.T. Lynskey¹, K.K. Bucholz¹, P. Madden¹ and N.G. Martin²,
¹Psychiatry, Washington University School of Medicine, St. Louis, MO and ²Genetic
Epidemiology Unit, Queensland Institute of Medical Research, Brisbane, QLD, Australia
- 2:45 *Bang costs \$50 a bean: Sources of diverted prescription drugs in the Miami club culture*
J.A. Inciardi, S.P. Kurtz and H.L. Surratt, University of Delaware, Coral Gables, FL
- 3:00 *Substance use in the Basque region of France: Prevalence estimation and evaluation of the
CSAPA BIZIA-MDM prevention program*
J. Daulouede¹, J.L. Pradeille¹, A. Aguerretxe Colina¹, V. Beltran^{3,1}, C. Maitre¹, C. Olaizola¹,
M. Auriacombe³ and J. Swendsen², ¹Addiction Clinic Bizia, ²Université Bordeaux 2,
Bordeaux, and ³Addiction Psychiatry, Université Bordeaux 2, Bordeaux, France
- 3:15 *Highlights from the 2007 Ontario Student Drug Use and Health Survey*
B. Brands^{1,2,3}, A. Boak² and E. Adlaf^{2,3}, ¹Office of Research and Surveillance, Health Canada,
Ottawa, and ²Centre for Addiction and Mental Health, and ³University of Toronto, Toronto,
ON, Canada

Oral Communications 13

**San Geronimo B
1:30 - 3:30 PM**

GETTING UP TO SPEED ON STIMULANT MECHANISMS

Chairs: Rae Matsumoto and Amy Goodwin

- 1:30 *Lobeline attenuates METH-induced hyperactivity but does not alter METH-mediated contextual
conditioning in male and female periadolescent rats*
S. Harrod, I.D. Longacre and A.A. Basilakos, Psychology, University of South Carolina,
Columbia, SC
- 1:45 *Attenuation of methamphetamine-induced effects through antagonism of sigma receptors:
Evidence from in vivo and in vitro studies*
R. Matsumoto¹, J. Shaikh¹, L.L. Wilson¹, S. Vedam¹, C.R. McCurdy¹ and A. Coop²,
¹University of Mississippi, University, MS and ²University of Maryland, Baltimore, MD
- 2:00 *The dopamine D3 receptor antagonist SB277011A inhibits methamphetamine self-
administration and methamphetamine-triggered reinstatement of drug-seeking behavior in rats*
E.L. Gardner, A. Higley and Z. Xi, Neuropsychopharmacology, National Institute on Drug
Abuse, Baltimore, MD
- 2:15 *Enrichment-induced differences in plasma corticosterone: A potential mechanism for
differential responses to amphetamine in rats*
D.J. Stairs¹, M.A. Prendergast² and M.T. Bardo², ¹Psychology, Creighton University,
Omaha, NE and ²Psychology, University of Kentucky, Lexington, KY
- 2:30 *GABAergic modulators fail to attenuate the discriminative stimulus effects of cocaine in
baboons*
A.K. Goodwin and E.M. Weerts, School of Medicine, Johns Hopkins University,
Baltimore, MD
- 2:45 *Ovarian hormones modulate the within-animal relationships between dopamine cell number,
cocaine-stimulated behavior and dopamine release*
Q.D. Walker, M.L. Johnson, J.M. Caster and C.M. Kuhn, Pharmacology, Duke Medical
Center, Durham, NC

- 3:00 *Inhibition of GSK3 β attenuates cocaine-induced locomotion and reward in mice*
J. Miller^{1,2} and E.M. Unterwald^{1,2}, ¹Pharmacology, and ²Center for Substance Abuse Research,
Temple University School of Medicine, Philadelphia, PA
- 3:15 *Low, but not high, dose cocaine induces greater striatal expression of c-fos and zif268 in adolescents compared to adults*
J. Caster and C.M. Kuhn, Pharmacology, Duke University, Durham, NC

Oral Communications 14

San Geronimo C
1:30 - 3:30 PM

EXPRESSION SESSION: GENETICS OF DRUG ABUSE

Chairs: Jamie Mangold and Teresa Franklin

- 1:30 *DNA methylation of CpG dinucleotides in the μ -opioid receptor gene promoter region occurs in vivo and is increased in lymphocytes of Caucasian former severe heroin addicts*
D.A. Nielsen¹, V. Yuferov¹, S. Hamon², M. Rouault¹, C. Jackson¹, J. Ott² and M.J. Kreek¹,
¹Laboratory of the Biology of Addictive Diseases, and ²Laboratory of Statistical Genetics,
The Rockefeller University, New York, NY
- 1:45 *Association of P2RX7 gene with alcohol use in comorbid bipolar patients*
U.E. Busto, B. Yasseen, K. Yang, J. Kennedy and L.A. Zawertailo, Neuroscience, Centre for
Addiction and Mental Health, Toronto, ON, Canada
- 2:00 *DAT genotype underlies the intensity and direction of corticolimbic activation to smoking cues*
T. Franklin¹, Z. Wang², F. Lohoff¹, Y. Li¹, K. Kampman¹, W. Berrettini¹, C.P. O'Brien¹ and
A.R. Childress¹, ¹Psychiatry, and ²Radiology, University of Pennsylvania, Philadelphia, PA
- 2:15 *Association between cannabis-related behaviors and OPRM1 in the Nicotine Addiction Genetics project*
A. Agrawal¹, M. Pergadia¹, M. Lynskey¹, J. Wang¹, S. Saccone¹, J. Rice¹, R. Todd¹, A. Heath¹,
N. Martin², G. Montgomery², A. Goate¹ and P. Madden¹, ¹Washington University School of
Medicine, St. Louis, MO and ²Queensland Inst. Medical Research, Brisbane, QLD, Australia
- 2:30 *Significant association of bitter taste receptor genes with nicotine dependence in African Americans*
J.E. Mangold¹, Q. Xu¹, G. Chen¹, T.J. Payne² and M.D. Li¹, ¹Psychiatry and Neurobehavioral
Sciences, University of Virginia, Charlottesville, VA and ²Otolaryngology, University of
Mississippi, Jackson, MS
- 2:45 *Smoking cessation outcomes at end of treatment using nicotine replacement therapy:
A candidate gene association study*
L.A. Zawertailo^{1,3}, D.S. Lobo², J.L. Kennedy^{2,3} and P. Selby^{1,3}, ¹Addictions Program, Centre
for Addiction and Mental Health, ²Neurogenetics Program, Centre for Addiction and Mental
Health, and ³Faculty of Medicine, University of Toronto, Toronto, ON, Canada

- 3:00 *Comparison of the prevalence of serotonin 2A receptor (5-HT_{2A}R) polymorphisms in MDMA users versus controls*
N. Moukaddam¹, D. Guo², K.A. Cunningham³ and F.G. Moeller¹, ¹Psychiatry, and ²Internal Medicine, University of Texas Health Science Center-Houston, Houston, TX and ³Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical School, Galveston, TX
- 3:15 *Dopamine transporter 3'-UTR VNTR genotype is associated with behavioral inhibition—a pharmacogenetic study with acute d-amphetamine administration*
A. Hamidovic¹, E. Cook² and H. de Wit¹, ¹Psychiatry, The University of Chicago, and ²Psychiatry, University of Illinois at Chicago, Chicago, IL

Oral Communications 15

**San Cristobal
3:45 - 4:45 PM**

DOPAMINE RECEPTORS/TRANSPORTERS

Chairs: Annette Fleckenstein and Michael Baumann

- 3:45 *Peripheral administration of cocaine, acting via D2 dopamine receptors, causes the release of endogenous opioid peptides that activate mu receptors within the striatum and VTA*
A.R. Soderman and E.M. Unterwald, Pharmacology, Temple University School of Medicine, Philadelphia, PA
- 4:00 *Amphetamine and dopamine interfere with dopamine transporter oligomerization and trafficking*
M.E. Reith, N. Chen and S.Y. Cheng, Psychiatry, New York University School of Medicine, New York, NY
- 4:15 *Methylphenidate-induced alterations in VMAT-2 function: Role of dopaminergic and muscarinic receptors*
A. Fleckenstein^{1,2}, T. Volz¹, S. Farnsworth² and G. Hanson^{1,2}, ¹Pharmacology and Toxicology, and ²Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT
- 4:30 *Evidence that stimulant effects of modafinil in rats involve dopamine transporters*
M.H. Baumann¹, D. Zolkowska¹, R. Jain¹, J.S. Partilla¹, T.E. Prisizano² and R.B. Rothman¹, ¹Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD and ²Medicinal and Natural Product Chemistry, University of Iowa, Iowa City, IA

Oral Communications 16

**San Geronimo A
3:45 - 4:45 PM**

NEUROBIOLOGY

Chairs: Gerald Zernig and Usoa Busto

- 3:45 *Cerebral morphological changes in human MDMA (ecstasy) polydrug users: A voxel-based morphometry study*
B. Cabaniss, N.D. Woodward, A.L. Bauernfeind, M.S. Dietrich and R. Cowan, Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN
- 4:00 *Nucleus accumbens core acetylcholine is selectively activated during drug- vs food-reinforcement acquisition*
G. Zernig, C.A. Crespo, P. Stöckl, K. Zorn and A. Saria, Psychiatry, Medical University Innsbruck, Innsbruck, Austria

- 4:15 *Ethanol increases extracellular glutamate levels in the ventral tegmental area via D1 receptor activation*

M.F. Olive and W.C. Griffin, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

- 4:30 *Dysfunctional reward processing in alcohol dependence assessed by functional magnetic resonance imaging in combination with a dopaminergic probe*

X.L. Balducci^{1,2,3}, T.W. Schmitz¹, B.A. Sproule^{1,3}, E. De Rosa¹, N. Herrmann^{1,2} and U.E. Busto^{1,3}, ¹University of Toronto, ²Sunnybrook Health Sciences Centre, and ³Centre for Addiction and Mental Health, Toronto, ON, Canada

Oral Communications 17

San Geronimo B

3:45 - 4:45 PM

SMOKING IN FEMALES

Chairs: Gabriele Fischer

- 3:45 *Impulsivity and cigarette smoking among pregnant women*

R. Rogers, S.T. Higgins and C.S. Thomas, University of Vermont, Burlington, VT

- 4:00 *Neonatal tobacco exposure in opioid-maintained pregnant women — Impact and consequences*

B. Winklbaur¹, A. Baewert¹, R. Jagsch³, K. Rohrmeister², C. Aschbach-Jachman¹, K. Thau¹ and G. Fischer¹, ¹Psychiatry and Psychotherapy, ²Neonatology, Medical University of Vienna, and ³Clinical, Biological and Differential Psychology, Faculty of Psychology, Vienna, Austria

- 4:15 *The relationship between cigarette use and maternal and neonatal outcomes among pregnant methadone-maintained patients*

M. Chisolm¹, M. Tuten², E. Strain² and H. Jones², ¹Johns Hopkins Bayview Medical Center, and ²Johns Hopkins University School of Medicine, Baltimore, MD

- 4:30 *Acute effects of progesterone on nicotine self-administration by female nonhuman primates*

N.K. Mello, J.L. Newman, I.M. Knudson, M. Kelly and P.A. Fivel, Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, MA

Symposium XIV

San Geronimo C

3:45 - 4:45 PM

INNOVATIVE APPLICATIONS OF TECHNOLOGY TO THE PREVENTION AND TREATMENT OF SUBSTANCE USE DISORDERS

Chairs: Lisa A. Marsch and Kathleen M. Carroll

- 3:45 *Computer-delivery of science-based drug abuse prevention for youth*

Lisa A. Marsch, National Development and Research Institutes, Center for Technology and Health, New York, NY

- 4:05 *Technological innovations in behavioral treatments for cigarette smoking*

Jesse Dallery, University of Florida, Gainesville, FL and National Development and Research Institutes, Center for Technology and Health, New York, NY

- 4:25 *Effectiveness of computer-based training in cognitive behavioral therapy: Main outcomes from a randomized clinical trial*

Kathleen Carroll, Yale University School of Medicine, West Haven, CT

Wednesday, June 18, 2008

CPDD BUSINESS MEETING
(Members Only)

San Cristobal
5:00 - 6:00 PM

DINNER AND DANCING

San Geronimo Ballroom
7:30 - 10:30 PM

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSION

POSTER SESSION IV (Breakfast)

**Expo Center
8:00 - 10:00 AM**

**Odd-numbered posters manned first hour;
Even-numbered, second hour**

**Set-up time begins Wednesday 1:00 PM
Must be removed by Thursday 12:00 NOON**

DRUG INTERACTIONS

- 1 *Methodology for assessing cocaine's effect on individual and combined actions of endogenous pressor agents*
N. Lamarre^{1,2} and R.J. Tallarida^{1,2}, ¹Pharmacology, and ²Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 2 *D-Cycloserine augments extinction learning and delays re-acquisition of cocaine self-administration in squirrel monkeys*
C. Achat-Mendes¹, D.M. Platt¹, K.M. Kantak² and R.D. Spealman¹, ¹NEPRC, Harvard Medical School, Southborough, MA and ²Psychology, Boston University, Boston, MA
- 3 *N-methyl D-aspartate receptor regulation of amphetamine-induced behavioral and molecular activation*
R. Hazim^{1,3,4}, W.L. Sun^{1,3,4}, L. Zhou^{1,2}, V.Q. Jenab^{1,3} and S. Jenab^{1,3}, ¹Psychology, ²Biological Sciences, and ³Biopsychology/Behavioral Neuroscience Doctoral Subprogram, CUNY Hunter College, and ⁴Psychology Doctoral Program, CUNY Graduate School and University Center, New York, NY
- 4 *The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine self-administration in the rat*
J. Haggkvist¹, S. Lindholm² and J. Franck¹, ¹Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden and ²Safety Pharmacology, AstraZeneca R&D, Södertälje, Sweden
- 5 *Effects of norBNI on the self-administration of ethanol in cross- and in-fostered Lewis and Fischer female rats*
J.A. Rinker¹, K.M. Serafine¹, P.G. Roma¹, K. Cheng², K.C. Rice² and A.L. Riley¹, ¹Psychopharmacology Lab, Psychology, American University, Washington, DC and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD
- 6 *Effects of norBNI on ethanol-induced conditioned taste aversions in both in- and cross-fostered Lewis and Fischer female rats*
K.M. Serafine¹, J.A. Rinker¹, P.G. Roma¹, K. Cheng², K.C. Rice² and A.L. Riley¹, ¹Psychology- Psychopharmacology Laboratory, American University, Washington, DC and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD
- 7 *Disulfiram enhances subjective effects of dextroamphetamine in humans*
R.A. Sewell¹, K. Hill¹, J. Poling¹, T.R. Kosten² and M. Sofuoglu¹, ¹Psychiatry, VA Connecticut Healthcare/Yale University School of Medicine, West Haven, CT and ²Psychiatry, Baylor College of Medicine, Houston, TX
- 8 *Effect of alcohol dependence diagnosis on efficacy of disulfiram in methadone-stabilized cocaine-dependent volunteers*
A. Oliveto, M.J. Mancino and Z.L. Feldman, Psychiatry, UAMS, Little Rock, AR

- 9 *Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers*
B.A. Kleykamp, R.R. Griffiths and M.Z. Mintzer, School of Medicine, Johns Hopkins University, Baltimore, MD
- 10 *Acamprosate efficacy in alcohol-dependent patients: Effect of nicotine and illicit substance use on treatment response*
B.J. Mason¹ and P. Leher², ¹Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA and ²Statistics, University of Mons, FUCAM, Mons, Belgium
- 11 *Comparing behavioral correlates of EEG variations between stimulant users, alcoholics and community controls*
S.J. Nixon¹, R.A. Prather¹ and N.A. Ceballos², ¹Psychiatry, University of Florida, Gainesville, FL and ²Psychology, Texas State University, San Marcos, TX

CLUB DRUGS

- 12 *The acute subjective effects of benzylpiperazine in healthy females*
H. Lee¹, J. Lin¹, N. Bangs¹, H. Hsiao¹, J. Krstik¹, I.J. Kirk² and B.R. Russell¹, ¹School of Pharmacy, and ²Research Centre for Cognitive Neuroscience, Psychology, The University of Auckland, Auckland, New Zealand
- 13 *Acute effects of MDMA on emotional processing*
G. Bedi and H. de Wit, Psychiatry, University of Chicago, Chicago, IL
- 14 *Alpha-1 noradrenergic receptors contribute to psychostimulant-like effects of MDMA in humans*
M. Baggott^{1,2}, G.P. Galloway¹, M. Jang¹, R. Didier¹ and J.E. Mendelson¹, ¹California Pacific Medical Center, San Francisco, CA and ²Helen Wills Neuroscience Institute, UC Berkeley, Berkeley, CA
- 15 *Cannabis use disorders affect the psychological consequences of MDMA*
A. Milosevic¹, L. Sander¹, H. Durdle¹, L.H. Lundahl¹, M.E. Tancer¹ and C.E. Johanson², ¹Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI and ²Loyola University, Chicago, IL
- 16 *Psychiatric disorders and health characteristics in MDMA users: Results from the NESARC*
N. Niv¹, D. Sarkisyan¹, U. Warda¹, C. Grella¹, A. Moore^{1,2} and M. Karno¹, ¹Integrated Substance Abuse Programs, and ²Division of Geriatrics, University of California-Los Angeles, Los Angeles, CA
- 17 *MDMA (ecstasy) produces withdrawal-like aftereffects in non-dependent users*
T. Justus¹, M. Baggott^{1,2}, A. Kielstein³, J.R. Coyle¹, J.C. Lopez¹, K.I. Bolla⁴, G.P. Galloway¹, J.E. Mendelson¹, ¹Addiction Pharm. Res. Lab, CA Pacific Med. Ctr. Res. Instit, San Francisco, CA, ²Helen Wills Neurosci. Instit., U. of CA, Berkeley, CA, ³Tagesklinik an der Sternbrücke, Magdeburg, Germany, ⁴Neurology, Johns Hopkins U. School of Med., Baltimore, MD
- 18 *Brief motivational intervention for ecstasy users: A pilot randomized trial*
G. Martin and J. Copeland, NCPIC, UNSW, Sydney, NSW, Australia
- 19 *The Marquis reaction as a harm reduction element in party atmospheres: An assessment of the on-site testing of ecstasy tablets*
J. Pradeille¹, N. Chakroun², V. Beltran^{3,1}, A. Aguerretxe-Colina¹, M. Auriacombe³ and J.P. Daulouede¹, ¹Addiction Clinic BIZIA, Bayonne, ²University of Clermont-Ferrand, UMR 6024, National Center for Scientific Research [CNRS], Clermont-Ferrand, and ³Addiction Psychiatry, JE2358, INSERM IFR 99, U. Victor Segalen Bordeaux 2, Bordeaux, France

BEHAVIOR

- 20 *D-serine reduces spatial learning and memory deficits by γ -hydroxybutyric acid in adolescent rat*
R. Sircar, D. Sircar and L. Wu, Psychiatry, The Zucker Hillside Hospital/Albert Einstein College of Medicine, Glen Oaks, NY
- 21 *Periadolescent male, but not female rats, acquire METH-induced CTA when the CS-US trace interval is extended beyond two hours*
R.T. Lacy, I.D. Longacre, L. Ballina and S. Harrod, Psychology, University of South Carolina, Columbia, SC
- 22 *Repeated methamphetamine produces time-dependent changes in accumbens dopamine and glutamate*
K.D. Lominac and K.K. Szumlinski, Psychology, University of California at Santa Barbara, Santa Barbara, CA
- 23 *Pre-exposure to methamphetamine impairs sexual motivation but not sexual performance*
B.L. Bolin and C.K. Akins, Psychology, University of Kentucky, Lexington, KY
- 24 *Sex differences in the development of cocaine-induced stereotyped behavior*
L. Zhou^{2,3}, W.L. Sun^{1,3}, J. Liu², Y.X. Liang², M. Timothy², K. Weierstall^{1,3}, A.C. Minerly^{1,3}, S. Jenab^{1,3} and V. Quinones-Jenab^{1,3}, ¹Psychology, and ²Biology, Hunter College, and ³Graduate Center of The City University of New York, New York, NY
- 25 *Potentiation of cue-induced reinstatement of cocaine seeking in female rats by yohimbine*
M.W. Feltenstein, M.J. Bongiovanni, A.R. Henderson, E.A. Byrd and R.E. See, Neurosciences, MUSC, Charleston, SC
- 26 *Effects of a differential-reinforcement-of-alternative-behavior schedule of alternative nondrug reinforcement on cocaine self-administration in rats*
M.G. LeSage, ¹Medicine, Minneapolis Medical Research Foundation, and ²Medicine, University of Minnesota, Minneapolis, MN
- 27 *Food restriction affects cocaine-induced priming but not maintained cocaine self-administration in rats*
V.L. Tsibulsky, W.B. Buesing, M.K. Norman and A.B. Norman, Psychiatry, University of Cincinnati, Cincinnati, OH
- 28 *Effect of the orexin 1 (hypocretin 1) receptor antagonist SB 334867 on high-fat food self-administration and relapse to food seeking in rats*
T. Adams-Deustch, S.G. Nair, S.A. Golden and Y. Shaham, Behavioral Neuroscience, NIDA/IRP/NIH/DHHS, Baltimore, MD
- 29 *Food restriction and high-fat diet differentially affect the behavioral effects of quinpirole and raclopride in rats*
M. Baladi¹ and C.P. France², ¹Pharmacology, and ²Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 30 *The effects of morphine on delay discounting in pigeons*
A. Acheson^{1,2} and C.P. France¹, ¹Pharmacology, and ²Research Imaging Center, University of Texas Health Science Center at San Antonio, San Antonio, TX
- 31 *Effects of acute and chronic cocaine on self-control behavior*
K. Dandy¹, J. Higa⁴, G. King³ and M. Gatch^{2,1}, ¹Psychology, Texas Christian University, and ²Pharmacology, University of North Texas Health Science Center, Fort Worth, TX, ³University of Hawaii, and ⁴University of Hawaii-Honolulu Community College, Honolulu, HI

- 32 *Impulsivity predicts the escalation of cocaine self-administration in female rats*
J.J. Anker¹, J.L. Perry², J.L. Pawlik¹ and M.E. Carroll¹, ¹University of Minnesota, St. Paul, MN and ²University of Kentucky, Lexington, KY
- 33 *Trait impulsiveness associates with cognitive deficits in non-human primates*
A.S. James¹, S.M. Groman¹, E. Seu¹, M.J. Jorgensen², L.A. Fairbanks² and J.D. Jentsch^{1,2}, ¹Psychology, and ²Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, CA
- 34 *Individual differences in impulsive-like behavior and sensitivity to money as a function of sensation-seeking status*
S. Babalonis^{1,2} and T.H. Kelly^{1,2,3}, ¹Behavioral Science, ²Psychology, and ³Psychiatry, University of Kentucky, Lexington, KY
- 35 *Methylphenidate self-administration in high- and low-impulsive sensation seekers using a progressive-ratio procedure*
D.C. Lee, G. Robbins, C.A. Martin, J.A. Lile and T.H. Kelly, Psychology, University of Kentucky, Lexington, KY
- 36 *Methylphenidate reinforcement in adults with and without Attention Deficit Hyperactivity Disorder*
S.H. Kollins, J. English, A.K. Chrisman, M. Hallyburton and R. Robinson, Psychiatry, Duke University Medical Center, Durham, NC

SUBSTANCE ABUSE IN ADOLESCENTS III

- 37 *The relationship between tobacco and cannabis use among teens in treatment for cannabis use disorders and ADHD*
C. Thurstone^{1,2}, M. deDios³ and P.D. Riggs², ¹Denver Health and Hospital Authority, and ²University of Colorado at Denver and Health Sciences Center, Denver, CO and ³Brown University, Providence, RI
- 38 *Correlates of ADHD comorbidity among adolescent smokers*
H. Upadhyaya¹, G.E. Gilbert², K.M. Gray¹, M. Carpenter¹, T. Randall¹ and D. Deas¹, ¹Psychiatry and Behavioral Sciences, and ²Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC
- 39 *Characteristics of psychopathy and delay discounting in adolescent smokers and nonsmokers*
S. Melanko^{1,2}, K. Leraas^{1,2}, C. Collins^{1,2}, M. Patak^{1,2} and B. Reynolds^{1,2}, ¹The Research Institute at Nationwide Children's Hospital, and ²Pediatrics, Ohio State University, Columbus, OH
- 40 *Delay discounting in children of smokers and nonsmokers*
C. Collins^{1,2}, K. Leraas^{1,2}, S. Melanko^{1,2} and B. Reynolds^{1,2}, ¹Pediatrics, Ohio State University, and ²The Research Institute at Nationwide Children's Hospital, Columbus, OH
- 41 *Delay discounting and self-reported stress in adolescents experimenting with cigarette smoking*
B. Reynolds^{1,2}, C. Collins^{1,2}, M. Patak^{1,2}, K. Leraas^{1,2}, S. Melanko^{1,2} and R. Penfold^{1,2}, ¹Pediatrics, Ohio State University, and ²The Research Institute at Nationwide Children's Hospital, Columbus, OH
- 42 *Impulsivity, self-efficacy and coping styles in adolescent tobacco users*
S. Krishnan-Sarin, A.E. Smith, D.A. Cavallo, T.S. Schepis, A. McFetridge and T. Liss, Psychiatry, Yale University School of Medicine, New Haven, CT

- 43 *Risk for preteen substance use from impulsivity, perceived safety, and others' use*
T.A. Ridenour^{1,2}, J.L. Maggs², M.T. Greenberg² and D.B. Clark¹, ¹Center for Education and Drug Abuse Research, University of Pittsburgh, Pittsburgh, PA and ²Prevention Research Center, The Pennsylvania State University, State College, PA
- 44 *Adolescents seeking cessation treatment: Level of tobacco dependence and reported morbidity*
S.J. Lo, C.C. Collins and E.T. Moolchan, TTATRC, NIDA IRP, Baltimore, MD
- 45 *Adolescent low-rate smokers desire and attempt to quit as much as heavier smokers*
M.J. Carpenter¹, A. Alberg¹, K. Cartmell¹, C. Vitoc², S. Biggers² and H. Upadhyaya¹, ¹Medical University of South Carolina, Charleston, SC and ²South Carolina Department of Health and Environmental Control, Columbia, SC
- 46 *Factors associated with tobacco smoking in Mexican high school students*
O. Campollo^{1,2}, C. Alvarez-Gonzalez¹, M. Bustos Gamiño¹, H. Sanchez¹ and J. Toro Guerrero¹, ¹Center of Studies on Alcohol and Addictions, Universidad de Guadalajara, and ²Clínica para dejar de fumar, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico
- 47 *Physician continuity and treatment outcome in an adolescent smoking cessation study*
A.S. Leinbach, M.J. Carpenter, G.E. Gilbert, E.M. Klintworth, K.M. Gray and H.P. Upadhyaya, Medical University of South Carolina, Charleston, SC
- 48 *A Web-based contingency management program with adolescent smokers*
K. Leraas^{1,2}, S. Melanko^{1,2}, C. Collins^{1,2}, J. Dallery³ and B. Reynolds^{1,2}, ¹Pediatrics, Ohio State University, and ²The Research Institute at Nationwide Children's Hospital, Columbus, OH and ³University of Florida, Gainesville, FL
- 49 *Does contingency management improve study retention and treatment outcomes in adolescent smoking cessation research?*
K.M. Gray¹, M.J. Carpenter^{2,1}, G.E. Gilbert³ and H.P. Upadhyaya¹, ¹Psychiatry and Behavioral Sciences, ²Hollings Cancer Center, and ³Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC
- 50 *Spending habits of adolescents participating in a contingency management-based smoking cessation research program*
D.A. Cavallo, T.S. Schepis, A.E. Smith, T.B. Liss, A.K. McFetridge, C. Nich, K.M. Carroll, B.J. Rounsaville and S. Krishnan-Sarin, Psychiatry, Yale University, New Haven, CT
- 51 *Preliminary study of varenicline for adolescent smoking*
D.C. Lott^{1,2,3} and C. Thurstone^{4,5}, ¹Linden Oaks Hospital, Naperville, ²University of Chicago, and ³University of Illinois at Chicago, Chicago, IL, ⁴University of Colorado at Denver and Health Sciences Center, and ⁵DHHA, Denver, CO
- 52 *Nicotine replacement therapy use and FTND scores in adolescents seeking tobacco cessation treatment*
C.E. Wiecezorek, C.C. Collins, C.S. Parzynski and E.T. Moolchan, TTATRC, NIDA IRP, Baltimore, MD
- 53 *Adolescent weight gain during the treatment phase of a nicotine replacement therapy trial: Relationship with medication compliance rates*
C.S. Parzynski, E.D. Thorner, C. Wiecezorek, M.J. Gasior, C.C. Collins and E.T. Moolchan, TTATRC, NIDA IRP, Baltimore, MD

PSYCHIATRIC COMORBIDITY II

- 54 *Contrasting models of genetic comorbidity for childhood conduct disorder and cannabis involvement*
M. Lynskey¹, A. Agrawal¹, K.K. Bucholz¹, P.A. Madden¹, A.C. Heath¹ and N.G. Martin²,
¹Washington University School of Medicine, St. Louis, MO and ²Queensland Institute of Medical Research, Brisbane, QLD, Australia
- 55 *Cannabis abuse and severity of psychotic and affective disorders in psychiatric inpatients*
G. Katz, R. Durst, E. Shufman, R. Bar-Hamburger and L. Grunhaus, Jerusalem Mental Health Center - Kfar Shaul Hospital, Jerusalem, Israel
- 56 *The role of anxiety in the treatment of marijuana dependence*
J.D. Buckner and K. Carroll, Yale University School of Medicine, New Haven, CT
- 57 *Scaling phenotype and envirotype for prediction of cannabis use disorder*
L. Kirisci, R. Tarter, M. Vanyukov, A. Mezzich, M. Reynolds and T. Ridenour, Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA
- 58 *Increased schizotypal traits and altered affect in young cannabis users*
R.K. Minas², R. Cowan¹ and S. Park², ¹Psychiatric Neuroimaging Program, and ²Psychology, Vanderbilt University, Nashville, TN
- 59 *Bupropion plus incentives for smoking reductions in outpatients with schizophrenia*
J.W. Tidey^{1,2}, D. Rohsenow^{2,1}, G. Kaplan³ and R. Swift^{2,1}, ¹Center for Alcohol and Addiction Studies, Brown University, and ²Research Service, VA Medical Center, Providence, RI and ³Mental Health Service, VA Boston Healthcare System, Brockton, MA
- 60 *High-dose nicotine and sensorimotor replacement effects on cognition in smokers with schizophrenia*
C.G. AhnAllen and J.W. Tidey, Center for Alcohol and Addictions Studies, Brown University, Providence, RI
- 61 *Smoking cues increase caffeine urges in outpatients with schizophrenia*
A.B. Adolfo¹, J.W. Tidey^{1,2} and C. Ahnallen¹, ¹Center for Alcohol and Addiction Studies, Brown University, and ²Research, Providence VA Medical Center, Providence, PR
- 62 *The Balloon Analogue Risk Task as a measure of impulsivity in alcohol-dependent individuals with bipolar disorder*
B.K. Tolliver, A.E. Waldrop and K.T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 63 *Quetiapine versus risperidone: A double-blind, randomized treatment trial in co-occurring bipolar disorder with cocaine or methamphetamine dependence*
V.A. Nejtek^{1,2}, M. Avila¹, L.A. Chen², A. Podawiltz¹, T. Zielinski², M. Djokovic¹, K. Kaiser¹ and A.J. Rush², ¹Psychiatry, University of North Texas Health Science Center, Fort Worth, TX and ²Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
- 64 *The effects of khat and posttraumatic stress on psychotic symptoms: A cross-sectional study in Somali combatants*
M. Odenwald¹, H. Hinkel², E. Schauer^{3,1}, F. Neuner¹, M. Schauer^{1,3}, B. Rockstroh¹ and T.R. Elbert¹, ¹Psychology, University of Konstanz, Konstanz, Germany, ²Multi-Country Demobilization and Reintegration Program, The World Bank, Goma, Congo, Dem. Rep. and ³Vivo Foundation, Ancona, Italy
- 65 *Lack of efficacy of fluoxetine in depressed cocaine-dependent subjects*
E.L. Winstanley, E. Strain and G. Bigelow, Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD

- 66 *Depressive symptoms and nonmedical use of prescription stimulants among college students*
C.J. Teter^{1,2,3}, S.E. McCabe^{3,4}, J.A. Cranford³ and C.J. Boyd^{3,4}, ¹School of Pharmacy, Northeastern University, Boston, and ²Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, ³Substance Abuse Research Center, and ⁴Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI
- 67 *Impulsivity and cocaine use as risk factors for high-risk sexual behavior in dually diagnosed outpatients*
K. Serowik¹, R.A. Black¹ and M.I. Rosen^{1,2}, ¹Psychiatry, Yale University School of Medicine, New Haven, CT and ²Psychiatry, VA Connecticut Healthcare System, West Haven, CT
- 68 *Treatment outcomes of methamphetamine-dependent adults with psychotic disorders*
S. Glasner-Edwards¹, L.J. Mooney¹, P. Marinelli-Casey¹, M. Hillhouse¹, A. Ang² and R.A. Rawson¹, ¹Integrated Substance Abuse Programs, and ²University of California-Los Angeles, Los Angeles, CA
- 69 *Cocaine/crack use is frequent among new admissions and predicts early dropout from psychiatric day treatment*
J. Spybrook¹, S. Magura^{1,2}, A. Rosenblum², C. Fong², C. Villano², H. Vogel² and T. Betzler³, ¹Evaluation Center, Western Michigan University, Kalamazoo, MI, ²National Development and Research Institutes, and ³Albert Einstein College of Medicine, NY, NY
- 70 *Baseline study of problem gambling and co-occurring substance use among students at the University of Iowa*
A.H. Skinstad¹, S. Hansen², K. Montes¹, M.O. Goransson¹ and K.M. Summers¹, ¹Community and Behavioral Health, College of Public Health, and ²Student Health Services, University of Iowa, Iowa City, IA
- 71 *Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs*
S.M. Gordon¹, A. Johnson², S. Greenfield^{3,6}, L. Cohen⁴, T. Killeen⁵ and P. Roman², ¹Seabrook House, Seabrook, NJ, ²University of Georgia, Athens, GA, ⁴Columbia University, New York, NY, ⁵Medical University SC, Charleston, SC, ³Harvard Medical School, Boston, and ⁶McLean Hospital, Belmont, MA

COCAINE: HUMAN STUDIES II

- 72 *The cocaine selective severity assessment: Self-report vs clinician-rating*
A. Umbricht, E.L. Winstanley, M.Z. Mintzer, E.C. Strain and G.E. Bigelow, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD
- 73 *The validity of measures for monitoring cocaine use in outpatient clinical trials*
W.V. Lechner¹, S.L. Hedden², R.J. Malcolm¹ and K. Hartwell¹, ¹Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC and ²Mental Health, Johns Hopkins Bloomberg School of Medicine, Baltimore, MD
- 74 *Monitoring daily self-reported cocaine use using Interactive Voice Response technology: Compliance and validation*
J. Lindsay, J.M. Schmitz and C.M. Green, University of Texas Health Science Center at Houston, Houston, TX
- 75 *Zero-inflation in ASI composite scores: Comparisons with concurrent validation measures*
K.G. Lynch^{1,2}, J.S. Cacciola^{2,1} and A.I. Alterman^{1,2}, ¹University of Pennsylvania, and ²Treatment Research Institute, Philadelphia, PA

- 76 *Reactive aggression and proactive aggression in suicidal ideation and attempts*
K.R. Conner^{1,2}, R.J. Houston³ and M.T. Swogger¹, ¹Psychiatry, University of Rochester Medical Center, Rochester, NY, ²VA Center of Excellence, Canandaigua, NY and ³Research Institute on Addictions, Buffalo, NY
- 77 *Clinical relationships between cognition, commitment language and behavioral change in cocaine-dependent patients*
P. Amrhein^{1,2}, E. Aharonovich², D. Hasin², A. Bisaga² and E. Nunes², ¹Psychology, Montclair State University, Montclair, NJ and ²Psychiatry, Columbia University, New York, NY
- 78 *Outpatient cocaine therapies: Pilot study on incentivizing study attendance and retention*
T. Polk^{1,3}, T. Gardner^{1,3}, K. McQueen^{2,4}, M. Stitzer⁵ and T. Kosten^{1,3}, ¹Psychiatry, and ²Medicine, Baylor College of Medicine, ³Michael E DeBakey VA Medical Center, Houston, and ⁴Ben Taub General Hospital, Houston, TX and ⁵Johns Hopkins University School of Medicine, Baltimore, MD
- 79 *Cocaine abstinence in a randomized controlled trial of 3 vs 9 months of voucher-based reinforcement therapy: Year 1 outcomes*
C.M. Carpenedo¹, B.E. Versek¹, E. Bresani¹, T.F. Case¹, J.E. Clement¹, M.C. Carter¹, B.J. Rosenwasser¹, K.L. Dugosh¹, K. Lynch^{2,1} and K.C. Kirby^{1,2}, ¹Behavioral Interventions, Treatment Research Institute, and ²University of Pennsylvania, Philadelphia, PA
- 80 *Randomized clinical trial of contingency management among parenting cocaine-dependent African American female recovery house residents*
L.E. Durant¹, J.L. Rounds-Bryant² and J. Dutta¹, ¹Duke University Medical Center, and ²Mental Health Solutions, Durham, NC
- 81 *Community Reinforcement Approach plus vouchers for cocaine addicts: Clinical variables outcomes*
O. Garcia-Rodriguez¹, R. Secades-Villa², J.R. Fernandez-Hermida² and J.L. Carballo², ¹Clinical Psychology, University of Barcelona, Barcelona, Spain and ²Psychology, University of Oviedo, Oviedo, Spain
- 82 *Cost-effectiveness of a contingency management intervention in a community setting*
R. Secades-Villa¹, O. Garcia-Rodriguez², J.R. Fernandez-Hermida¹ and E. Sanchez-Hervas³, ¹Psychology, University of Oviedo, Oviedo, ²Clinical Psychology, University of Barcelona, Barcelona, and ³Valencia State Health Agency, Valencia, Spain
- 83 *Contingency management and CBT in intensive outpatient treatment for cocaine dependence*
J.R. McKay, K.G. Lynch, D. Coviello, R. Morrison and C. Dackis, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 84 *A randomized controlled trial of a money-management-based intervention targeting substance use*
M.I. Rosen^{1,2}, K.M. Carroll^{1,2}, E.A. Stefanovics^{2,1} and R.A. Rosenheck^{2,1}, ¹Psychiatry, Yale University School of Medicine, New Haven, and ²Psychiatry, VA Connecticut Healthcare System, West Haven, CT
- 85 *A Transtheoretical Model group therapy for cocaine abusers*
M.M. Velasquez¹, A.L. Stotts², K.L. von Sternberg¹, C.L. Dorrill² and J.P. Carbonari³, ¹University of Texas-Austin, Austin, ²University of Texas Medical School-Houston, and ³University of Houston, Houston, TX

- 86 *Abstinence during contingency management treatment predicts abstinence at follow-up in three clinical trials with homeless cocaine-dependent persons*

R. Vuchinich¹, J. Milby¹, J. Schumacher¹, D. Wallace², S. Kertesz¹ and S. Mennemeyer¹,
¹University of Alabama at Birmingham, Birmingham, AL and ²RHO Federal Systems
Division, Inc., Chapel Hill, NC

- 87 *Employment-based abstinence reinforcement as a maintenance intervention for the treatment of persistent cocaine use in methadone patients: A molecular analysis*

A. DeFulio¹, M. Needham¹, W.D. Donlin², C.J. Wong³ and K. Silverman¹, ¹Johns Hopkins
University School of Medicine, Baltimore, MD, ²University of North Carolina Wilmington,
Wilmington, NC and ³University of Kentucky College of Medicine, Lexington, KY

OPIOIDS: HUMAN STUDIES II

- 88 *Selective GABA reuptake inhibition for methadone induction and early stabilization*

G. Gonzalez^{1,2}, M. Romero-Gonzalez^{1,2}, M. Randall^{1,2}, R. Desai^{1,2}, H. Patwa^{1,2}, H. Tokuno^{1,2},
R. Hart^{1,2}, J. Napoleone^{1,2} and I. Petrakis^{1,2}, ¹Yale University, New Haven, CT and ²VA CT
Healthcare System, West Haven, CT

- 89 *Poor objective sleep among methadone-maintained patients is associated with chronic pain but not with methadone dose*

E. Peles¹, S. Schreiber^{1,2}, R.B. Hamburger³ and M. Adelson¹, ¹Dr. Miriam & Sheldon G.
Adelson Clinic for Drug Abuse Treatment and Research, and ²Psychiatry, Tel-Aviv Sourasky
Medical Center, Tel Aviv, and ³Israel National, Anti-Drug Authority, Jerusalem, Israel

- 90 *Is methadone treatment and indication missing from the medical record? A patient safety issue*
A.Y. Walley, D. Farrar, D.M. Cheng, D.P. Alford and J.H. Samet, Section of General Internal
Medicine, Boston University School of Medicine, Boston, MA

- 91 *Consistent use of methadone maintenance is associated with lower cost to the managed care organization*

K. Stoller¹, A. Schuster^{2,3}, D.A. Tompkins¹, P. Fagan^{1,2}, L. Dunbar², C. Schmidt^{1,2} and
R. Brooner¹, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University School of
Medicine, Baltimore, ²Johns Hopkins HealthCare, LLC, Glen Burnie, and ³Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD

- 92 *Methadone vs. non-methadone patients in a therapeutic community: Test of equivalency*

J.L. Sorensen¹, S. Andrews¹, K.L. Delucchi¹, B. Greenberg², J. Guydish¹ and C.L. Masson¹,
¹Psychiatry, University of California, San Francisco, and ²Walden House Inc.,
San Francisco, CA

- 93 *A therapeutic workplace for the long-term treatment of drug addiction in methadone patients: Eight-year outcomes*

W.M. Aklin¹, C.J. Wong², D. Svikis³, M.L. Stitzer¹, G.E. Bigelow¹ and K. Silverman¹,
¹Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, ²Psychiatry, University of
Kentucky College of Medicine, Lexington, KY and ³Psychology, Virginia Commonwealth
University, Richmond, VA

- 94 *Predictors of treatment enrollment in syringe exchange participants*

V.L. King, J. Peirce, R. Brooner and M. Kidorf, Psychiatry, Johns Hopkins School of
Medicine, Baltimore, MD

- 95 *One-year-treatment outcomes for patients referred from syringe exchange versus other sources*

K.J. Neufeld, M. Cutler, J. Peirce, R. Brooner, V. King and M. Kidorf, Psychiatry, Johns
Hopkins University School of Medicine, Baltimore, MD

- 96 *Predictors of outcomes for opiate IDUs in methadone treatment*
K.F. Corsi, W.K. Lehman and R.E. Booth, Psychiatry, University of Colorado Denver Health Sciences Center, Denver, CO
- 97 *Relationship between patient satisfaction and methadone treatment outcomes*
S. Kelly¹, R.P. Schwartz¹, K.E. O'Grady² and B.S. Brown^{1,3}, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland, College Park, MD and ³University of North Carolina, Wilmington, NC
- 98 *Personality factors associated with methadone maintenance dose*
H.W. Murray¹, R.K. McHugh¹, J. Hogan¹, E. Behar², T. Markowitz¹ and M.W. Otto¹, ¹Boston University, Boston, MA and ²University of Illinois at Chicago, Chicago, IL
- 99 *Relation between vulnerable attachment styles and drug abuse among methadone maintenance treatment patients*
D. Potik, Y. Abramsohn, E. Peles, S. Schreiber and M. Adelson, The Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, Tel-Aviv, Israel
- 100 *Integrated psychiatric services are associated with improved service delivery and better treatment response*
R.K. Brooner, V. King, K. Neufeld, K. Stoller, J. Peirce, M. Kidorf, M. Clark and W. Aklin, School of Medicine, Johns Hopkins University, Baltimore, MD
- 101 *Dissolution of a VA harm reduction program for opiate agonist treatment: Impact on substance use and service utilization*
B.J. Hartzler¹, D. Calsyn^{1,3}, A. Cotton^{2,3}, R. Guerra² and N. Gignoux², ¹Alcohol & Drug Abuse Institute, University of Washington, ²Addiction Treatment Center, VA Puget Sound Healthcare System, and ³Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA
- 102 *Using an Internet-based platform to deliver intensified services in treatment seeking opioid-dependent patients*
K. Kindbom¹, V. King¹, K. Stoller¹, R. Brooner¹, M. Kidorf¹, S. Hursh² and T. Brady³, ¹School of Medicine, Johns Hopkins University, and ²Institute for Behavior Resources, Baltimore, MD and ³CRC Health Group, San Jose, CA
- 103 *Mobile telephones: Feasibility for prospective follow-up of injecting-heroin users in Sweden*
A. Hakansson, C. Wallin, P. Isendahl and M. Berglund, Lund University, Malmö, Sweden
- 104 *Impact of telephone reminder calls on adherence to scheduled counseling sessions in a methadone substitution clinic*
M.L. Cutler, R. Brooner, M. Kidorf and K. Neufeld, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD
- 105 *Abstinence and use of benzodiazepines are major risk factors for fatal opiate overdose: Objective evidence from blood and segmental hair analysis*
J.J. Strandberg¹, K. Alkass¹, F.C. Kugelberg², I. Nyström², R. Kronstrand² and H. Druid¹, ¹Forensic Medicine, Karolinska Institutet, Stockholm, Sweden and ²Forensic Genetics and Toxicology, National Board of Forensic Medicine, Linköping, Sweden
- 106 *Potential triggers for overdose among individuals with substance dependence*
J.D. Wines¹, R. Saitz², D. Allensworth-Davies³, D.M. Cheng³ and J.H. Samet², ¹Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA, ²Medicine, Boston Medical Center-Boston University School of Medicine, Boston, MA and ³Data Coordinating Center, Boston University School of Public Health, Boston, MA

- 107 *Risk factors for oxygen desaturation after injection of heroin or methadone: A laboratory model of overdose susceptibility*
N. Lintzeris^{1,2}, T.B. Mitchell¹, J. Strang¹, S. Mayet¹ and L. Forzisi¹, ¹National Addiction Centre, Institute of Psychiatry, Kings College London, London, UK and ²Drug Health Services, Sydney South West Area Health Service, Sydney, NSW, Australia
- 108 *Source of methadone in overdose deaths in rural western Virginia in 2004*
M.J. Wunsch¹, M. Weimer² and K. Nakamoto³, ¹Addiction Medicine, Virginia College of Osteopathic Medicine, Blacksburg, VA, ²Internal Medicine, Oregon Health Sciences Center, Portland, OR and ³Marketing, Virginia Tech, Blacksburg, VA

GENDER DIFFERENCES

- 109 *Gender differences in mortality among heroin, cocaine and methamphetamine users*
L. Liang¹, M. Brecht² and Y. Hser², ¹Medicine, and ²Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 110 *Gender differences in problem gambling and comorbid substance use behaviors in the Canadian general population*
L.A. Ghandour, S. Martins and C. Storr, Mental Health, Johns Hopkins University, Baltimore, MD
- 111 *Gender differences in cortisol reactivity among African American polysubstance users*
R.M. Schuster¹, S. Daughters¹, M. Sargeant¹, C. Forst¹, C. Lejuez¹ and R. Sinha², ¹Psychology, University of Maryland, College Park, MD and ²Psychiatry, Yale University, New Haven, CT
- 112 *Effects of IM progesterone administration upon responses to acute psychosocial stress*
E. Childs, N.T. Van Dam and H. de Wit, Psychiatry, The University of Chicago, Chicago, IL
- 113 *Gender differences in stress and cue-related adrenergic response in cocaine-dependent patients compared with social-drinking controls*
K. Hong, H. Fox, G. Anderson and R. Sinha, Psychiatry, Yale University, New Haven, CT
- 114 *Alcohol use and problems: A focus upon sex-associated variation for US-born versus immigrant Latinos and Asians in US households, 2002-2003*
H. Cheng and J.C. Anthony, Michigan State University, East Lansing, MI
- 115 *Alcohol-associated social maladaptation, cannabis use, and male-female differences: A latent class analysis*
M. Radovanovic¹, J. Posada-Villa³, J.C. Anthony¹, M.E. Medina-Mora² and World Mental Health Surveys Consortium⁴, ¹Epidemiology, Michigan State University, East Lansing, MI, ²Institute of Psychiatry, Ciudad de Mexico, Mexico, ³Saldarriaga Concha Foundation, Bogota, Colombia and ⁴WMHS Consortium, Boston, MA
- 116 *Gender differences in subjective and physiological response to oral THC in cannabis-dependent humans*
L.H. Lundahl¹, H. Lockhart¹, M.E. Tancer¹ and C.E. Johanson², ¹Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI and ²Loyola University, Chicago, IL
- 117 *Gender differences in progression to dependence in non-treatment-seeking adult cannabis users*
M.L. Copersino^{1,2}, K.H. Levin², S.J. Heishman² and D.A. Gorelick², ¹McLean Hospital/Harvard Medical School, Belmont, MA and ²IRP NIDA/NIH/DHHS, Baltimore, MD
- 118 *Gender moderates stereotype threat in cannabis users*
A. Looby and M. Earleywine, Psychology, University at Albany, SUNY, Albany, NY

- 119 *Gender differences in coping motives and substance use disorder severity*
R. McHugh, H.W. Murray, E.M. Pratt, J.B. Hogan, T.C. Rowley and M.W. Otto, Psychology, Boston University, Boston, MA
- 120 *Substance use disorder treatment is associated with lower incidence of traumatic events for women*
J. Peirce, W.M. Aklin, K.B. Stoller, M.S. Kidorf and R.K. Brooner, Johns Hopkins University School of Medicine, Baltimore, MD
- 121 *Gender differences in lifetime experiences of intimate partner violence among heroin users in a 25-year follow-up*
L. Rodriguez and C. Grella, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 122 *Gender differences in the association between victimization history and substance abuse with regard to prevalence and risk factors*
C.K. Danielson¹, A. Amstadter¹, C.W. Lejuez², H. Resnick¹, B. Saunders¹ and D. Kilpatrick¹, ¹MUSC, Charleston, SC and ²University of MD, College Park, MD
- 123 *Gender differences in the social and support networks of inner-city current and former drug users*
A.S. Buchanan and C.A. Latkin, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD
- 124 *Gender differences in HIV risk: Results from a randomized clinical trial*
M. Wilson¹, R.P. Schwartz¹, K.E. O'Grady², D. Highfield¹ and J.H. Jaffe¹, ¹Friends Research Institute, Baltimore, MD and ²University of Maryland, College Park, MD
- 125 *Children as motivation to reduce HIV risk: Gender differences among IDUs in treatment*
M. Copenhaver¹, A. Merz² and I. Lee³, ¹Allied Health Sciences and Psychology, University of Connecticut, Storrs, and ²Public Health, University of Connecticut, Farmington, CT and ³Psychology, National Chengchi University, Taipei, Taiwan
- 126 *Inclusion of women and minorities in clinical trials of FDA-approved pharmacotherapy for smoking cessation*
D.L. Dickerson¹, R.F. Leeman², C.M. Mazure² and S.S. O'Malley², ¹ISAP, University of California-Los Angeles, Long Beach, CA and ²Yale University, New Haven, CT
- 127 *Male-female differences in tobacco dependence: Colombia, 2003*
J.E. Salinas¹, J. Posada-Villa², H. Cheng¹, J.C. Anthony¹ and World Mental Health Survey Consortium³, ¹Epidemiology, MSU, East Lansing, MI, ²Saldarriaga Concha Foundation, Bogota, Colombia and ³WMHS Consortium, Boston, MA
- 128 *Male-female differences in tobacco dependence: Mexico, 2001-2002*
M.M. Catacora¹, M.E. Medina-Mora², G. Borges², H. Cheng¹, J.C. Anthony¹ and World Mental Health Survey Consortium³, ¹Epidemiology, Michigan State University, East Lansing, MI, ²National Institute of Psychiatry and Metropolitan Autonomous University, Mexico F.D., Mexico and ³WMHS Consortium, Boston, MA
- 129 *Gender differences in prevalence, risk and clinical correlates of smoking comorbidity in schizophrenia in a Chinese population*
X.Y. Zhang^{1,2}, D.F. Zhou², G.Y. Wu¹, T.A. Kosten¹ and T.R. Kosten¹, ¹Psychiatry, Baylor College of Medicine, Houston, TX and ²Psychiatry, Peking University, Beijing, China
- 130 *Evaluation of gender differences in subjective craving and stress reactions to smoking and stress cues in nicotine-dependent individuals*
M.E. Saladin, H. Upadhyaya, M. Carpenter, S. LaRowe, S. DeSantis and K. Brady, Medical University of South Carolina, Charleston, SC

- 131 *Individual differences in stimulant-induced increases in cigarette smoking*
M.M. Poole¹, A.R. Vansickel^{1,2}, W.W. Stoops² and C.R. Rush^{1,2,3}, ¹Psychology, ²Behavioral Science, and ³Psychiatry, University of Kentucky, Lexington, KY
- 132 *Male-female differences and risk of developing a dependence syndrome soon after onset of extra-medical use of psychostimulant compounds*
O.A. Adelaja and J.C. Anthony, Epidemiology, Michigan State University, East Lansing, MI
- 133 *Gender and sexual relationship power among out-of-treatment methamphetamine users*
D.J. Rinehart, K.F. Corsi and R.E. Booth, University of Colorado at Denver and Health Sciences, Denver, CO
- 134 *d-Amphetamine self-administration in women and men*
F. Wagner¹, A.R. Vansickel^{1,2}, W.W. Stoops¹ and C.R. Rush^{1,2,3}, ¹Behavioral Science, ²Psychology, and ³Psychiatry, University of Kentucky, Lexington, KY

POLICY

- 135 *Drug-endangered children: Parental methamphetamine use and manufacture*
N.P. Messina, R. Rawson and P. Marinelli-Casey, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 136 *The impact of a three-hour neuroscience of addiction curriculum on college students' knowledge and attitudes: Preliminary results of the NIDA enters college project*
J.A. Hartje¹, M.S. Berry¹, W.L. Woods¹, A.D. Broadus¹, N.A. Roget¹ and P. Riggs², ¹CASAT, University of Nevada, Reno, NV and ²Health Sciences Center, University of Colorado, Denver, CO
- 137 *High-risk offenders in California's Proposition 36*
Y. Hser and E. Evans, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 138 *Readiness to change as a predictor of drug-related behaviors in a sample of rural felony probationers*
J.L. Duvall, C.B. Oser and C.G. Leukefeld, University of Kentucky, Lexington, KY
- 139 *National study of Departments of Corrections as purchasers of community-based treatment*
S. Pimlott Kubiak¹, C.L. Arfken² and E.D. Shifflet Gibson¹, ¹School of Social Work, Michigan State University, East Lansing, and ²Wayne State University, Detroit, MI
- 140 *Measuring perceptions of coercion in research with addicted offenders*
K.L. Dugosh, D.S. Festinger and J.R. Croft, Treatment Research Institute, Philadelphia, PA
- 141 *Do client perceptions of drug court influence their outcomes?*
P.L. Arabia, D.B. Marlowe, D.S. Festinger and K.L. Dugosh, Treatment Research Institute, Philadelphia, PA
- 142 *Recall of informed consent information: It pays to remember*
D.S. Festinger, D.B. Marlowe, J.R. Croft, K.L. Dugosh, P.L. Arabia and K.M. Benasutti, Law and Ethics, Treatment Research Institute, Philadelphia, PA
- 143 *Does corrected feedback improve recall of informed consent information?*
J.R. Croft, D. Festinger and K. Dugosh, Law and Ethics, Treatment Research Institute, Philadelphia, PA
- 144 *Preference-based utility values for drug use and drug disorders*
K.L. Kraemer¹, Q. Dang¹, A. Gordon¹, J. Cornelius¹, M. Roberts¹, R. Saitz², J. Conigliaro³ and L. Settles¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Boston University, Boston, MA and ³Medicine, University of Kentucky, Lexington, LA

- 145 *Access to substance abuse treatment for people from historically disadvantaged South African communities*
B. Myers, Alcohol and Drug Abuse Research Unit, South African Medical Research Council, Tygerberg, South Africa
- 146 *Work- and health-related disparities for low-income working adults with mental health and/or substance misuse disorders*
T.M. Bohman¹, L. Wallisch¹, E. Nwokeji¹, A. Pittman¹, R.T. Spence¹, B. Ostermeyer² and B. Reed², ¹University of Texas, Austin, and ²Baylor College of Medicine, Houston, TX
- 147 *Distance traveled and cross-state commuting among patients in opioid agonist treatment programs*
M. Parrino², A. Rosenblum¹, C. Fong¹, C. Maxwell² and S. Magura^{3,1}, ¹National Development and Research Institutes, Inc., and ²American Association for the Treatment of Opioid Dependence, New York, NY and ³Western Michigan University, Kalamazoo, MI
- 148 *Barriers for buprenorphine treatment in the Veterans Health Administration*
J. Liberto¹, G.J. Kavanagh¹, R. Ramgopal², S. Paidisetty² and A.J. Gordon², ¹VA Maryland Health Care System, Baltimore, MD and ²VA Pittsburgh Healthcare System, Pittsburgh, PA
- 149 *Enabling factors for buprenorphine treatment in the Veterans Health Administration*
A.J. Gordon¹, G.J. Kavanagh², R. Ramgopal¹, S. Paidisetty¹ and J. Liberto², ¹VA Pittsburgh Healthcare System, Pittsburgh, PA and ²VA Maryland Health Care System, Baltimore, MD
- 150 *Opioid pharmacotherapy maintenance: Supply, demand and service system modelling*
A. Ritter and J. Chalmers, Drug Policy Modelling Program, University of New South Wales, Sydney, NSW, Australia

PROGRAM DESCRIPTION II

- 151 *A mosaic and tapestry approach to training drug abuse researchers in the Responsible Conduct of Research*
C.L. Striley, E.L. Murdock and L.B. Cottler, Psychiatry, Washington University, St. Louis, MO
- 152 *Developing models for community-based research: Lessons learned from NIDA studies*
L.B. Cottler, C. Striley and C. Callahan, Psychiatry, Washington University School of Medicine, St. Louis, MO
- 153 *Innovation adoption: Lessons learned from recruiting drug treatment agencies into a randomized control trial*
A. Pulvermacher¹, J.H. Ford¹, A. Quanbeck¹, D. Gustafson¹, D. McCarty², J. McConnel² and K. Hoffman², ¹University of Wisconsin - Madison, Madison, WI and ²Oregon Health and Sciences University, Portland, OR
- 154 *Translating ideas into practice: Implementation of a process improvement RCT for 200 drug treatment agencies*
J.H. Ford¹, A. Quanbeck¹, A. Pulvermacher¹, D. Gustafson¹, D. McCarty², K. Hoffman² and J. McConnel², ¹University of Wisconsin - Madison, Madison, WI and ²Oregon Health Sciences University, Portland, OR
- 155 *National multidisciplinary French training program to improve the quality of treatment for opiate addiction patients and to make a professional's care easier: Objectives and outcome*
D.P. Touzeau¹, C. Bronner², S. Personnic² and B. Mouret³, ¹Clinique Liberté, Bagneux, ²IRMG, and ³Sante et Public, Paris, France

- 156 *Evaluation of Treatnet—The international network of drug dependence treatment and rehabilitation resource centres*
J. Tomas-Rossello¹, E. Saenz-Miranda¹, A. Busse¹, B. Sibanda², B. Torggler², G. Gerra¹ and Treatnet Network¹, ¹Division of Operations, Global Challenges Section, Prevention, Treatment and Rehabilitation Unit, and ²Independent Evaluation Unit, United Nations Office on Drugs and Crime, Vienna, Austria
- 157 *Evaluation of a drug treatment program for families engaged in the child welfare system*
M.S. Shafer, B. Arthur, M. Mellacheruvu and L. Crone-Koshel, College of Human Services, Arizona State University, Phoenix, AZ
- 158 *Implementing evidence-based practices in a transitional housing program*
W. Beauchamp¹, M.S. Shafer¹, R. Rhode¹, N. Jones², B. Arthur¹ and T. Litwicki², ¹Arizona State University, Phoenix, AZ and ²Old Pueblo Community Foundation, Tucson, AZ
- 159 *Access to Recovery: A federal initiative to increase substance abuse treatment capacity*
H. Clark, A. Kopstein, D. Avula, N. Lu, J. Stein and R. Kopanda, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD
- 160 *Outcomes monitoring as a clinical intervention*
J.S. Cacciola^{1,2}, D. Carise^{1,2}, J.R. McKay^{2,1} and A.T. McLellan^{1,2}, ¹Treatment Research Institute, and ²University of Pennsylvania, Philadelphia, PA
- 161 *The NOBLE Study: Assessing the effectiveness of residential vs. intensive outpatient prison-based treatment and inmates' views on HIV/AIDS-related behaviors and services*
W.M. Burdon, J. St. De Lore and M.L. Prendergast, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 162 *Project BRITE: Developing and implementing a positive behavioral reinforcement intervention to increase treatment engagement in prison-based substance abuse treatment*
J. St. De Lore, W.M. Burdon and M.L. Prendergast, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 163 *An intervention to increase medical assessment of in-treatment socially precarious polydrug users. Impact of a focused group counseling session*
A. Van Paemelen², A. Larraburu², C. Denis^{1,2}, E. Lavie^{1,2}, M. Fatseas^{1,2} and M. Auriacombe^{1,2}, ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, and ²Addiction Treatment Center, CHCP, CHU, Bordeaux, France
- 164 *Developing a curriculum for conflict resolution education for use by substance abuse counselors with adult substance abusers*
R. Oser¹, C. Tuohy², D. Petska¹, S. Libretto¹, H. Wong¹ and J. Hoffman¹, ¹Danya International, Silver Spring, MD and ²NAADAC, Alexandria, VA
- 165 *Teaching medical students to perform screening and brief interventions for unhealthy substance use*
D.P. Alford¹, T.W. Kim¹, L. Ellenberg¹, D. Clark², N. Radhakrishnan¹ and M. Brolin³, ¹Medicine, Boston University School of Medicine, and ²Boston Public Health Commission, Boston, and ³Brandeis University, Waltham, MA
- 166 *Screening, brief intervention, and referral to treatment in an undergraduate nursing program*
R. Shipley, D. Langer and H. Hagle, Institute for Research, Education and Training in Addictions, Pittsburgh, PA
- 167 *Recent chemical controls in response to deaths attributed to the illicit manufacture of fentanyl*
T.L. Boos, D.E. Peters, L.L. Wong, S.M. Carr and C.A. Sannerud, Drug Enforcement Administration, Washington, DC

- 168 *Current drug-scheduling reviews reported by the Drug Enforcement Administration*
S.R. Tella, G.K. Feussner, M.D. Walker, P.M. Brundage, S.G. Ghosland, J.M. Tolliver,
S.M. Carr and C.A. Sannerud, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC
- 169 *Scheduling process at DEA - the example of cannabidiol*
S.G. Ghosland, J.M. Tolliver, S.M. Carr and C.A. Sannerud, Office of Diversion Control -
Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC

Symposium XV

San Geronimo A
10:00 AM - 12:00 PM

PRECLINICAL RESEARCH ON THE DISCOVERY OF GLUTAMATERGIC THERAPEUTICS FOR THE TREATMENT OF ADDICTION

Chairs: David A. White and Athina Markou

- 10:00 *Possible glutamatergic targets for the treatment of high-dose substituted amphetamine exposure*
Bryan K. Yamamoto, Boston University School of Medicine, Boston, MA
- 10:25 *The role of NMDA and AMPA receptors in cocaine addiction*
Ainhua Bilbao, Central Institute of Mental Health, Mannheim, Germany
- 10:50 *mGluR-Homer-P13K signaling mechanisms in addiction-related behaviors*
Karen K. Szumlanski, University of California, Santa Barbara, CA
- 11:15 *Allosteric modulators of mGluRs as a novel approach to treatment of drug abuse and other CNS disorders*
Carrie Jones, Vanderbilt University School of Medicine, Nashville, TN
- 11:40 *Discussant*
Athina Markou, University of California, San Diego, CA

Oral Communications 18

San Geronimo B
10:00 AM - 12:00 PM

EXTINCTION/REINSTATEMENT: ON AGAIN, OFF AGAIN

Chairs: John Roache and Xiu Liu

- 10:00 *Modulation of the neuroadaptive changes in glutamate and dopamine transporters during the extinction of cocaine self-administration*
E. Ambrosio, M. Miguéns, J.A. Crespo, N. Del Olmo, A. Higuera-Matas, G.L. Montoya and
C. García-Lecumberri, Psychobiology, Universidad Nacional de Educación a Distancia
[UNED], Madrid, Spain
- 10:15 *Conditioning and extinction of cue-reactivity in cocaine-dependent human subjects*
J.D. Roache¹, C.L. Wallace¹, R.J. Lamb¹, T. Newton², J. Mojsiak³ and A. Elkashef³,
¹University of Texas Health Science Center, San Antonio, TX, ²University of California-Los
Angeles, Los Angeles, CA and ³NIDA, Washington, DC

- 10:30 *Can baclofen and varenicline facilitate extinction of the limbic brain response to brief cocaine cues?*
A. Childress^{1,2}, R.N. Ehrman^{2,1}, Z. Wang¹, Y. Li¹, T. Franklin¹, M. Goldman¹, J. Suh^{1,2}, A. Fornash^{1,2}, J. Hakun¹, W. Jens¹, J. Cruz¹, J. Plebani¹, K. Kampman¹ and C.P. O'Brien^{1,2},
¹Psychiatry, University of Pennsylvania School of Medicine, and ²VA VISN 4 MIRECC, Philadelphia VAMC, Philadelphia, PA
- 10:45 *D-Cycloserine and cocaine cue extinction*
K.T. Brady, A.L. McRae, M.E. Saladin, M.M. Moran and K.L. Price, Psychiatry, Medical University of South Carolina, Charleston, SC
- 11:00 *Naltrexone attenuates cue-induced reinstatement of nicotine-seeking but does not change nicotine self-administration in rats*
X. Liu, A.R. Caggiula, M.I. Palmatier, E.C. Donny and A.F. Sved, University of Pittsburgh, Pittsburgh, PA
- 11:15 *Reinstatement of heroin-seeking in rats is potentiated by infusions of morphine into the substantia nigra*
K.M. Banna¹, K.L. Blough², J.L. Rogers¹, A.Q. Carnell¹ and R.E. See¹, ¹Neurosciences, Medical University of South Carolina, Charleston, SC and ²Virginia Commonwealth University, Richmond, VA
- 11:30 *Differential sensitivity of the rostral and caudal basolateral amygdala to modulation of cocaine-seeking behavior by the D1 receptor antagonist SCH 23390*
Y. Mashhoon, L.A. Tsikitas and K.M. Kantak, Psychology, Boston University, Boston, MA
- 11:45 *Drug cravings following trauma cue exposure among crack/cocaine-dependent patients with and without PTSD*
M.J. McDermott^{1,2}, M.T. Tull^{1,2} and C.W. Lejuez^{1,2}, ¹Psychology, University of Maryland, and ²Center for Addictions, Personality, and Emotion Research [CAPER], College Park, MD

Oral Communications 19

San Geronimo C
10:00 AM - 12:00 PM

DEVIATING FROM THE SCRIPT: EPIDEMIOLOGY OF Rx DRUG ABUSE

Chairs: Sean McCabe and Jennifer Havens

- 10:00 *Trends in recent-onset extramedical opioid analgesic use in the US from 1990 to 2005*
S.S. Martins¹, C.L. Storr¹, H. Zhou¹ and H.D. Chilcoat^{1,2}, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD and ²GlaxoSmithKline Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC
- 10:15 *Prevalence of non-medical prescription opioids and illegal opioids use in Canada*
J. Patra, J. Rehm, S. Popova, S. Mohapatra and B. Fischer, Social, Prevention and Health Policy Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 10:30 *Nonmedical use of prescription opioids and other drug use: What comes first?*
S.E. McCabe, B.T. West, J.A. Cranford and C.J. Boyd, University of Michigan, Ann Arbor, MI
- 10:45 *Incidence and persistence of nonmedical use of prescription analgesics among college students*
K. Caldeira¹, A. Arria¹, K. Vincent¹, K. O'Grady² and E. Wish¹, ¹Center for Substance Abuse Research, and ²Psychology, University of Maryland, College Park, MD

- 11:00 *Characterizing opioid analgesic injectors: Results from a national sample*
J.R. Havens¹, L.A. Simmons², C.B. Oser^{3,1} and L.M. Shannon¹, ¹CDAR, ²Family Studies, and ³Sociology, University of Kentucky, Lexington, KY
- 11:15 *A latent class analysis of prescription opioid abuse in the National Addictions Vigilance Intervention and Prevention Program*
T.G. Green² and S.F. Butler¹, ¹Inflexxion, Inc, Newton, MA and ²School of Public Health, Yale University, New Haven, CT
- 11:30 *Characterization of buprenorphine abuse using RADARS® System Poison Center data*
A. Spaeth¹, J.E. Bailey¹ and R.C. Dart^{1,2}, ¹Research, Rocky Mountain Poison and Drug Center, and ²University of Colorado Health Sciences Center, Denver, CO
- 11:45 *Profile of buprenorphine-naloxone injectors in Malaysia: A community survey*
M. Mazlan³, V. Balasingam Kasinather², M.C. Chawarski¹ and R.S. Schottenfeld¹, ¹Yale University, New Haven, CT and ²University Sains Malaysia, Pulau Pinang, and ³Substance Abuse Center, Muar, Malaysia

Oral Communications 20

San Cristobal
10:00 AM - 12:00 PM

IMAGING: VIEW FROM THE TOP

Chairs: Edythe London and Mark Greenwald

- 10:00 *Adolescents with substance/conduct problems: Risky decisions and brain activation*
T.J. Crowley¹, M. Dalwani¹, S. Mikulich-Gilbertson¹, K. Raymond¹, C. Lejuez² and M. Banich³, ¹Division of Substance Dependence, Psychiatry, University of Colorado Denver School of Medicine, Denver, and ³Psychology, University of Colorado, Boulder, CO
²Psychology, University of Maryland, College Park, MD
- 10:15 *Effects of cannabis use on brain reward circuitry in teenagers: An fMRI study*
G. Jager¹, R.I. Block², J.M. van Ree¹, M. Luijten¹, C. Fruehling-Wall² and N.F. Ramsey¹, ¹Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, Netherlands and ²University of Iowa, Iowa, IA
- 10:30 *Heavy marijuana users show altered neurofunctional activity during decision making and feedback processing while performing the Iowa Gambling Task*
M. Wesley, C. Hanlon, M.D. Miller and L.J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC
- 10:45 *Women on nicotine replacement therapy show significant brain activity in response to smoking cues*
A.C. Janes¹, B.B. Frederick¹, C. Burbridge¹, S. Richardt¹, A.E. Evins², M. Fava³, P.F. Renshaw¹ and M.J. Kaufman¹, ¹Brain Imaging Center, McLean Hospital, Belmont, ²Center for Addiction Medicine, Massachusetts General Hospital, and ³Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA
- 11:00 *Neural correlates of negative emotion response and regulation in methamphetamine-dependent and comparison subjects*
E.D. London, K. Baicy and J. Monterosso, Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA

- 11:15 *Does chronic cocaine use affect a mother's brain response to baby face cues? A pilot fMRI study*
L. Strathearn^{1,2} and T.R. Kosten^{3,2,4}, ¹Pediatrics, ²Neuroscience, and ³Psychiatry and Behavioral Sciences, Baylor College of Medicine, and ⁴Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX
- 11:30 *Anterior cingulate glutamate measured with high-field, short-TE, single-voxel 1H-MRS is greater during low- vs. high-dose methadone maintenance*
M.K. Greenwald, D. Khatib, M. Keshavan and J. Stanley, Wayne State University, Detroit, MI
- 11:45 *MDMA (ecstasy) use is associated with altered brain activation to word encoding and recall: An fMRI study*
V. Raj, A.L. Bauernfeind, M. Dietrich and R.L. Cowan, Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN

BRUNCH WITH CHAMPIONS (Pre-Registrants Only)

Las Olas
12:00 - 1:30 PM

Symposium XVI

San Geronimo A
1:30 - 3:30 PM

PHARMACOGENETICS OF MEDICATIONS FOR THE TREATMENT OF ADDICTIONS

Chairs: Ivan D. Montoya and Joni Rutter

- 1:30 *Genetic factors associated with the differential efficacy and side effects of smoking cessation medications*
Caryn Lerman, University of Pennsylvania, Philadelphia, PA
- 1:55 *The role of pharmacogenetics in the evaluation of medications for the treatment of cocaine addiction*
Thomas Kosten, Baylor College of Medicine, Houston, TX
- 2:20 *Genetics of the opioid receptor and response to opioid agonist, partial agonist, and antagonist treatment*
Mary Jeanne Kreek, The Rockefeller University, New York, NY
- 2:45 *Genetic variations in the cannabinoid system and response to pharmacotherapies for marijuana addiction*
Bernard Le Foll, University of Toronto, Toronto, ON, Canada
- 3:10 *Genetics and the outcome of addiction treatments*
George Uhl, NIDA Intramural Research Program, Baltimore, MD

Oral Communications 21

San Geronimo B
1:30 - 3:30 PM

STIMULANT TREATMENT: WHAT'S UP?

Chairs: Steve Shoptaw and Joy Schmitz

- 1:30 *Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence*
S. Shoptaw^{1,2}, K.G. Heinzerling¹, E. Rotheram-Fuller¹, T. Steward¹, J. Wang¹, A. Swanson¹, R. De La Garza², T. Newton² and W. Ling², ¹Family Medicine and ²Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA
- 1:45 *Randomized placebo-controlled trial of modafinil for methamphetamine withdrawal: Results of an Australian pilot study*
N.K. Lee¹, A. Pennay¹ and R. Hester², ¹Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia and ²University of Queensland, Brisbane, QLD, Australia
- 2:00 *Acute modafinil treatment does not improve cognitive function in methamphetamine-dependent volunteers*
B. Jackson, A.D. Kalechstein, R. De La Garza II and T.F. Newton, Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, CA
- 2:15 *High-dose naltrexone therapy for cocaine-alcohol dependence*
J.M. Schmitz¹, J. Grabowski², C. Green¹, D. Herin¹ and J. Lindsay¹, ¹University of Texas-Houston, Houston, TX and ²University of Minnesota, Minneapolis, MN
- 2:30 *Preexisting anti-cocaine IgM antibody associated with low antibody responses to cocaine conjugate vaccine*
F.M. Orson^{2,1}, B.M. Kinsey^{2,1}, R.A. Singh¹, Y. Wu¹, W. Huang^{2,3} and T.R. Kosten^{2,3}, ²Medical Service, Veterans Affairs Medical Center, and ¹Internal Medicine, and ³Psychiatry, Baylor College of Medicine, Houston, TX
- 2:45 *The effects of γ -vinyl- γ -aminobutyric acid (GVG, vigabatrin) on the subjective, cardiovascular and reinforcing effects produced by methamphetamine (METH) in METH-dependent volunteers*
T.F. Newton¹, R. De La Garza, II¹, A. Lee¹, R.A. Donovan¹, K.G. Heinzerling^{1,2} and S. Shoptaw^{2,1}, ¹Psychiatry, and ²Family Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA
- 3:00 *Impact of DSM-IV diagnoses on abstinence outcomes for homeless clients undergoing contingency-managed treatment*
J.B. Milby¹, J. Schumacher¹, D. Wallace², K. Crouch¹, R. Cusimano¹, S. Kertesz³, S. Mennemeyer¹ and R. Vuchinich¹, ¹University of Alabama at Birmingham, and ³VAMC, Birmingham, AL, and ²RHO Federal Systems Division Inc, Raleigh-Durham, NC
- 3:15 *Continuing care for stimulant recovery: An experimental test of telephone support*
D.J. Farabee, R. Rawson, V.J. Pearce, A. Bellows, J. Hemberg, S.J. Cousins, S. Patel and J. Brummer, ISAP, University of California-Los Angeles, Los Angeles, CA

Oral Communications 22

San Geronimo C
1:30 - 3:30 PM

IMPULSIVITY—WHAT'S THE RUSH?

Chairs: Marilyn E. Carroll and Jennifer Perry

- 1:30 *A laboratory model of relapse to smoking: Effects of incentives for not smoking and relationship to temporal discounting*
W.K. Bickel¹, B.P. Kowal¹, R. Yi¹, M.L. Stitzer^{1,2} and R.D. Landes¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR and ²Psychiatry, The Johns Hopkins University - School of Medicine, Baltimore, MD
- 1:45 *Effects of sustained abstinence and impulsivity on the relative reinforcing effects of cigarette smoking*
M.P. Bradstreet, S.T. Higgins, J.H. Yoon, L.L. Chivers, J. Plebani-Lussier and C. Thomas, Psychiatry/Psychology, University of Vermont, Burlington, VT
- 2:00 *Evaluating aspects of discounting behavior in adolescent substance users and controls*
S.K. Mikulich-Gilbertson, L.L. Thompson and T.J. Crowley, Division of Substance Dependence, Psychiatry, University of Colorado at Denver School of Medicine, Denver, CO
- 2:15 *Substance abuser impulsivity decreases with a 9-month stay in a therapeutic community*
S.M. Bankston¹, F.G. Moeller², J. Schmitz², S. Cron¹, L.K. Granmayeh¹, D.D. Carroll¹ and M. T. Marcus¹, ¹University of Texas Health Science Center at Houston School of Nursing, and ²University of Texas Health Science Center at Houston Medical School, Houston, TX
- 2:30 *Impulsivity (delay discounting) and drug self-administration in rhesus monkeys*
M.E. Carroll¹, J.L. Mach¹, J.L. Perry² and J.L. Newman³, ¹Psychiatry, and ²Pharmacology and Toxicology, University of Minnesota, Medical Research Foundation, Minneapolis, MN and ³McLean Hospital, Harvard Medical School, Belmont, MA
- 2:45 *Temporal discounting of saccharin as a reinforcer by rhesus monkeys*
K.B. Freeman and W. Woolverton, Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS
- 3:00 *Stress and behavioral sensitization to nicotine in a rodent model of impulsivity*
K.R. Hamilton, A.K. Starosciak and N.E. Grunberg, Uniformed Services University of the Health Sciences, Bethesda, MD
- 3:15 *Role of dopamine and serotonin receptors in medial prefrontal cortex in impulsive choice*
J.L. Perry¹ and M.T. Bardo², ¹Minneapolis Medical Research Foundation, Minneapolis, MN and ²Psychology, University of Kentucky, Lexington, KY

SWEEPSTAKES DRAWING

San Cristobal
3:35 PM

***YOU MUST BE SEATED IN ONE OF THE SESSIONS AT
3:15 PM IN ORDER TO HAVE YOUR BADGE COLLECTED***

*HAVE A SAFE TRIP HOME
SEE YOU IN RENO, NEVADA, JUNE 20-25, 2009*

AUTHOR INDEX

- Abbara, C. 54
 Abdrakhmanova, G. 31
 Abrams, L. 8
 Abramsohn, Y. 40, 86
 Achat-Mendes, C. 77
 Acheson, A. 79
 Acosta, A. 15
 Acosta, M.C. 26, 70
 Adam, T. 57
 Adams-Deustch, T. 79
 Adamson, J. 71
 Addou, S. 13
 Adelaja, O.A. 89
 Adelson, M. 40, 53, 85, 86
 Adinoff, B.H. 5, 44, 57, 58
 Adkins, J.E. 7
 Adlaf, E. 72
 Adler, L. 48
 Adler, M.W. 1, 9, 13
 Adolfo, A.B. 82
 Agrawal, A. 73, 82
 Agrawal, S. 61
 Aguerretxe-Colina, A. 72, 78
 Aguilar, V.R. 49
 Agulló, V. 10, 38, 44
 Aharonovich, E. 12, 84
 Ahmed, A. 21
 Ahmed, M.S. 32
 Ahmedani, B.K. 63
 AhnAllen, C.G. 82
 Ainette, M. 62
 Ait-Daoud, N. 60
 Akins, C.K. 79
 Aklin, W.M. 85, 86, 88
 Alberg, A. 81
 Albert, S. 16
 Albizu-Garcia, C.E. 38, 41
 Alburges, M.E. 34
 Aleixandre-Benavent, R. 38, 44
 Alexander, M. 33
 Alford, D.P. 85, 91
 Ali, R. 26, 42
 Alkass, K. 86
 Allen, C. 69
 Allen, N. 46
 Allensworth-Davies, D. 86
 Allsop, S. 67
 Alonso, A. 38
 Alterman, A.I. 19, 83
 Altice, F. 15
 Alvanzo, A. 35, 62
 Alvarado, G.F. 14, 29
 Alvarez, Y. 11
 Alvarez-Gonzalez, C. 81
 Amador, N.J. 8
 Amaechi, O. 15
 Amble, P. 18
 Ambrosio, E. 92
 Ames, S. 59
 Ammann, M.A. 28
 Amodeo, M. 19, 57
 Amodio, K. 10
 Amrhein, P. 84
 Amstadter, A. 88
 Anastasio, N. 31
 Andersen, R.M. 19
 Andersen, V. 11
 Anderson, G. 87
 Anderson, K.G. 71
 Anderson, L. 60
 Andorn, A.C. 61
 Andrews, S. 85
 Anen, S.J. 37
 Ang, A. 83
 Anglin, D.M. 20
 Anker, J.J. 34, 80
 Anokhin, A.P. 59
 Anthony, J.C. 12, 14, 38, 29, 59, 63, 87, 88, 89
 Arabia, P.L. 18, 89
 Arasteh, K. 4
 Arenella, L. 54
 Arfken, C.L. 89
 Arkes, J. 67
 Arnold, S. 63
 Arria, A. 24, 35, 59, 60, 64, 93
 Arribas, M. 7
 Arthur, B. 91
 Ary, A.W. 53
 Aschbach-Jachman, C. 75
 Aston-Jones, G. 5
 Astone-Twerell, J. 41
 Ator, N.A. 23
 Auclair, C. 12, 17
 Augustino, D.K. 17
 Auriacombe, M. 9, 10, 26, 65, 72, 78, 91
 Austin, E. 19
 Authier, N.A. 17
 Avila, M. 82
 Avula, D. 91
 Babalonis, S. 55, 80
 Back, S. 41
 Back, S.E. 11, 50
 Badger, G.J. 58
 Baewert, A. 75
 Baggott, M.J. 55, 56, 78
 Baicy, K. 94
 Bailey, G. 45
 Bailey, J.E. 64, 94
 Baillie, A. 61
 Baker, A. 41, 46, 57
 Baladi, M. 79
 Balasingam Kasinather, V. 94
 Balducci, X.L. 75
 Baldwin, G.C. 3, 42
 Balester Mouret, S. 61
 Ball, S.A. 17, 40, 58
 Balleine, B.W. 5
 Ballina, L. 79
 Bandstra, E. 47
 Bangs, N. 78
 Banich, M. 94
 Bankston, S.M. 97
 Banna, K.M. 93
 Banta-Green, C.J. 26, 64
 Bantchevska, D. 45
 Bar-Hamburger, R. 82
 Barahona, M. 16
 Bardo, M.T. 13, 72, 97
 Barker, M. 16
 Barksdale, W. 38
 Baron, M. 56
 Barrick, C. 67
 Barry, D.T. 26
 Barth, K. 15
 Bartle-Haring, S. 45

AUTHOR INDEX

- Barton, D. 3
 Basilakos, A.A. 72
 Batel, P. 61
 Batis, J. 32, 54
 Batki, S.L. 10
 Bauernfeind, A.L. 74, 95
 Baumann, M.H. 74
 Beadnell, B. 45
 Beatty, J.R. 36
 Beauchamp, W. 91
 Becher, J. 42
 Beck, O. 56
 Becker, W.C. 15, 64
 Bedi, G. 78
 Behar, E. 86
 Beitel, M. 26
 Bejjani, A. 54
 Bell, G.H. 34
 Bellows, A. 96
 Beltran, V. 72, 78
 Ben Abdallah, A. 12
 Benamar, k. 13
 Benasutti, K.M. 89
 Bender, R. 48
 Benoit, E. 62
 Bentley, T. 67
 Benyamina, A. 54
 Benzano, D. 61
 Berdah, C. 9
 Berenson, A.B. 40
 Berge, D. 17
 Berger, D. 12
 Berglund, M. 86
 Bergman, J. 60, 69
 Bergquist, K.L. 10, 27, 49
 Beringer, K. 23
 Berko, J. 17
 Berrettini, W. 15, 73
 Berry, M.S. 89
 Berterame, S. 45
 Beseler, C. 12
 Best, A.M. 20
 Betzler, T. 83
 Beveridge, T.J. 55
 Bevins, R.A. 69
 Bian, H. 59
 Bickel, W.K. 37, 58, 97
 Bidlack, J.M. 7
 Biederman, J. 71
 Bierut, L. 58
 Bigelow, G.E. 36, 37, 82, 83, 85
 Biggers, S. 81
 Bilbao, A. 92
 Billa, S. 8
 Binswanger, I.A. 20
 Birk, T.J. 19
 Bisaga, A. 37, 84
 Bjork, J. 25
 Black, R.A. 83
 Blanchette, J. 44
 Blanco, C. 24
 Blank, M.B. 43
 Block, R.I. 94
 Bloom Oquendo, J. 21
 Blough, B. 31
 Blough, K.L. 93
 Boak, A. 72
 Bobashev, G. 43
 Bogenschutz, M.P. 18, 19, 35, 46
 Bohman, T.M. 61, 90
 Bohn, L.M. 31
 Bohnert, K.M. 59
 Bois, F. 54
 Bokarius, A.V. 54
 Bolan, B. 3
 Bolin, B.L. 79
 Bolla, K.I. 78
 Bolo, N. 54
 Bond, A.J. 70
 Bongiovanni, M.J. 79
 Bonhomme-Faivre, L. 54
 Boos, T.L. 6, 91
 Booth, B.M. 11
 Booth, R.E. 20, 42, 43, 86, 89
 Borges, G. 88
 Bornovalova, M. 45
 Bossert, J.M. 8
 Boudov, M. 71
 Boudreau, D.M. 26, 64
 Bourseul, V. 9
 Bowen, S. 32
 Bowers, C. 15
 Boyd, C.J. 64, 65, 83, 93
 Boyé, A. 17
 Brackeen, M.F. 13, 49
 Bradstreet, M.P. 97
 Brady, J.V. 1
 Brady, K.T. 11, 13, 41, 50, 59, 82, 88, 93
 Brady, T. 86
 Branch, M.N. 34
 Brands, B. 40, 70, 72
 Brasel, C.M. 7
 Braskie, M.N. 54
 Brason III, F.W. 16
 Brecht, M. 18, 38, 42, 87
 Breitmeyer, B.G. 62
 Bresani, E. 84
 Breslau, N. 59
 Breslow, J. 9
 Brewer, D.D. 16
 Brewer, J. 55
 Brewster, J.T. 42
 Brim, R.L. 69
 Brimijoin, S. 32
 Britton, P.C. 17
 Broadbear, J.H. 23
 Broadus, A.D. 89
 Brolin, M. 91
 Bronner, C. 90
 Brooks, A.C. 19, 37
 Brooks, D.J. 10, 12, 43
 Brooner, R.K. 19, 85, 86, 88
 Brosh, J. 16
 Brown, A.H. 56, 57
 Brown, B.S. 38, 86
 Brown, C.H. 43, 59
 Brown, L. 2
 Brown, S.A. 46, 53, 71
 Brown, Jr., L.S. 15
 Brownell, K.D. 2
 Brownstein, J.S. 64
 Bruce, R.D. 15
 Brummer, J. 57, 96
 Brundage, P.M. 92
 Bryan, B.R. 43
 Buchanan, A.S. 88
 Buchhalter, A. 37

AUTHOR INDEX

- Buchman, A.C. 65, 66
 Bucholz, K.K. 59, 72, 82
 Buckner, J.D. 82
 Budman, S.H. 16, 39
 Budney, A.J. 47, 58, 59
 Bueno, F. 38
 Buesing, W.B. 79
 Buffalari, D. 69
 Bukstein, O.G. 60
 Bulbena, A. 17
 Bumaguin, D. 62
 Burakov, A. 37
 Burbridge, C. 94
 Burdon, W.M. 91
 Burgess, J.P. 13, 49
 Burke, C. 37
 Burne, K. 17
 Burns, L. 36
 Burt, M. 38
 Bushara, N. 37
 Busse, A. 45, 91
 Busto, U.E. 14, 73, 75
 Bustos Gamiño, M. 81
 Butelman, E.R. 8
 Butler, S.F. 16, 39, 64, 94
 Byrd, E.A. 79

 Cabaniss, B. 74
 Cacciola, J.S. 19, 83, 91
 Cachay, C. 40
 Caetano, R. 62
 Caggiula, A.R. 93
 Cain, M.E. 14, 34
 Caldeira, K.M. 59, 60, 64, 93
 Calderon, S.N. 28
 Callahan, C.L. 20, 90
 Calsyn, D.A. 9, 26, 43, 64, 86
 Cami, J. 11
 Camilleri, A. 19
 Campagna, E.J. 64
 Campbell, A. 9, 41
 Campbell, J.E. 69
 Campbell, N.D. 25, 50
 Campollo, O. 81
 Cañadas, F. 8
 Canfield, K.M. 10

 Caraballo, G. 38
 Carballo, J.L. 84
 Carbonari, J.P. 84
 Carbonaro, T. 31
 Cargile, C. 37, 56
 Caris, L.H. 38
 Carise, D. 19, 40, 91
 Carlezon, W.A. 4
 Carlin, J.B. 59
 Carlo, G. 18
 Carlson, R. 65
 Carnell, A.Q. 93
 Carpenedo, C.M. 84
 Carpenter, K.M. 37
 Carpenter, M.J. 13, 80, 81, 88
 Carr, S.M. 91, 92
 Carroll, D.D. 97
 Carroll, F.I. 13, 31
 Carroll, K.M. 55, 57, 58, 75, 81, 82, 84
 Carroll, M.E. 34, 80, 97
 Carroll, S. 46
 Carter, C.S. 4
 Carter, L.P. 23
 Carter, M.C. 84
 Carter, R.E. 9, 13
 Carter, T. 62
 Cartmell, K. 81
 Casadonte, P.P. 15, 53
 Casarella, J. 62
 Case, T.F. 84
 Cassidy, T. 16
 Castel, S. 40
 Castellano, M. 10
 Caster, J.M. 72, 73
 Castro, F.G. 21
 Catacora, M.M. 88
 Catania, L. 46
 Caulkins, J. 67
 Cavallo, D.A. 59, 80, 81
 Cavazos-Rehg, P. 58
 Ceballos, N.A. 78
 Cely, I.C. 5
 Ceperich, S.D. 24, 61
 Chakrapani, S. 54
 Chakroun, N. 78

 Chalmers, J. 90
 Chan, Y.F. 44
 Chang, C. 32
 Chang, I. 32
 Chang, L.T. 7
 Chang, N. 64
 Chaplin, T.M. 35
 Chapman, C. 16
 Chapman, J.E. 16
 Chappin, S.R. 39
 Chase, S.K. 36
 Chatterjee, P. 41
 Chaudhry, A.A. 3
 Chawarski, M.C. 39, 42, 94
 Chen, C. 32, 58
 Chen, G. 73
 Chen, H. 4
 Chen, K.L. 42
 Chen, L.A. 82
 Chen, N. 74
 Chen, T. 43
 Chen, W.J. 58
 Chen, X. 9
 Cheng, D.M. 19, 85, 86
 Cheng, H. 87, 88
 Cheng, K.J. 7, 23, 77
 Cheng, S.Y. 74
 Cherek, D.R. 20
 Cherrier, M. 56
 Chhatre, S. 42
 Chilcoat, H.D. 3, 4, 61, 93
 Childress, A.R. 2, 26, 27, 73, 93
 Childs, E. 87
 Chisolm, M. 75
 Chivers, L.L. 97
 Chopra, M.P. 37, 56
 Chrisman, A.K. 80
 Chu, M. 15, 18
 Chuang, L. 60
 Chun, J. 63
 Cilente, J. 18
 Ciskowski, S. 18
 Clair, M. 21
 Clark, A. 44
 Clark, D. 91
 Clark, D.B. 58, 60, 81

AUTHOR INDEX

- Clark, H. 91
 Clark, H.W. 67
 Clark, J. 55
 Clark, M. 86
 Clark, N. 66
 Clark, W. 24
 Clarke, J. 44
 Clatts, M.C. 43
 Clayton, T. 60
 Clement, J.E. 84
 Clements, K. 45
 Clerkin, S. 54
 Coen, K. 14
 Coffey, C. 59
 Coffin, L.S. 65
 Coffin, P. 64
 Cohen, L. 9, 83
 Coles, C.D. 35
 Collins, C. 80, 81
 Collins, C.C. 60, 81
 Collins, G.T. 69
 Comegys, D. 37
 Comer, S.D. 36
 Comerford, M. 4, 42
 Condon, T.P. 5
 Conigliaro, J. 89
 Conklin, C.A. 22
 Conner, B.T. 21
 Conner, K.R. 17, 84
 Cook, E. 74
 Cook, J.M. 60
 Cook, M. 61
 Coolon, R.A. 14, 34
 Coop, A. 72
 Cooper, Z.D. 13, 70
 Coors, M.E. 45
 Copeland, J. 16, 78
 Copenhaver, M. 15, 88
 Copersino, M.L. 12, 87
 Corbly, C.R. 55
 Corley, M. 62
 Corley, R. 58
 Cornelius, J.R. 40, 48, 60, 89
 Cornelius, M.D. 35, 59
 Corrigall, W.A. 13
 Corsi, K.F. 86, 89
 Cortizo, R. 17
 Cosgrove, K.P. 54
 Costello, M.J. 63
 Costenbader, E. 43
 Cottler, L.B. 12, 20, 43, 58, 90
 Cotton, A. 86
 Courty, P. 12, 17
 Cousins, S.J. 43, 57, 96
 Coviello, D.M. 21, 84
 Cowan, R.L. 74, 82, 95
 Coyle, J.R. 78
 Coyle, M. 24, 35
 Cranford, J.A. 65, 83, 93
 Crawford, N.D. 43
 Crespo, C.A. 74
 Crespo, J.A. 92
 Crits-Christoph, P. 16, 57
 Croft, J.R. 89
 Cron, S. 97
 Crone-Koshel, L. 91
 Crooks, P.A. 13, 14
 Croom, C. 33
 Cropsey, K.L. 20, 63
 Crouch, K. 96
 Crowley, T.J. 12, 45, 58, 94, 97
 Cruciani, R. 26
 Cruz, J. 93
 Cruz, V.O. 40
 Cui, C.L. 4
 Cui, J. 7
 Culbertson, C. 56
 Cummings, A. 61
 Cummins, E. 8
 Cunningham, K.A. 33, 68, 69, 74
 Curtin, J.J. 61
 Cusimano, R. 96
 Cutler, M.L. 85, 86
 Cutler, S.J. 7
 Czoty, P.W. 69
 D'Amante, D. 45
 Daamen, M. 12
 Dabre, Z. 37
 Dackis, C. 48, 84
 Dakin, L.A. 33
 Dakof, G.A. 21, 60
 Dallery, J. 14, 34, 62, 63, 75, 81
 Dalwani, M. 94
 Damaj, M.I. 31
 Dandy, K. 79
 Dang, Q. 89
 Daniels, M.A. 54
 Danielson, C.K. 88
 Daniulaityte, R. 65
 Dart, R.C. 64, 94
 Dasgupta, N. 16
 Datko, M.C. 53
 Daughters, S.B. 11, 38, 40, 42, 87
 Daulouede, J.P. 9, 10, 72, 78
 Davies, R. 45, 60
 Davis, C.M. 7, 8
 De Genna, N.M. 59
 De La Garza, II, R. 42, 56, 96
 de la Torre, R. 53
 de Lédinghen, V. 9
 De Rosa, E. 75
 de Wit, H. 74, 78, 87
 Deas, D. 44, 80
 DeBoni, R. 62
 deDios, M. 80
 DeFulio, A. 85
 Degenhardt, L. 47, 59
 DeGruttola, V. 42
 Del Olmo, N. 92
 dela Cruz, A.M. 33
 Delile, J.M. 9
 Delucchi, K.L. 63, 85
 Dembro, K.A. 26
 Denis, C. 9, 10, 26, 65, 91
 Dennis, M.L. 17, 18, 29, 44, 46
 Denton, W.H. 57
 DePaolo, S. 4
 Deren, S. 10, 57
 Dermen, K.H. 17
 Dersch, C.M. 7
 Des Jarlais, D.C. 4, 65
 Desai, R. 85
 DeSantis, S.M. 50, 88
 DeSouza, C. 10
 Detre, J. 26
 Detrick, C. 61

AUTHOR INDEX

- DeVane, C.L. 15
Devine, S. 18
Dewey, W.L. 1, 2, 7, 22
Diaz, G. 34
Diaz, S.E. 34
Dick, D.M. 59
Dickerhoof, R.M. 56
Dickerson, D.L. 88
Dickinson, J. 16
DiClemente, C. 59
Didier, R. 78
Dietrich, M.S. 74, 95
Dillon, P. 67
DiPietro, J.A. 36
DiRocco, D. 38, 60
Djazayeri, S. 69
Djokovic, M. 82
Dodrill, C.L. 84
Doebrick, C. 17
Dominguez, G. 15
Donlin, W.D. 85
Donnini, C. 45
Donny, E.C. 14, 93
Donovick, R.A. 96
Dore, G. 3
Dornelas, E. 24
Douaihy, A.B. 48
Doyle, S.R. 26, 43, 64
Dragonetti, R. 63
Drexler, K. 62
Druid, H. 86
Du, J. 4
DuBose-O'Hagan, T. 10
Dubray, C. 17
Ducate, E. 53
Dufault, D.L. 55
Dufka, F. 55
Dugosh, K.L. 18, 84, 89
Duke, A. 32
Dumchev, K. 39, 42
Dunbar, D. 42
Dunbar, L. 85
Duncan, A.E. 59
Dunlap, E. 62, 66
Dunlop, A. 57
Dunn, K.E. 26, 38, 50
Duplinsky, M.S. 45, 58
DuPree, J. 4
Durant, L.E. 84
Durdle, H. 63, 78
Durell, T. 48
Durham, T.G. 67
Durst, R. 82
Dutta, J. 84
Duvall, J.L. 20, 44, 89
Dvoryak, S. 42
Dwoskin, L.P. 13, 14
Dy, S. 19
Dykstra, L.A. 4, 9, 34
Eachus, S. 43
Eaddy, J.L. 34
Earleywine, M. 87
Easton, C.J. 18, 20
Edmundson, E. 67
Edwards, E.P. 36, 61
Egan, J.E. 37
Egleston, B.L. 63
Egorova, V. 37
Ehrman, R.N. 26, 27, 93
Eibner, C. 67
Eiden, R.D. 35, 36
Eisenberg, M.M. 42, 43
Eisenstein, T.K. 9
Elbert, T.R. 82
Eldridge, G.D. 20
Elkader, A. 70
Elkashef, A. 10, 92
Elkavich, A. 66
Elko, A. 36
Elkus, Y. 37
Ellenberg, L. 91
Elmore, J.G. 20
Elsken, C. 31
English, J. 80
Epstein, D.H. 19
Erickson, S.J. 19, 35
Ertischek, M.E. 66
Eschaliel, A. 17
Esterlis, I. 54
Evans, E. 21, 38, 42, 89
Evans, R.J. 12
Evans, S.M. 36
Everly, J.J. 37
Evins, A.E. 62, 94
Fabbri, S. 24, 61
Fagan, P. 19, 85
Fahy, T. 35
Fairbanks, L.A. 80
Falck, R. 65
Faller, S. 61
Fals-Stewart, W. 11, 17
Fan, C. 4
Fan, J. 54
Fang, S. 32
Fansler, A.C. 61
Fant, R.V. 65, 66
Fantegrossi, W.E. 70
Farabee, D.J. 96
Faraone, S.V. 71
Farid araki, K. 14
Farinotti, R. 54
Farnsworth, S. 74
Farnum, S. 17
Farrar, D. 85
Farrar, J. 22
Farre, M. 11, 53
Farrell, L. 24, 61
Fatseas, M. 9, 10, 26, 65, 91
Fava, M. 94
Febo, M. 34
Feldman, Z.L. 50, 77
Feltenstein, M.W. 79
Ferguson, L. 56
Fernandez-Hermida, J.R. 84
Ferris, C. 34
Festinger, D.S. 18, 89
Feussner, G.K. 92
Field, C. 58
Fields, H.L. 8, 54
Fiellin, D.A. 37, 39
Fiestas, F.A. 12
Fingerhood, M. 37
Fiore, D. 42
Fischer, B.D. 4, 9, 34, 93
Fischer, G. 24, 35, 75
Fishback, J.A. 53

AUTHOR INDEX

- Fitzgerald, J.P. 66
 Fitzgerald, T. 9
 Fivel, P.A. 75
 Flaherty, M. 6
 Flannery, D. 66
 Fleckenstein, A. 74
 Flores-Ortega, Y.G. 59
 Flower, K. 56
 Floyd, L.J. 4, 39, 43
 Fokina, V. 32
 Foley, K. 18
 Foltin, R.W. 10, 23, 27, 36, 55
 Fong, C. 83, 90
 Fonseca, F. 11, 17, 53
 Forcehimes, A.A. 18, 46
 Ford, C.L. 66
 Ford, II, J.H. 58, 67, 90
 Foremny, G. 4
 Foresti-Zubaran, K. 32
 Forman, R. 16, 57
 Fornash, A. 93
 Forst, C. 87
 Forster, M.J. 31
 Forzisi, L. 87
 Foucher, J. 9
 Fox, H.C. 10, 87
 France, C.P. 5, 23, 79
 Franceschini, P. 32
 Franck, J. 56, 77
 Frank, I. 42
 Franklin, T. 73, 93
 Frasca, J. 69
 Frascella, J. 2
 Frederick, B.B. 94
 Freeman, K.B. 97
 Freeman, R. 17
 Freese, T. 51
 Friedman, E. 41
 Friedman, S.R. 4, 10
 Frisman, L. 43, 44
 Froimowitz, M. 33
 Fruehling-Wall, C. 94
 Fuchs, R.A. 34
 Fulbright, R.K. 49
 Fuller, C.M. 43
 Funk, R. 46
 Furr, E.B. 7
 Gabra, B.H. 7
 Gallagher, R.M. 15, 64
 Gallop, R. 48, 61
 Galloway, G.P. 55, 56, 78
 Galloway, M.P. 55
 Gamal Eddin, I.H. 13
 Gandhi, D. 38
 Gao, Y. 32
 García-Lecumberri, C. 92
 Garcia-Rodriguez, O. 84
 Gardner, E.L. 33, 72
 Gardner, T. 11, 84
 Garner, B.R. 44, 46
 Garnet, B. 26
 Garnier, C. 17
 Garnier, L. 64
 Garrett, N.R. 69
 Garrity, T.F. 11, 58
 Gasior, M.J. 81
 Gass, J. 37
 Gatch, M.B. 31, 79
 Gatchalian, K.M. 37
 Gates, P. 67
 Gauchet, A. 10, 61
 Gaughan, J.P. 9
 Geaghan, T. 17
 Gelberg, L. 19
 Gelhorn, H.L. 58
 Geller, E.B. 9, 13
 Gentilin, S. 15
 Gentry, W. 56
 George, S.R. 48
 Gerak, L.R. 32
 Gerbaud, L. 12
 German, D. 18
 Gerra, G. 45, 91
 Gerstenberger, E. 19, 57
 Gervais, A. 9, 10
 Ghandour, L.A. 87
 Ghoddoussi, F. 55
 Ghozland, S.G. 6, 92
 Gifford, E. 16
 Gignoux, N. 86
 Gilbert, G.E. 80, 81
 Gill, M.J. 34
 Gillespie, D. 27
 Gilliam, A.F. 13, 49
 Gillikin, C. 21
 Gilson, A.M. 66, 71
 Gines, J.M. 17
 Gingras, M. 21
 Glaser, P.E. 56, 70
 Glasmacher, C. 12
 Glasmann, A. 24
 Glasner-Edwards, S. 83
 Gleghorn, A. 15
 Glick, A. 20
 Gnegy, M.E. 13
 Goate, A. 73
 Godinez, M. 43
 Godley, M.D. 46
 Godley, S.H. 46
 Goeders, N.E. 5
 Gold, M. 38
 Goldberger, B. 38
 Golden, S.A. 79
 Goldman, M. 26, 27, 93
 Goldsamt, L.A. 43
 Goletiani, N. 54
 Golub, S.A. 71
 Gómez, E. 10, 44
 Gonzales, R. 18, 57
 González, G. 38, 85
 Gonzalez-Perez, J.L. 21
 Goodwin, A.K. 23, 72
 Goransson, M.O. 16, 83
 Gorbach, P. 44
 Gordon, A.J. 38, 89, 90
 Gordon, M.S. 21
 Gordon, S.M. 83
 Gorelick, D.A. 12, 18, 40, 87
 Gorka, S.M. 11, 38, 40
 Gould, R.W. 69
 Goulding, S.P. 54
 Gourarier, L. 9, 10, 61
 Gourevitch, M.N. 38, 60
 Gowin, J.L. 20
 Grabinski, M. 63
 Grabowski, J. 11, 96
 Grady, J.J. 40

AUTHOR INDEX

- Graff, F. 48
 Graham, C.M. 10
 Graham, J. 16
 Graham, N.A. 38
 Granger, D. 35
 Granmayeh, L.K. 97
 Grant, B. 24
 Grant, J.D. 59
 Grant, K.M. 69
 Grasing, K.W. 10
 Gray, K.M. 80, 81
 Green, C.M. 11, 53, 83, 96
 Green, T.G. 94
 Greenbaum, P.E. 60
 Greenberg, A.E. 41
 Greenberg, B. 85
 Greenberg, M.T. 81
 Greene, J. 24
 Greenfield, S.F. 61, 83
 Greenwald, M.K. 15, 36, 38, 63, 95
 Grekin, E.R. 12
 Grella, C. 19, 71, 78, 88
 Grey, J. 13
 Griffin, B. 66
 Griffin, M. 48
 Griffin, W.C. 75
 Griffing, S. 18
 Griffiths, R.R. 23, 31, 78
 Grinenko, A. 37
 Grohman, K. 61
 Groman, S.M. 26, 80
 Grosheider, T.J. 38
 Grossman, E. 38, 60
 Grov, C. 71
 Grunberg, N.E. 97
 Grunhaus, L. 82
 Gu, Y. 33
 Guenther, G. 63
 Guerra, R. 86
 Gunderson, E.W. 23, 25, 55, 64
 Guo, D. 53, 74
 Gust, S.W. 30
 Gustafson, D. 67, 90
 Gutierrez, S. 36
 Guldish, J.R. 63, 85
 Gyarmathy, A. 43
 Gyarmathy, V. 4
 Habecker, E. 54
 Haber, J.R. 59
 Haddox, J.D. 64, 66
 Hader, S. 41
 Hagan, H. 4, 65
 Haggkvist, J. 77
 Hagle, H. 91
 Hakansson, A. 86
 Hakun, J. 26, 27, 93
 Hall, D.R. 16
 Hall, E. 20
 Haller, D.L. 26, 70, 71
 Hallyburton, M. 80
 Halperin, J. 54
 Halpern, J.H. 31
 Hamann, S. 35
 Hamburger, R.B. 85
 Hamidovic, A. 74
 Hamilton, F. 41
 Hamilton, K.R. 97
 Hamilton, W. 38
 Hammarberg, A. 56
 Hammond, C. 38
 Hamon, S. 73
 Han, D.H. 54, 55
 Han, J.S. 4
 Haney, M. 10, 12, 13, 23, 27, 70
 Hankins, G. 32
 Hanley, K. 60
 Hanlon, C.A. 27, 55, 94
 Hannigan, J. 32
 Hanselka, L.L. 56
 Hansen, S. 83
 Hanson, G.R. 34, 74
 Hao, C. 42
 Harford, T. 39
 Harper-Castle, S. 60
 Harrand, A. 17
 Harris, A.C. 14
 Harris, E. 36
 Harris, T.R. 58
 Harrod, S. 72, 79
 Hart, C.L. 10, 23, 27, 55
 Hart, R. 85
 Hartje, J.A. 16, 89
 Hartman, C. 58
 Hartwell, K. 11, 83
 Hartzler, B.J. 86
 Harui, A. 3
 Harvey, R.C. 26
 Hashimoto, K. 8
 Hasin, D.S. 12, 24, 39, 84
 Hatch-Maillette, M.A. 15, 43
 Hathazi, D. 44
 Haug, N. 63
 Havens, J.R. 18, 20, 43, 44, 94
 Hawken, A. 20, 21
 Haynes, L. 9
 Hays, L.R. 55, 70
 Hazim, R. 33, 77
 Heath, A.C. 72, 73, 82
 Heckman, C. 63
 Hedden, S.L. 10, 11, 17, 24, 83
 Heil, S.H. 24, 26, 35, 36, 38
 Heimer, R. 27
 Heinzerling, K.G. 56, 96
 Heishman, S.J. 12, 60, 87
 Helmbrecht, T. 63
 Heltshe, S.L. 64
 Hemberg, J. 96
 Henderson, A.R. 79
 Henderson, C.E. 21, 60
 Henggeler, S.W. 16
 Henningfield, J.E. 1, 65, 66
 Henry, III, F.E. 4, 9, 34
 Herbeck, D. 42
 Herin, D.V. 11, 96
 Hernandez, A. 41
 Hernandez, P. 34
 Hernitche, T. 41
 Herrin, A.E. 9
 Herrmann, N. 75
 Hersh, D. 15
 Hershberger, J. 20
 Herting, J. 21
 Hester, R. 96
 Hetteima, J.E. 19, 58
 Hewitt, J. 58
 Hides, L. 46
 Hien, D. 41

AUTHOR INDEX

- Higa, J. 79
Higgins, S.T. 1, 24, 26, 36, 38, 67, 75, 97
Higgs, S. 13
Highfield, D. 21, 88
Higley, A. 72
Higuera-Matas, A. 92
Hij, A. 10, 61
Hill, K.P. 11, 77
Hillhouse, M. 42, 83
Hinkel, H. 82
Hirshon, J. 18, 40
Hjelmstad, G.O. 8
Ho, A. 8, 53
Hoffman, I.F. 4
Hoffman, J. 91
Hoffman, K. 90
Hofmann, M. 63
Hogan, J.B. 86, 88
Holzer, C. 40
Homish, D.L. 17
Homish, G.G. 40, 67
Hong, K.A. 37, 49, 87
Hong, K.X. 42
Hopfer, C. 58
Hoppe, M.J. 45
Hopwood, S. 41
Horton, Jr., A.M. 67
Horvatic, P.K. 51
Hossain, M.B. 39
Houston, R.J. 84
Hser, Y.Y. 38, 40, 87, 89
Hsiao, H. 78
Hsin, L.W. 7
Hu, M. 9
Hu, X. 35
Huang, D. 38, 40
Huang, S.L. 58
Huang, W. 33, 54, 96
Huang, Y. 49
Hucks-Ortiz, C. 44
Huebner, K.R. 11
Huizink, A.C. 27, 59
Hulbert, A. 62
Hunter, D. 8
Hunter, J. 18
Huntley, K. 28, 51
Hurd, Y.L. 25
Hursh, S. 86
Hurt, H. 3
Hussain, S. 63
Hutchison, M. 70
Hwang, J. 55
Hyde, E.M. 36, 55
Hyman, S.M. 37
Hyun Rhee, S. 27
Ialongo, N. 43
Icenhower, M. 69
Iguchi, M. 2
Inciardi, J.A. 41, 43, 44, 65, 72
Indarte, M. 49
Indlekofer, F. 12
Ingersoll, K.S. 24, 61
Ingram, B.L. 66
Inoue, T. 8
Inturrisi, C. 22
Iordanou, J.C. 34
Irtenkauf, S. 32
Irvine, R.J. 23
Isasi, C. 62
Isendahl, P. 86
Islam, L. 24
Ivanov, I. 54
Ives, M. 44, 46
Izenwasser, S. 25, 49, 50
Jackson, B. 96
Jackson, C. 53, 73
Jackson, D.O. 63
Jackson, L. 37
Jackson Bloom, J. 44
Jacob, T. 59
Jacobs, P. 68
Jacobson, A.E. 7
Jaehne, E.J. 23
Jaffe, C. 56
Jaffe, J.H. 21, 28, 88
Jaffee, W. 45, 48
Jager, G. 94
Jagsch, R. 75
Jagust, W.J. 54
Jain, R. 74
James, A.S. 80
Janes, A.C. 94
Jang, M. 78
Jansson, L.M. 36
Jayaram-Lindstrom, N. 56
Jenab, S. 8, 33, 34, 77, 79
Jenab, V.Q. 77
Jens, W. 26, 27, 93
Jentsch, J.D. 26, 80
Ji, F. 53
Jiang, D. 40
Jiang, H. 37
Johanson, C.E. 78, 87
John-Hull, C. 15
Johnson, A. 83
Johnson, B.A. 60
Johnson, B.D. 66
Johnson, F. 32, 37
Johnson, K.M. 31
Johnson, M.L. 72
Johnson, M.W. 31
Johnson, N. 44
Jones, C. 92
Jones, H.E. 1, 24, 35, 36, 37, 75
Jones, J. 37
Jones, N. 91
Jones, J.B. 32
Jorgensen, M.J. 80
Joseph, H. 20, 26, 38
Joseph, J.E. 55
Joshi, D. 26
Jospitre, T. 18
Jullien, V. 9
Jungman, J. 9
Justus, T. 78
Jutkiewicz, E.M. 13
Kadrnka, C. 71
Kaiser, K. 82
Kalechstein, A.D. 96
Kaltenbach, K. 1, 24, 35, 47
Kaminski, B.J. 23
Kampman, K.M. 48, 50, 73, 93
Kang, S.Y. 10, 57

AUTHOR INDEX

- Kantak, K.M. 22, 26, 77, 93
 Kapasova, Z. 54
 Kaplan, G. 82
 Kaprio, J. 59
 Karakashian, M. 61
 Karjane, N. 60
 Karno, M. 19, 78
 Kasinather, V.B. 39
 Katz, E.C. 38
 Katz, G. 82
 Katz, H. 12
 Kaufman, M.J. 1, 94
 Kaushal, N. 33, 49
 Kavanagh, G.J. 90
 Kay-Lambkin, F. 46
 Keith, D. 54
 Kellam, S. 43
 Kelley, C.J. 33
 Kelley, M.L. 11, 17
 Kellogg, S. 57
 Kelly, B.C. 71
 Kelly, M. 75
 Kelly, S. 21, 86
 Kelly, T.H. 55, 62, 63, 80
 Kelly, T.M. 48
 Kemp, J. 19
 Kennedy, A. 56
 Kennedy, J.L. 73
 Kerndt, P. 3, 71
 Kerstetter, K.A. 49
 Kertesz, S. 85, 96
 Keshavan, M. 95
 Kessler, F.H. 61
 Keyes, K. 24
 Keyler, D.E. 14, 33
 Keyser-Marcus, L. 24
 Khan, M.R. 45
 Khatib, D. 95
 Khazan, B. 18
 Khurana, A. 45
 Kichko, I. 49
 Kidorf, M. 85, 86
 Kidorf, M.S. 88
 Kielstein, A. 78
 Kiertscher, S. 3
 Killeen, T.K. 13, 41, 59, 83
 Kilmer, B. 67
 Kilpatrick, D. 88
 Kilts, C. 55
 Kim, T.W. 19, 91
 Kindbom, K. 86
 King, G. 79
 King, S. 38
 King, V.L. 85, 86
 Kinlock, T.W. 21
 Kinsey, B.M. 33, 96
 Kippin, T.E. 49
 Kirby, K.C. 84
 Kirchner, K. 48
 Kirillova, G. 45
 Kirisci, L. 45, 48, 82
 Kirk, I.J. 23, 78
 Kirkpatrick, M.G. 55
 Kirsner, R.S. 19
 Kish, J. 65
 Kivlighan, K.T. 36
 Kleber, H.D. 25
 Klein, C. 45
 Klein, H. 39
 Kleykamp, B.A. 78
 Kline, A.T. 66
 Klintworth, E.M. 81
 Kloczynski, T.A. 54
 Kluth, J.T. 54
 Knackstedt, P.T. 5
 Knapp, B.I. 7
 Knauer, H. 36
 Knudsen, H. 43, 44
 Knudson, I.M. 75
 Ko, M.C. 33
 Kobayashi, Y. 4
 Koek, W. 23
 Kohut, S.J. 49
 Kollins, S.H. 80
 Koob, G.F. 69
 Kopanda, R. 91
 Kopstein, A. 91
 Korhonen, T. 59
 Kosten, T.A. 33, 49, 88
 Kosten, T.R. 11, 26, 77, 84, 88, 95, 96
 Koutsky, J.R. 17
 Kowal, B.P. 97
 Kowalczyk, W.J. 36
 Kozlov, A.P. 4, 43
 Kracen, A. 61
 Kraemer, K.L. 89
 Kramer, L.A. 26
 Kranzler, H.R. 24, 56
 Krauss, M. 58
 Kreek, M.J. 8, 34, 53, 73, 95
 Krishnan-Sarin, S. 54, 59, 80, 81
 Kritz, S.A. 15
 Kronborg, I.J. 3
 Kronstrand, R. 86
 Krstik, J. 78
 Krueger, P.M. 20
 Krupitsky, E. 37
 Kubiak, S.P. 63
 Kugelberg, F.C. 86
 Kuhn, C.M. 72, 73
 Kulaga, A. 16, 57
 Kuo, I. 41
 Kuper, L. 61
 Kurahashi, K. 4
 Kurtz, S.P. 65, 72
 Kushner, R. 46
 Kuzumaki, N. 8
 Lacadie, C.M. 49
 Lacy, R.T. 79
 Lam, K. 11
 Lam, W.K. 17
 Lamarre, N. 77
 Lamb, R.J. 10, 92
 Landes, R.D. 37, 97
 Lane, S.D. 20, 26
 Lanfranco, M.F. 33
 Langer, D. 91
 Langhorst, D. 35, 62
 Langohr, K. 53
 Langston, T.L. 49
 Languerand, E. 61
 Lanier, R.K. 36
 Lankenau, S.E. 44
 LaPaglia, D. 40
 Laranjeira, R. 62
 Larkby, C. 35

AUTHOR INDEX

- Larkins, S. 44
 LaRowe, S. 62, 88
 Larraburu, A. 91
 Larson, M.J. 17, 19, 57
 Latimer, W.W. 4, 10, 17, 24, 39, 43, 45
 Latkin, C.A. 4, 18, 41, 42, 43, 88
 Laudet, A.B. 18
 Lavie, E. 9, 10, 26, 65, 91
 Lawson, A.L. 4, 39, 43
 Le Blanc, C. 17
 Le Foll, B. 14, 95
 Léal, F. 9
 Leamon, M.H. 56
 Lebeau, R. 21
 Lechner, W.V. 83
 Lederman, C.S. 21
 Ledgerwood, D.M. 63
 Lee, A. 96
 Lee, B. 26, 54
 Lee, D.C. 80
 Lee, D.Y. 4
 Lee, H. 23, 78
 Lee, I. 15, 88
 Lee, J.D. 20, 38, 60
 Lee, N.K. 70, 96
 Leech, S.L. 35
 Leeman, R.F. 88
 Leff, M.K. 60
 Lehert, P. 78
 Lehman, W.K. 42, 86
 Leigh, B.C. 16, 45
 Leimsider, E. 37
 Leinbach, A.S. 81
 Lejuez, C.W. 11, 38, 40, 45, 58, 87, 88, 93, 94
 Leon, J.F. 7
 Leonard, K.E. 40
 Leonardi, C. 45
 Leoni, G. 49
 Leowen, G. 32
 Leraas, K. 80, 81
 Leri, F. 8, 69
 Lerman, C. 95
 LeSage, M.G. 13, 14, 79
 Leukefeld, C.G. 11, 18, 20, 37, 43, 44, 89
 Leventhal, A.M. 62
 Levin, F.R. 10, 12, 43, 52, 64, 68
 Levin, K.H. 12, 87
 Levine, R.A. 10
 Levran, O. 53
 Levy, A.M. 69
 Lewis, B. 35
 Li, C. 27
 Li, C.R. 49
 Li, H. 21
 Li, J. 5, 33
 Li, L. 42
 Li, M.D. 54, 73
 Li, N. 4
 Li, X. 33
 Li, Y. 26, 27, 62, 73, 93
 Li, Z. 35
 Liang, L. 87
 Liang, S. 42
 Liang, Y.X. 79
 Liautaud, J. 20
 Liberto, J. 90
 Libretto, S. 16, 91
 Licari, A. 16
 Licata, S.C. 17
 Liddle, H.A. 21, 29, 60
 Lieb, R. 12
 Lile, J.A. 55, 80
 Lim, J. 15
 Lin, J. 78
 Lin, J.L. 19
 Lin, K. 32
 Lin, M. 15
 Linares Scott, T. 36
 Lincoln, M.F. 61
 Lindholm, S. 77
 Lindsay, J. 83, 96
 Ling, W. 15, 25, 26, 96
 Link, T.C. 58
 Lintzeris, N. 70, 87
 Linzy, S. 53
 Liroy, K. 16
 Liss, T.B. 59, 80, 81
 Listerud, J. 37
 Little, S. 15
 Litwicki, T. 91
 Liu, C.Y. 58
 Liu, H. 4
 Liu, J. 79
 Liu, R. 1
 Liu, X. 93
 Liu, Y. 49, 53
 Llorca, P. 17
 Llorens, N. 38
 Llosa, T. 66
 Lloyd, J.J. 44
 Lo, S.J. 81
 Lobo, D.S. 73
 LoCastro, J.S. 19
 Locey, M. 14
 Lockhart, H. 87
 Lofwall, M.R. 36
 Lohman, M. 45
 Lohoff, F. 73
 Lomas, L. 9
 Lominac, K.D. 79
 London, E.D. 26, 28, 54, 56, 94
 Londono, D. 53
 Long, E. 2
 Longacre, I.D. 72, 79
 Longshore, D. 21
 Looby, A. 17, 87
 Lopacinski, S.M. 21
 Lopez, C. 32, 44
 Lopez, E. 67
 Lopez, J.C. 78
 Lopez, L.M. 9
 Lopez Vargas, E. 21
 Lord, S.E. 16, 45
 Loree, A. 36
 Lorenz, D.J. 64
 Lorenzi, F. 67
 Lott, D.C. 81
 Louie, B. 15
 Love, M. 19
 Lu, N. 91
 Lubman, D.I. 46
 Luftman, V. 63
 Luijten, M. 94
 Lukas, S.E. 13, 17, 60

AUTHOR INDEX

- Lundahl, L.H. 35, 78, 87
 Lundgren, L. 9
 Luther, J. 38
 Ly, T. 24, 61
 Lynch, K.G. 19, 48, 50, 83, 84
 Lynch, M.E. 35
 Lynch, W.J. 14
 Lynskey, M.T. 72, 73, 82
 Lyoo, I. 54, 55
- Ma, J.Z. 54
 Ma, Y. 4
 Maccarelli, L. 40
 Mach, J.L. 97
 Mackey, D. 16
 Mackey, D.H. 51
 Mackey, D.L. 58
 MacPherson, L. 45, 58
 Madden, L. 17, 67
 Madden, P.A. 72, 73, 82
 Madray, C. 15
 Madura, J.D. 49
 Maggs, J.L. 81
 Magidson, J. 42
 Magnus, M. 41
 Magura, S. 20, 26, 38, 83, 90
 Mahony, A. 10
 Maidment, N.T. 5
 Maitre, C. 72
 Malagon, M.A. 17
 Malcolm, R.J. 11, 62, 83
 Mallet, P. 47
 Malte, C.A. 56
 Mancha, B.E. 43
 Mancino, M.J. 37, 50, 56, 77
 Mandell, W. 18
 Mangold, J.E. 73
 Mangrum, L.M. 6, 57
 Manser, K. 10
 Manteuffel, B. 58
 Manubay, J.M. 25
 Marcus, M.T. 97
 Mardekian, S.K. 14
 Mardikian, P.N. 62
 Margolis, E.B. 8
 Mariani, J.J. 10, 12, 43
- Marinelli-Casey, P. 83, 89
 Markou, A. 92
 Markowitz, T. 86
 Marlowe, D.B. 18, 29, 89
 Marsch, L.A. 20, 26, 37, 58, 75
 Martell, B. 11
 Martin, B.R. 1, 31
 Martin, C.A. 55, 62, 63, 80
 Martin, C.N. 40
 Martin, G. 78
 Martin, N.G. 72, 73, 82
 Martin, P. 24, 35
 Martin, R. 21
 Martín-Santos, R. 53
 Martínez, D.C. 17
 Martins, S.S. 29, 87, 93
 Marusich, J.A. 34
 Masalov, D. 37
 Mascarella, W.S. 13
 Mashhoon, Y. 93
 Mason, B.J. 78
 Masson, C.L. 15, 85
 Masuda, A. 15
 Mateu-Gelabert, M. 10
 Mateyoke-Scrivner, A. 18
 Mathur, D. 10
 Matsumoto, R.R. 33, 49, 53, 72
 Mattick, R.P. 36
 Maurer, M.A. 66
 Maxwell, C. 90
 Maxwell, J.C. 38, 44
 Mayes, L.C. 35
 Mayet, S. 87
 Mazlan, M. 39, 42, 94
 Mazure, C.M. 88
 McCabe, S.E. 64, 65, 83, 93
 McCaffrey, D.F. 66
 McCann, U.D. 31
 McCarty, D. 67, 90
 McClernon, J. 22
 McClure, B. 16, 57
 McConnell, J. 67, 90
 McCoy, C.B. 4, 42
 McCuller, W.J. 21, 57
 McCurdy, C.R. 7, 33, 49, 72
 McDermott, M.J. 38, 93
- McDonald, C.L. 18
 McFetridge, A.K. 59, 80, 81
 McGaugh, J.D. 56
 McHugh, R.K. 86, 88
 McKay, J.R. 37, 84, 91
 McKetin, R. 57
 McKnight, C. 4, 15
 McLaren, J.A. 67
 McLellan, A.T. 91
 McMahan, L. 13
 McNees, E. 37
 McNeil, J.F. 60
 McNicholas, L.F. 26, 37
 McQueary, S. 62
 McQueen, K. 61, 84
 McRae, A.L. 13, 50, 59, 93
 Meade, C. 48
 Medina-Mora, M. 12
 Medina-Mora, M.E. 87, 88
 Meissler, J.J. 9
 Melanko, S. 80, 81
 Melia, D. 53
 Melin, P. 61
 Mellacheruvu, M. 91
 Mello, N.K. 54, 75
 Mendelson, J. 55
 Mendelson, J.E. 56, 78
 Mendez, A. 59
 Mennemeyer, S. 85, 96
 Mennes, C.E. 12
 Meredith, C.W. 56
 Mericle, A.A. 40
 Merlo, L. 38
 Merrill, J.O. 20, 26, 64
 Merritt, C. 44
 Merrouche, W. 9
 Merz, A. 88
 Mesangeau, C. 7, 33, 49
 Meshberg-Cohen, S. 41
 Messina, N.P. 89
 Metzger, D.S. 42, 43, 66
 Mezzich, A.C. 45, 82
 Michaels, M.S. 55
 Miele, G. 9
 Miguelez, M. 32
 Miguéns, M. 92

AUTHOR INDEX

- Mikulich-Gilbertson, S.K. 45, 60, 94, 97
- Milby, J.B. 85, 96
- Miles, D. 60
- Miles, J. 18
- Miller, E.K. 62
- Miller, J. 73
- Miller, L.L. 4, 34
- Miller, M.D. 94
- Mills, K.L. 41
- Milner, J.E. 40
- Milosevic, A. 78
- Minas, R.K. 82
- Minerly, A.C. 79
- Minnes, S. 35
- Mino, M.E. 10, 57
- Mintzer, M.Z. 23, 36, 78, 83
- Mitchell, J.M. 8, 15, 54
- Mitchell, M.M. 24
- Mitchell, T.B. 87
- Miyagawa, K. 34
- Miyatake, M. 34
- Mizuo, K. 34
- Moberg, C.A. 61
- Moberg, P. 6
- Moeller, F.G. 20, 26, 53, 74, 97
- Mohapatra, S. 93
- Mojsiak, J. 10, 92
- Molina, S.G. 68
- Monroy, M.A. 9
- Montbach, J. 41
- Monterosso, J. 54, 94
- Montes, K. 83
- Montgomery, G. 73
- Montoya, A.M. 64
- Montoya, G.L. 92
- Montoya, I.D. 52
- Monuteaux, M.C. 71
- Moolchan, E.T. 60, 81
- Mooney, J. 20, 44
- Mooney, L.J. 83
- Moore, A. 19, 78
- Moore, B.A. 37
- Moore, M. 59
- Moore, R.D. 3
- Moore, S.K. 58
- Morales, C. 44
- Morales-Manrique, C. 10
- Moran, M.M. 93
- Moran-Santa Maria, M. 50
- Morgan, D. 4
- Morgello, S. 53
- Morgen, K. 41
- Moron-Concepcion, J. 8, 33, 68
- Moroz, L. 39, 42
- Morral, A.R. 21, 66
- Morris, R.J. 43
- Morrison, D.M. 45
- Morrison, R. 84
- Moukaddam, N.J. 11, 74
- Mountford, A. 11
- Mouret, B. 90
- Moyers, W. 2
- Moyers, W.C. 1
- Mullett, T. 63
- Mumford, G.K. 1
- Murdock, E.L. 90
- Murff, W.L. 10
- Muroff, J. 57
- Murphy, D. 42
- Murray, H.W. 86, 88
- Murray, J.E. 69
- Murray, K.A. 12
- Murtaugh, M.P. 33
- Mustroph, M.L. 34
- Mutebi, M.M. 26
- Myers, B. 90
- Nader, M.A. 3, 28, 55, 69
- Nair, S.G. 79
- Nakamoto, K. 87
- Nakamura, A. 4, 8
- Nakonezny, P.A. 57
- Nandi, A. 43
- Nanovskaya, T.N. 32
- Napier, T.C. 68
- Napoleone, J. 85
- Narasimhan, D. 33, 69
- Narayana, P.A. 26
- Narayanan, S. 33, 49
- Narita, M. 4, 8, 34
- Nathan, P. 6
- Natividad, L.A. 14
- Navarro, H.A. 49
- Needham, M. 85
- Negro-Vilar, A. 32
- Negus, S.S. 4, 7
- Neisewander, J.L. 25
- Nejtek, V.A. 82
- Netherland, J. 37
- Neufeld, K.J. 85, 86
- Neumark, Y. 32, 44
- Neuner, F. 82
- Newberry, A.M. 65
- Newcorn, J. 54
- Newman, J.L. 75, 97
- Newton, T.F. 42, 56, 92, 96
- Nic Dhonnchadha, B. 69
- Nich, C. 81
- Nielsen, D.A. 53, 73
- Nielsen, S. 70
- Niikura, K. 4
- Nilson, D. 41
- Niv, N. 19, 78
- Nixon, S.J. 78
- Nolan, T.L. 7, 33
- Nordahl, T.E. 56
- Norman, A.B. 79
- Norman, M.K. 79
- Nunes, E.V. 9, 10, 11, 37, 41, 84
- Nurhidayat, A. 66
- Nuzzo, P.A. 36, 62, 63
- Nwokeji, E. 90
- Nyberg, F.J. 49
- Nyström, I. 86
- O'Brien, C.P. 22, 26, 27, 48, 50, 73, 93
- O'Dell, L.E. 14
- O'Grady, K.E. 21, 24, 35, 59, 60, 64, 86, 88, 93
- O'Hara, K. 53
- O'Malley, S.S. 54, 88
- O'Neill, J. 54
- Obara, I. 54
- Ober, A. 44
- Obot, I.S. 39

AUTHOR INDEX

- Odell, T. 16
- Odenwald, M. 82
- Okutsu, D. 4
- Olaizola, C. 72
- Olfson, M. 24
- Olive, M.F. 75
- Oliveto, A. 50, 56, 77
- Olson, D. 54
- Olson, G. 6
- Oncken, C. 24
- Ondersma, S.J. 12, 24, 35, 36, 63
- Orson, F.M. 33, 96
- Osborne, V. 65
- Oser, C.B. 20, 43, 44, 89, 94
- Oser, R. 16, 91
- Oslin, D.W. 15, 37, 64
- Ostermeyer, B. 90
- Ostrowski, M. 40
- Ott, J. 53, 73
- Otto, M.W. 86, 88
- Ouellet, L. 27
- Pacula, R. 67
- Paddock, S. 67
- Page, K. 13
- Pagnoni, G. 55
- Paidisetty, S. 90
- Pallas, D. 18
- Palmatier, M.I. 93
- Palmer, C. 17
- Palmer, J. 43
- Pantin, M. 59
- Park, S. 82
- Paronis, C.A. 60
- Parrino, M. 90
- Parrish, A.B. 49
- Parsons, J.T. 11, 71
- Partilla, J.S. 74
- Parzynski, C.S. 60, 81
- Pascal, M. 10, 61
- Passalacqua, E. 63
- Passeti, L.L. 44, 46
- Passik, S. 71
- Pasternak, G. 22
- Pastor, A. 53
- Patak, M. 80
- Patapis, N.S. 18
- Patel, S. 96
- Patra, J. 93
- Patton, G.C. 59
- Patwa, H. 85
- Pavlicova, M. 9
- Pawlik, J.L. 34, 80
- Payne, R. 64
- Payne, T.J. 54, 73
- Pearce, V.J. 57, 96
- Pechansky, F. 61, 62
- Pecora, A. 19
- Pecorarro, A. 19
- Peirce, J. 85, 86, 88
- Peles, E. 40, 53, 85, 86
- Penberthy, J.K. 24, 61
- Penetar, D.M. 13, 17, 60
- Penfold, R. 80
- Pennay, A. 96
- Pentel, P.R. 14, 33
- Pepper, N. 15
- Pereira Do Carmo, G. 4
- Peres, B. 7
- Perez, A.Y. 23, 55
- Pérez de los Cobos, J.C. 10, 38, 44
- Pergadia, M. 73
- Perlman, D.C. 4, 15, 65
- Perrine, S.A. 55
- Perry, E. 54
- Perry, J.L. 80, 97
- Personnic, S. 90
- Peters, C.H. 16
- Peters, D.E. 91
- Peters, E. 17
- Peterson, J.A. 41
- Petrakis, I. 85
- Petska, D. 91
- Pettinati, H.M. 48, 50
- Peyret, E. 61
- Pfister, H. 12
- Philbrook, M.A. 66
- Phillips, T.R. 55
- Phipps, L.B. 60
- Piazza, M. 62
- Picetti, R. 8, 34
- Picker, M.J. 4, 9
- Piechatzek, M. 12
- Pieper, B. 19
- Pimlott Kubiak, S. 89
- Pinsky, I. 62
- Pittenger, S.T. 14
- Pittman, A. 61, 90
- Pivavarchyk, M. 14
- Platt, D.M. 32, 60, 77
- Plebani, J.G. 50, 93
- Plebani-Lussier, J. 97
- Podawiltz, A. 82
- Podus, D. 38
- Poduska, J. 43
- Poldrack, R.A. 54
- Polgar, W.E. 7
- Poling, J. 11, 77
- Polk, T. 84
- Pollock, J. 5
- Polydorou, S. 64
- Poole, M.M. 89
- Popova, S. 93
- Popuch, R. 61
- Porkorny, S. 59
- Porrino, L.J. 27, 55, 94
- Portenoy, R.K. 26
- Portoghese, P.S. 48
- Posada-Villa, J. 12, 87, 88
- Potenza, M.N. 2, 49, 55
- Potik, D. 40, 86
- Potter, J.S. 25, 41
- Potter, L.B. 41
- Poudyal Chhetri, M.B. 12
- Poupaert, J.H. 33, 49
- Poznyak, V. 66
- Pradeille, J.L. 72, 78
- Prather, K. 25, 41
- Prather, R.A. 78
- Pratt, E.M. 88
- Prendergast, M.A. 72
- Prendergast, M.L. 20, 91
- Preston, K.L. 19
- Price, K.L. 93
- Price, R.K. 39
- Prisinzano, T.E. 7, 8, 69, 74
- Prochaska, J.J. 62

AUTHOR INDEX

- Provost, S. 25
Pulkkinen, L. 59
Pulvermacher, A. 90
- Qian, H.Z. 42
Qin, G.M. 42
Quanbeck, A. 67, 90
Quina, K. 21
Quinones-Jenab, V. 8, 33, 34, 79
Quirk, G. 22
- Raby, W.N. 10, 11, 37
Radhakrishnan, N. 91
Radovanovic, M.E. 12, 29, 87
Raehal, K.M. 31
Raggi, M.A. 45
Rahmim, A. 33
Raiff, B.R. 14
Raj, V. 95
Rajagopalan, K. 26
Rallapalli, S. 60
Ramchand, R. 21
Ramgopal, R. 38, 90
Ramirez, D.R. 34
Ramo, D. 46
Ramsey, N.F. 94
Randall, M. 85
Randall, T. 80
Randall-Thompson, J.F. 7
Randesi, M. 53
Rataemane, L. 57
Rataemane, S. 57
Raugei, R. 8, 53
Rauhut, A.S. 14
Rawls, A.L. 41
Rawls, S.M. 70
Rawson, R.A. 18, 56, 57, 83, 89, 96
Ray, B. 53
Raymond, K. 16, 94
Raymond, K.M. 45
Reed, B. 90
Rees, J. 37
Rehm, J. 93
Reiber, C. 21
Reichel, C.M. 69
- Reid-Quinones, K. 35
Reiller, B. 9
Reiner, S. 16
Reissig, C.J. 23
Reith, M.E. 74
Renshaw, P.F. 17, 54, 55, 94
Resnick, H. 88
Reynaud, M. 54
Reynolds, B. 80, 81
Reynolds, C.R. 67
Reynolds, E.K. 45, 58
Reynolds, M. 82
Rhee, S.H. 58
Rhode, R. 91
Rhodes, G.L. 15
Rice, J. 73
Rice, K.C. 7, 8, 23, 49, 77
Richards, B.D. 31
Richards, J.M. 38
Richards, W.A. 31
Richardson, G.A. 35
Richardson, K.A. 5
Richardt, S. 94
Ridenour, T.A. 45, 81, 82
Riehman, K.S. 58
Riggs, P.D. 45, 60, 68, 80, 89
Riley, A.L. 7, 8, 49, 70, 77
Riley, L.A. 21
Rinehart, D.J. 89
Ring-Kurtz, S. 16, 57
Ringel, J. 67
Rinker, J.A. 77
Ríos-Bedoya, C.F. 14, 29, 39
Risk, N. 39
Ritter, A. 90
Roache, J.D. 10, 92
Robbins, G. 80
Roberts, M. 89
Roberts, S.C. 66
Robinson, J. 56
Robinson, R. 80
Rocha, B. 28
Rocha, N.S. 61
Rockstroh, B. 82
Rodolico, J. 17
Rodriguez, L. 88
- Rodriguez Orengo, J. 21
Roehrs, T. 36
Roerig, S. 48
Rogers, J.L. 93
Rogers, N. 28, 51
Rogers, R. 75
Roget, N.A. 16, 51, 89
Rohan, M. 54
Rohrmeister, K. 75
Rohsenow, D. 82
Roiko, S.A. 14, 33
Roma, P.G. 77
Romach, M. 37
Roman, P. 83
Romanova, T. 37
Romero-Gonzalez, M. 85
Roscop, N. 65
Rose, R.J. 59
Rosen, M.I. 83, 84
Rosenblum, A. 20, 26, 38, 83, 90
Rosengard, C. 29
Rosenheck, R.A. 84
Rosenwasser, B.J. 84
Ross, C.A. 33
Ross, J. 64
Ross, J.T. 13
Roth, A.L. 27
Roth, M.D. 3
Roth, T. 36
Rotheram-Borus, M.J. 66
Rotheram-Fuller, E. 56, 96
Rothman, R.B. 7, 31, 74
Rotrosen, J. 16, 53, 57, 60
Rouault, M. 73
Rounds-Bryant, J.L. 84
Rounsaville, B.J. 55, 81
Rowe, C.L. 60
Rowlett, J. 32
Rowley, T.C. 88
Roy, J. 18
Ruan, Y.H. 42
Rubin, E. 10
Rudy, E.T. 3
Ruedi-Bettschen, D. 60
Ruglass, L. 65
Rus, S. 8

AUTHOR INDEX

- Rush, A.J. 82
 Rush, B.R. 40
 Rush, C.R. 55, 56, 62, 70, 89
 Russell, B.R. 23, 78
 Rutledge, M. 31
 Ruttenber, A.J. 31
 Rutter, J. 5
 Ryan, E.T. 17, 60

 Saavedra, J. 40
 Saccone, S. 73
 Saenz-Miranda, E. 45, 91
 Sage, R.E. 18
 Saitz, R. 19, 86, 89
 Sakai, J. 39, 58
 Saladin, M.E. 50, 88, 93
 Salama, C.H. 4, 39, 43
 Salem, A. 23
 Salinas, J.E. 88
 Salles, S. 62
 Salloum, I.M. 48, 60
 Sally, E.J. 7
 Salo, R.E. 56
 Samet, J.H. 19, 85, 86
 Sananes, M. 9
 Sanchez, H. 81
 Sanchez, J.P. 39
 Sanchez-Hervas, E. 84
 Sander, L.M. 35, 78
 Sanders, B. 44
 Sandoval, M. 10
 Sands, B. 18
 Sanfilippo, L.C. 11
 Sankey, H. 24
 Sannerud, C.A. 6, 91, 92
 Sannibale, C. 41
 Santana, N. 20
 Santhanam, P. 35
 Santiago, G. 34
 Santiago, O.J. 14
 Sargeant, M.N. 40, 87
 Saria, A. 74
 Sarkisyan, D. 78
 Sasadeusz, J. 3
 Satayathum, S. 35
 Saunders, B. 88

 Savage, S.R. 26
 Sawyer, G.W. 7
 Saxon, A.J. 15, 56
 Schauer, E. 82
 Schauer, M. 82
 Schepis, T.S. 59, 80, 81
 Scherrer, J.F. 59
 Schiller, M.J. 40
 Schillinger, M. 71
 Schlussman, S.D. 8
 Schmid, C.L. 31
 Schmidt, C. 85
 Schmidt, K.T. 34
 Schmidt, W.K. 71
 Schmitz, J.M. 11, 15, 53, 83, 96, 97
 Schmitz, T.W. 75
 Schnoll, S.H. 65, 66, 71
 Schottenfeld, R.S. 26, 37, 39, 42, 94
 Schramm Sapyta, N. 25
 Schreiber, S. 40, 85, 86
 Schrode, K. 4
 Schuetze, P. 35, 36
 Schuh, L. 48
 Schulz, K. 54
 Schumacher, J.E. 39, 42, 85, 96
 Schurig, M. 58
 Schuster, A. 19, 85
 Schuster, C.R. 3, 36
 Schuster, R.M. 40, 42, 87
 Schütz, C.G. 12
 Schwartz, R.P. 21, 38, 86, 88
 Scott, C.K. 17, 18
 Scott, M.C. 20
 Scott, T. 24
 Scotto di Cesare, E. 9
 Secades-Villa, R. 84
 Seddig, E.L. 16
 See, R.E. 22, 69, 79, 93
 Seewald, R. 57
 Segarra, A.C. 21, 34
 Seibyl, J.P. 54
 Seidman, G. 34
 Selby, P. 24, 35, 63, 70, 73
 Sellers, E. 32, 37

 Seltzman, H.H. 13, 49
 Selzer, J. 25
 Seo, D. 4
 Sepulveda, D.R. 65
 Serafine, K.M. 77
 Serowik, K. 83
 Setnik, B. 32, 37
 Settles, L. 89
 Seu, E. 26, 80
 Sevak, R. 55
 Severtson, S.G. 17, 24, 41, 45
 Sewell, R.A. 77
 Shacham, E. 43
 Shafer, M.S. 91
 Shaffer, J.H. 40
 Shaham, Y. 8, 79
 Shaikh, J. 33, 49, 53, 72
 Shaller, N.S. 60, 69
 Shannon, L.M. 18, 94
 Shao, Y.M. 42
 Sharkoski, T. 48
 Sheer, A.J. 18, 40
 Sheidow, A.J. 16
 Sheikhattari, P. 39
 Shelley, D. 13
 Shelley, K.D. 41
 Shelton, K.L. 32
 Sherbin Coffin, L. 65
 Sherwood, A.R. 31
 Shifflet Gibson, E.D. 89
 Shiokawa, M. 8
 Shipley, R. 91
 Shippenberg, T.S. 68
 Shivers, K.Y. 8
 Shmueli, D. 62
 Shoaib, M. 14
 Shoptaw, S. 3, 27, 44, 56, 96
 Short, E. 35
 Shropshire, C. 20
 Shufman, E. 82
 Shurtleff, D. 5
 Shuster, K. 16
 Sibanda, B. 91
 Sigmon, S.C. 24, 26, 36, 38, 50
 Silverman, K. 3, 37, 85
 Simmons, L.A. 94

AUTHOR INDEX

- Simoneau, J. 70
 Simpson, D. 7
 Simpson, D.S. 8
 Simpson, S.A. 13
 Singer, L. 35
 Singh, N. 33
 Singh, R.A. 33, 96
 Singleton, E.G. 12, 56
 Sinha, N. 8
 Sinha, R. 5, 10, 27, 35, 37, 49, 87
 Sinitsyna, L. 42
 Sircar, D. 79
 Sircar, R. 79
 Sizemore, G.M. 34
 Skinstad, A.H. 6, 16, 51, 83
 Slade, T. 61
 Slavina, T. 37
 Slawiak, L. 67
 Slesnick, N. 45
 Slobodyanyuk, P. 39, 42
 Smith, A.E. 59, 80, 81
 Smith, C. 35, 41
 Smith, F.L. 7
 Smith, H.R. 55
 Smith, M.A. 34
 Smith, M.L. 67
 Smith, M.Y. 64, 65, 66
 Smyth, E. 10
 Sobell, L.C. 61
 Sobell, M.B. 61
 Soderman, A.R. 74
 Sofuoglu, M. 11, 77
 Sokolowska, M. 37
 Solomon, P. 43
 Sonne, S.C. 15
 Sorensen, J.L. 15, 58, 63, 85
 Soto, G. 16
 Spaeth, A. 94
 Spealman, R.D. 77
 Spence, P.B. 9
 Spence, R.T. 61, 90
 Spence, S. 15
 Spiller, H.A. 64
 Spitznagel, E. 58
 Sproule, B.A. 63, 70, 75
 Spybrook, J. 83
 St. De Lore, J. 91
 Stairs, D.J. 72
 Staley, J.K. 54
 Stallings, M. 58
 Standish, K. 43
 Stanger, C. 59
 Stanick, V. 18
 Stanley, J. 95
 Starosciak, A.K. 97
 Staton-Tindall, M. 20, 37, 43, 44
 Stauffer, J. 32
 Staying Safe Valencia, G. 10
 Stefanovics, E.A. 84
 Stefanski, A. 32
 Stein, J. 91
 Stein, L. 21, 29
 Steinberg, J.L. 20, 26, 71
 Steinmiller, C. 38
 Stephens, R. 58
 Stephens, S.L. 36
 Stevens, C.W. 7
 Stevens, D. 60
 Stevenson, G.W. 8
 Steward, T. 96
 Sticht, M. 69
 Stiklus, S. 54
 Stine, S. 24, 35
 Stitzer, M.L. 20, 37, 57, 63, 84, 85, 97
 Stöckl, P. 74
 Stoddard, A.M. 17
 Stoller, K.B. 19, 85, 86, 88
 Stoops, W.W. 55, 56, 62, 70, 89
 Storr, C.L. 58, 87, 93
 Stotts, A.L. 15, 84
 Stovall, D. 60
 Stover, S.K. 45, 60
 Strain, E.C. 26, 36, 52, 75, 82, 83
 Strandberg, J.J. 86
 Strang, J. 87
 Strathearn, L. 95
 Straub, A. 55
 Street, C. 16
 Striley, C.L. 90
 Stutz, S.J. 69
 Su, Z. 34
 Suh, J.J. 26, 27, 93
 Sullivan, L.E. 37, 39
 Sullivan, M.A. 10, 36, 37
 Summers, K.M. 16, 83
 Sumpter, R. 15
 Sun, W.L. 33, 77, 79
 Sunahara, R.K. 33, 69
 Surratt, C.K. 49
 Surratt, H.L. 41, 43, 65, 72
 Suttorp, M. 67
 Suzuki, M. 4, 8
 Suzuki, T. 4, 8, 34
 Sved, A.F. 93
 Svikis, D.S. 18, 24, 35, 41, 60, 62, 85
 Swanson, A. 56, 96
 Sweitzer, M.M. 14
 Swendsen, J. 72
 Swieter, M. 28, 51
 Swift, R. 82
 Swift, W. 59, 67
 Swogger, M.T. 84
 Sydnor, K. 39
 Szumlinski, K.K. 53, 54, 79, 92
 Tafazoli, S. 54
 Taffe, M.A. 13
 Tai, B. 1
 Tajima, B. 63
 Takeda, K. 34
 Takei, D. 8
 Tallarida, R.J. 77
 Tamagnan, G.D. 54
 Tancer, M.E. 55, 78, 87
 Tapia, E. 62
 Tapp, A. 56
 Tartarini, W. 13
 Tarter, R. 82
 Tashkin, D.P. 3
 Tassini, K. 19
 Tatarsky, A. 57
 Taylor, D.A. 70
 Teesson, M. 41, 61
 Tejeda, H.A. 14
 Tella, S.R. 6, 92

AUTHOR INDEX

- Temes, C. 16, 57
 Templin, T.N. 19
 Ten Have, T. 43
 Tennille, J. 43
 Terry, P. 13, 47
 Teter, C.J. 65, 83
 Tetrault, J.M. 39
 Thau, K. 75
 The PACARDO Research Consortium 59
 Thiruvazhi, M. 31
 Thomas, B.F. 13, 49
 Thomas, C. 15, 97
 Thomas, C.S. 75
 Thomas, L.M. 65
 Thombs, D. 59
 Thompson, A. 40
 Thompson, L.L. 97
 Thompson, R.E. 3
 Thorell, M. 32
 Thorner, E.D. 81
 Thostenson, J. 59
 Thurstone, C. 80, 81
 Tiburcio, N.J. 20
 Tidey, J.W. 82
 Tidgewell, K. 8
 Tilburt, J. 19
 Tilekar, S. 3
 Timothy, M. 79
 Tirado, C.F. 44
 Tobias, M. 54
 Tobin, K.E. 4
 Todd, R. 73
 Tokuno, H. 85
 Toll, L. 7
 Tolliver, B.K. 82
 Tolliver, J.M. 92
 Tomás, S. 44
 Tomás-Rosselló, J. 45, 91
 Tompkins, D.A. 19, 85
 Tompkins, Jr., W. 24
 Toneatto, T. 40
 Tonigan, J.S. 18, 19, 35, 46
 Torggler, B. 91
 Toro Guerrero, J. 81
 Torrens, M. 11, 53
 Torres, O.V. 14
 Torrijos, M.J. 44
 Torruella, R. 66
 Touzeau, D.P. 90
 Toyooka, N. 14
 Treatnet Network 91
 Trecki, J. 70
 Trksak, G.H. 13
 Tross, S. 9, 39
 Trudeau, K. 45
 Trzepacz, P. 48
 Tsibulsky, V.L. 79
 Tsikitas, L.A. 93
 Tsoi, M. 37
 Tsuneki, H. 14
 Tsurukawa, Y. 8, 34
 Tull, M.T. 38, 93
 Tulloch, B. 57
 Tulloch, I. 34
 Tuohy, C. 91
 Turner, C. 29
 Tuten, M. 37, 75
 Tuttle, J.P. 36
 Tzilos, G.K. 15, 36
 Uhl, G. 95
 Ullrich, T. 8
 Umbricht, A. 37, 83
 Unterwald, E.M. 7, 70, 73, 74
 Upadhyaya, H. 59, 62, 80, 81, 88
 Upadhyaya, H.P. 50, 68, 81
 Upwood, E.F. 45
 Urada, D. 21
 Urschel, III, H.C. 56
 Vadhan, N.P. 10, 27
 Vahabzadeh, M. 19
 Valderrama-Zurián, J.C. 10, 38, 44
 Van Dam, N.T. 87
 van Gorp, W.G. 27
 Van Paemelen, A. 91
 van Ree, J.M. 94
 Vandrey, R. 57
 VanScoyoc, J. 59
 Vansickel, A.R. 56, 62, 89
 Vanyukov, M. 45, 82
 Varela, T. 41
 Vaughn, M. 62
 Vedam, S. 72
 Veira, Y. 35
 Velasquez, M.M. 61, 84
 Velez, M. 36
 Venner, K.L. 19
 Verbitskaya, E. 37
 Versek, B.E. 84
 Vesga, O. 24
 Vicknasingam, B. 42
 Vidal, A. 44
 Viguié, P. 17
 Villalobos, G.C. 20, 63
 Villano, C. 83
 Villars, S. 9
 Vincent, K.B. 59, 60, 64, 93
 Vitoc, C. 81
 Vlahov, D. 43
 Vogel, H. 83
 Volkow, N.D. 1
 Volz, T. 74
 Von Diemen, L. 62
 von Sternberg, K.L. 61, 84
 von Thomsen, S. 17
 Vosburg, S.K. 10, 25, 36
 Vuchinich, R. 85, 96
 Wagner, C.C. 61
 Wagner, F.A. 29, 39, 89
 Wagner, G. 32
 Wagner, K. 44
 Waldron, M. 72
 Waldrop, A.E. 11, 50, 59, 82
 Walker, A.W. 69
 Walker, C. 62
 Walker, D. 48
 Walker, M. 54
 Walker, M.D. 92
 Walker, Q.D. 72
 Walker, R. 18, 37
 Wallace, C.L. 10, 92
 Wallace, D. 85, 96
 Walley, A.Y. 85
 Wallin, C. 86

AUTHOR INDEX

- Wallis, A.B. 16
- Wallisch, L. 61, 90
- Walsh, R. 52
- Walsh, S.L. 36
- Wang, D. 4
- Wang, F.L. 45, 58
- Wang, J. 44, 65, 73, 96
- Wang, Y. 35
- Wang, Z. 26, 27, 73, 93
- Ward, S.J. 34
- Warda, U. 19, 20, 78
- Wartella, J.E. 24
- Wassum, K. 5
- Waters, A.J. 62
- Waters, V. 61
- Watkins, D.J. 49
- Watson, D.W. 21, 57
- Weaver, M.F. 20, 63
- Weaver, M.T. 34
- Webster, J.M. 11, 58
- Wechsberg, W. 35
- Wee, S. 69
- Weed, M.R. 33
- Weeks, K. 19
- Weerts, E.M. 23, 72
- Weierstall, K. 79
- Weimer, M. 87
- Weintraub, D. 2
- Weiss, F. 5
- Weiss, L. 37
- Weiss, R.D. 25, 41, 45, 48
- Welch, C. 20
- Wells, A. 8
- Wells, B. 11
- Weltman, M. 3
- Wente, A.O. 58
- Wenzel, S.L. 18
- Werch, C.C. 59
- Wermeling, D.P. 55
- Wesley, M.J. 27, 55, 94
- Wesnoski, S.A. 21
- West, B.T. 93
- West-Ojo, T. 41
- Westerberg, D. 71
- Whitaker, D.E. 10, 43, 45
- White, M.C. 20
- White, M.K. 46
- White, W.L. 18
- Whittaker, K. 42
- WHO Opioid Substitution
Therapy Study Group 42
- Widner, G. 39
- Wieczorek, C. 81
- Wieczorek, C.E. 81
- Wiedemer, N. 15
- Wihbey, K.A. 8
- Wilcox, C.E. 54
- Wilcox, K.M. 33
- Wilens, T.E. 48, 68, 71
- Wilkinson, J. 18
- Williams, A.M. 67
- Willner-Reid, J. 19
- Wills, T.A. 62
- Wilson, K. 15
- Wilson, L.L. 72
- Wilson, M. 21, 88
- Win, S. 38
- Windham, A.M. 43
- Windsor, L. 39, 62
- Wines, Jr., J.D. 17, 86
- Wing, V.C. 14
- Winhusen, T. 35
- Winklbaaur, B. 75
- Winstanley, E.L. 82, 83
- Winter, M. 19
- Winters, K. 6, 46
- Wisdom, J.P. 58
- Wise, M.E. 58
- Wish, E.D. 59, 60, 64, 93
- Wisner, K. 47
- Wittchen, H.U. 12
- Wodak, A. 57
- Wolf, M.E. 68
- Wong, C.J. 62, 63, 85
- Wong, D.F. 33
- Wong, H. 16, 91
- Wong, L.L. 91
- Wood, D.S. 60
- Woods, J.H. 13, 33, 69, 70
- Woods, W.L. 16, 89
- Woodward, N.D. 74
- Woody, G.E. 37, 42, 46, 66
- Woolverton, W. 97
- Wooters, T. 13
- Worhunsy, P. 55
- World Mental Health Survey
Consortium 12, 88
- World Mental Health Surveys
Consortium 87
- Worley, P.F. 53
- Wu, E. 32
- Wu, G.Y. 88
- Wu, H. 5, 40
- Wu, L. 79
- Wu, Y. 33, 96
- Wunsch, M.J. 87
- Wupperman, P. 18, 20
- Xi, Z.X. 33, 72
- Xia, Y.F. 8
- Xie, H. 48
- Xing, H. 42
- Xu, H. 7
- Xu, Q. 73
- Yamamoto, B.K. 92
- Yan, P. 27
- Yanasak, E. 56
- Yang, K. 73
- Yang, M.H. 17
- Yango, E. 25
- Yasseen, B. 73
- Yeatts, S.D. 11
- Yekkirala, A. 48
- Yeung, A. 61
- Yi, R. 97
- Yin, L. 42
- Yoon, J.H. 67, 97
- Yoshihara, M. 3
- Young, J.H. 19
- Young, S. 58
- Yu, S. 4
- Yuan, C. 4
- Yuferov, V. 53, 73
- Yurgelun-Todd, D. 47
- Zacny, J.P. 36
- Zaharovits, I. 56

AUTHOR INDEX

Zakharova, E. 49
 Zaleski, M. 62
 Zammarelli, L. 63
 Zanis, D.A. 21
 Zavadil, F. 16
 Zawertailo, L.A. 63, 73
 Zerden, L. 9
 Zernig, G. 74
 Zezula, J. 7
 Zezyulin, O. 39, 42
 Zhan, C.G. 69
 Zhang, S. 48
 Zhang, X.Y. 49, 88
 Zhang, Y. 8, 13, 49
 Zhang, Z. 13, 14
 Zhao, M. 4
 Zharikova, O. 32
 Zheng, G. 14
 Zhou, D.F. 88
 Zhou, H. 93
 Zhou, L. 33, 77, 79
 Zhou, Y. 8, 33
 Zhu, J.L. 42
 Zhu, S. 39
 Zhuo, J. 3, 42
 Ziedonis, D. 63
 Zielinski, T. 82
 Zolkowska, D. 74
 Zonana, H. 18
 Zorick, T.S. 56
 Zorn, K. 74
 Zosel, A.E. 64
 Zubaran, C. 32
 Zule, B. 27
 Zule, W. 43
 Zvartau, E. 37

SYMPOSIA

Sunday, June 15

*Of vice and men: Shared brain vulnerabilities for drug
and non-drug (food, sex, gambling) rewards*

Chairs: Anna Rose Childress and Marc Potenza

Emerging brain, behavioral and genetic data point to substantial overlap in the vulnerabilities for compulsive pursuit of drug and non-drug (e.g., food, sex, and money) rewards. Overlapping vulnerabilities have been linked both to the mesolimbic dopamine reward system and to its failed regulation by frontal regions. Dr. Joe Frascella will review neuroimaging evidence that low dopamine (DA) D2 receptor availability, a feature linked to increased cocaine administration in primates, occurs not only in several drug addictions, but also in obesity. Dr. Lucy Brown will describe activation of the ventral tegmental area (origin of midbrain DA cell bodies) and dorsal striatum (r. caudate, a DA terminal region) in individuals viewing their target of intense, early infatuation. Dr. Marc Potenza will offer several parallels between pathological gambling and drug addiction, noting that frontal regulatory regions are less active when gamblers are engaged by a gambling scenario. Underscoring the role of DA in both drug and non-drug rewards, Dr. Dan Weintraub will describe emergence of problematic sexual, gambling, eating, shopping, repetitive “punding” behaviors, and compulsive medication/drug use, in Parkinsons patients on DA replacement therapy. Following the presentations, Dr. Childress will open an audience discussion on their theoretical, treatment, and nosological implications. For example, by targeting shared vulnerabilities, both prevention and treatment efforts may be able to impact multiple disorders simultaneously (“one-stop shopping”). Our addiction nosology, which has thus far compartmentalized the compulsive pursuit of drug from non-drug rewards, may eventually reflect the rapidly advancing knowledge of shared brain vulnerabilities.

*Cocaine dependence and social disadvantage:
Evidence from the laboratory, clinic, and community*

Chair: Stephen T. Higgins

Cocaine use in the U.S. has followed a pattern that is common with drugs of abuse wherein use is introduced by the more socio-economically affluent and gradually diffuses overtime to the socio-economically disadvantaged. Then as the serious health and other adverse consequences of the drug use are realized, use among the more educated drops off precipitously while use among the less educated and socio-economically disadvantaged persists. The aforementioned pattern has substantial implications for basic and clinical researchers of cocaine and other drug dependence. For example, what basic determinants of cocaine or other drug dependence explain these striking pattern? Can we reconcile what are deemed to be the basic determinants of drug dependence with these epidemiological trends? Do we have to consider potential novel interactions between more molar and molecular determinants to explain these patterns? What implications do these patterns have for the development of effective interventions to prevent and treat cocaine and other drug dependence? This symposium has been organized to address the following three overarching aims: (a) to underscore the importance of the influence of socio-economic disadvantage to understanding and eliminating cocaine and other drug dependence, (b) to illustrate the exciting, cross-disciplinary research that is being conducted on this topic, and (c) to articulate the important scientific, clinical, and policy implications of this research.

SYMPOSIA

Monday, June 16

Addiction liability and pain relief medication: Raymond Houde Memorial Symposium

Chairs: Charles P. O'Brien and Charles Inturrisi

This symposium is dedicated to the memory of Raymond Houde, MD, and will feature up-to-date reviews of the science of opiate analgesics and the methodologies Houde pioneered. Charles Inturrisi will discuss Houde's contributions to the modern analgesic table and the pharmacological basis of opioid rotation. Gavril Pasternak will review current concepts of multiple opiate receptors and how Houde's clinical analgesic research impacted on basic science. John Farrar will review the development of measures of analgesic efficacy as pioneered by Houde and Houde's impact on modern analgesic study design. William Dewey will discuss Houde's impact on new analgesic drug development and present a perspective on analgesics of the future.

Understanding extinction learning and its translation to drug addiction

Chairs: Paul Schnur and David Shurtleff

Drug addiction is a chronic relapsing disorder characterized by a persistent desire or compulsion to use a drug, loss of control of drug intake, reduction in other important activities, continued use despite knowledge of harm, tolerance, and an abstinence syndrome when the drug is unavailable. Becoming addicted to drugs usually begins with occasional use, which over time gives way to compulsive, uncontrollable use. Alternating cycles of relapse and periods of abstinence are common. Basic research suggests that becoming addicted involves long-term neuroadaptations that underlie learning and memory consolidation. Research further suggests that relapse often follows exposure to drug-related cues and that the motivation to self-administer drugs increases (i.e., incubates) during abstinence. Basic research aimed at understanding extinction mechanisms in order to enhance extinction learning might pave the way for treatment approaches with improved effectiveness. Enhancing extinction of drug seeking is challenging for several reasons: Drugs of abuse, in comparison to natural appetitive rewards, significantly increase neural activity that may lead to exaggerated habit learning and enhanced motivational significance (i.e., salience) of cues associated with drug taking. Moreover, exposure to drugs of abuse may cause epigenetic changes, changes in gene expression, and protein modifications leading to profound neurobiological deficits that may impair cognitive and behavioral abilities such as relearning, inhibitory control, conditioned inhibition or other processes critical for extinction learning. This Symposium will highlight recent research exploring the mechanisms of extinction learning and its translation to therapies for reducing drug seeking. Speakers will focus on the behavioral paradigms employed, the neural circuitry involved in extinction learning and the therapeutic application of extinction procedures to drug addiction.

Adults may be from Mars but adolescents are from Venus

Chairs: Minda R. Lynch and James Bjork

Adolescence is an especially vulnerable period in development that has been associated with enhanced risk taking and a high incidence of drug abuse initiation. There is also evidence that the risk for developing dependence and addiction is greater during this early developmental stage. Researchers using animal models in adolescence are capitalizing on recent developments in genetic, cellular, systems neurobiology and behavioral approaches to understand adolescent responsivity and sensitivity to rewards. Findings from these studies suggest that adolescent exposure to drugs of abuse has enduring effects on the subsequent vulnerability for addiction. Investigations have begun to examine events in brain development that set the stage for altered behavioral sensitivity to reinforcement, stress reactivity, and conditioning to emotionally salient

SYMPOSIA

stimuli along a developmental continuum. Developmental differences are being probed with sensitive behavioral assessments to identify phenotypes and model social or environmental influences that confer enhanced sensitivity to drug rewards during adolescence. This symposium will bring together research from animal models in adolescent stress, emotion and motivation, with perspectives from human neuroimaging research on reward reactivity in adolescents, to discuss how behavioral and neurobiological changes in development might account for an enhanced vulnerability to drug abuse.

Sexual acquisition and transmission of HIV from and among drug-using populations

Chairs: Martin Y. Iguchi and Richard Jenkins

NIDA's Sexual Acquisition and Transmission of HIV Cooperative Agreement Program (SATHCAP) seeks to better understand the behavioral, biological, and environmental influences on the sexual transmission of HIV/STIs among drug-using populations and the diffusion of infections from drug users (DUs) to non-drug users. To date, over 7,000 DUs, men who have sex with men (MSM), and sexual partners (SPs), have been recruited in four cities by a coordinating center (RAND) and collaborating institutions: Los Angeles (UCLA); Chicago (UIC); Raleigh-Durham (RTI); and St. Petersburg, Russia (Yale and Biomedical Center). Data were collected from all sites using a common sampling approach and data collection instrument. SATHCAP utilized a relatively novel sampling approach, Respondent-Driven Sampling (RDS), with HIV seroincidence estimated from cross-sectional data using the serologic testing algorithm for recent HIV seroconversions (STAHRS). Several unique and important cross-site and site-specific findings are reported. In WAVE 1 (n=3,269), 9%, 11%, and 31% of study participants in Chicago, Raleigh-Durham, and Los Angeles (respectively) were men who reported sex with both men and women (MSMW). Almost all MSMW were African American, not gay identified, and using stimulants (primarily crack). We also report contrasting epidemic features between US sites (varied prevalence and low seroincidence) and our Russian site (high HIV prevalence and incidence), comparisons of rural and urban populations, molecular versus behavioral indicators of HIV transmission, biological and behavioral indications of intervention reach and effectiveness, as well as identification of potential bridge groups and related risk behaviors (e.g. MSMWs engaging in anal sex with women).

The twin design: Studying genes and environment on substance use behaviors

Chairs: Arpana Agrawal and Michael T. Lynskey

The goal of our symposium is to introduce our colleagues to exciting new findings emerging from three independent twin registries (two from the U.S. and one international) that inform the etiology of alcohol, tobacco, cannabis and other illicit drug use behaviors. The twin design can partition individual differences in substance use behaviors into genetic, familial environmental and individual-specific environmental influences and explain the extent to which the co-occurrence of substance-related behaviors is attributable to common genetic liability. Presentations will aim to specify the role of such common genetic and environmental influences on earlier (Huizink) and later (Rhee) stages of drug use. The role of genetic vulnerability to seemingly 'environmental' measures will be exemplified through peer group deviance and its relationship with drug use (Gillespie). A long-term goal of this symposium is to allow for enthusiastic dialogue between twin researchers and CPDD attendees and initiate discussions for subsequent workshops and training opportunities in the twin method at CPDD.

SYMPOSIA

Tuesday, June 17

The consequences of chronic cannabis abuse: From neurochemistry to treatment

Chair: Philip Terry

After a period during which cannabis consumption became more socially acceptable in several developed countries, serious concerns are again being expressed about the effects of long-term cannabis use on psychological well-being. Reported rates of cannabis dependence have increased considerably in the USA, the EU, Australia and South Africa over the last 10 years, and the numbers of people entering treatment for problems associated with cannabis have also increased dramatically. For example, over 40% of new clients entering treatment in Germany, Denmark, and Hungary now cite cannabis abuse as their main concern. The aim of the symposium is to provide an overview of our current understanding of how long-term cannabis abuse affects brain and behavior, and to evaluate the implications of recent research for therapeutic intervention. Such an overview is also apposite given the increasing availability of cannabinoid drugs in clinical practice. The symposium will first review recent preclinical studies that have characterized the effects of repeated cannabis use on various neurotransmitter systems, drawing out their functional implications. Next, it will describe the impacts of cannabis use on two aspects of psychological function that have attracted considerable research attention over recent years: cognition and mental health, focusing on the association between cannabis use and psychosis. Recent brain imaging studies will be presented, linking behavioral changes to functional changes in the brain. Often neglected, the significance of these changes for the everyday lives of long-term cannabis users will also be examined. Finally, recent approaches to the treatment of cannabis abuse will be reviewed.

Neonatal responses to maternal substance use

Chairs: Karol Kaltenbach and Loretta Finnegan

In-utero exposure to illicit drugs and/or treatment medications may precipitate abstinence symptoms and other complications in the neonatal period. Common exposures in pregnant women, including opiates/opioids (heroin, oxycodone, methadone, and buprenorphine), cocaine, and antidepressant medications, will be discussed. Infants prenatally exposed to opioids/opiates have a high incidence of neonatal abstinence syndrome (NAS), characterized by predictable symptoms. Considerable controversies exist concerning the choice of treatment medications for NAS and determination of treatment and efficacy of current regimens will be described. Data from prospective studies on growth and neurobehavioral outcomes of neonates exposed *in utero* to cocaine will be presented. Strengths and limitations of the available clinical research on this topic will be summarized as well as the implications for long-term consequences on the developing child. Early reports of Selective Serotonin Reuptake Inhibitor (SSRI) use during pregnancy in relatively small samples did not identify an increased risk for major malformations; however, as data accrued, other adverse reproductive outcomes were associated with exposure. Research regarding exposure to *in utero* SSRIs or major depression will be described with regard to 1) minor physical anomalies, 2) maternal weight gain, 3) the rate of premature birth, and 4) neonatal adaptation. Data related to buprenorphine in the treatment of opiate dependence in pregnancy and neonatal outcome data will be summarized and implications presented. Although much has been learned over the past several decades from research of *in utero* drug exposure, continued evidence-based studies are essential if we are going to determine the intricacies of NAS and the effects upon the newborn. The symposium will provide clear directions as to how to continue to advance the science and improve the treatment of pregnant substance-dependent women and their *in utero* exposed children.

SYMPOSIA

Functional and clinical relevance of opioid receptor heterodimers

Chair: Philip S. Portoghese

Opioid receptors are members of the class A group in the superfamily of G Protein-coupled receptors (GPCRs). Over the past decade, there have been numerous reports that opioid receptors and other GPCRs can undergo heterodimerization in cultured cells. Given the potential pharmacological and physiological diversity that may arise from such heterodimerization, an important challenge in opioid research is the development of selective tools for the investigation of opioid receptor heterodimers in vivo. Such tools would be useful for in vivo investigations and would clarify the functional roles of heterodimeric opioid receptors in experimental animals. This may provide a basis for the development of potent analgesics with reduced tolerance, dependence, and other side effects. In this symposium, the first speaker will discuss evidence for opioid receptor heterodimers. The second and third speakers will present results of experiments with ligands that selectively activate opioid heterodimers in experimental animals. Evidence will be presented for the selective activation of opioid receptor heterodimers that are clinically employed as analgesics. The finding that these ligands have little or no tolerance or physical dependence in mice suggest that targeting opioid receptor heterodimers is a viable approach to the development of analgesics that are free of side effects.

Wednesday, June 18

Trafficking signals and addictive processes

Chairs: Kathryn A. Cunningham and Toni S. Shippenberg

The trajectory from drug use to addiction begins against a background of vulnerability based upon genetic and environmental factors, and progresses as neuronal plasticity in key brain circuits develops. This plasticity is related to both the pharmacological impact of the abused substance as well as the learning and memory processes that associate drugs and environmental cues. The means to reverse neuroplastic events and therapeutically improve function in the addicted brain is an important quest and one ripe for near-term therapeutic potential with positive outcomes. One important advance in understanding the mechanisms underlying plasticity is the characterization of protein trafficking and cellular webs of proteins associated with key neurotransmitter systems in addiction. The present symposium focuses on specific advances in the mechanisms of addiction that may involve trafficking and protein movement within cellular structures.

Advances in the development of medications for comorbid ADHD and substance use disorders

Chairs: Petra Jacobs and Frances R. Levin

Studies have shown an epidemiological and clinical association between Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD). Individuals with ADHD have a high risk of developing SUDs, and conversely, individuals with SUDs often have a history of ADHD symptoms. Furthermore, history or current diagnosis of ADHD can affect the outcome of the treatment of SUDs. Adequate treatment of ADHD appears to reduce the risk of SUDs. The pharmacological treatment of comorbid ADHD and SUD can pose important challenges for the clinician. Some medications for the treatment of ADHD carry a risk of dependence or diversion, and some drugs of abuse can worsen the symptoms of ADHD. However, recent findings about possible shared neurobiological mechanisms between both disorders are offering new opportunities for the development of medications for the treatment of this comorbidity. For example, dopamine dysfunction has been associated with symptoms of inattention and may contribute to the SUD vulnerability in individuals with ADHD, and dopaminergic medications

SYMPOSIA

such as methylphenidate and amphetamines may be promising pharmacological approaches for the treatment of this comorbidity. In addition, new long-acting formulations of stimulant medications to treat ADHD may be a promising approach because they carry a lower risk for misuse or diversion compared with immediate release formulations. The purpose of this symposium is to review the advances in the development of medications, for the treatment of comorbid ADHD and SUDs in both adolescents and adults.

Opioid analgesics: Protecting their use and preventing abuse

Chairs: Sharon L. Walsh and Sidney H. Schnoll

The aim of this symposium is to present current data on the intersection of and balance between providing adequate pain treatment with opioid analgesics while appropriately managing the risks of their abuse and diversion. The approach presented here is translational and will cover the spectrum from pharmacological and formulation strategies to national policy implications. Dr. Schmidt will review current strategies for developing abuse-resistant medications for acute and chronic pain and provide profiles of products in advanced clinical development. Dr. Haller will provide an overview of findings from Project Pain, NIDA's first treatment development project focusing on opioid analgesic abuse in patients with chronic non-cancer pain. This will include a review of the research protocol and treatment interventions, both behavioral and pharmacological, and the factors found to impact (or not) 4 key treatment outcomes (pain severity, functional interference, opioid adherence and other drug abuse). Dr. Passik will review the concept of aberrant drug taking and the data from empirical/clinical surveys of pain patients. The documentation, differential diagnosis and management of aberrant drug taking will be discussed. Dr. Gilson will describe the Federal policy obligation to prevent the abuse and diversion of prescription pain medications while ensuring their adequate availability for legitimate medical purposes. A conceptual framework will be offered as a means to focus diversion control efforts better so that they do not interfere with clinical practice and patient pain care. Published evidence will demonstrate the need for a variety of safe and effective approaches to stem prescription pain medication abuse and diversion.

Innovative applications of technology to the prevention and treatment of substance use disorders

Chairs: Lisa A. Marsch and Kathleen M. Carroll

Empirically supported technology has the potential to play a critical role in improving community-based substance abuse prevention and treatment interventions in a manner that enables rapid diffusion of science-based interventions and which may be cost-effective. Although informational technology continues to rapidly expand and bring about profound changes in our society in general, it has been infrequently employed in the substance abuse treatment field to date. In this symposium, the scientists' pioneering research on computer-assisted interventions related to substance use disorders will present results from their research in this area. Dr. Lisa Marsch will present results from a controlled trial evaluating the effectiveness of a multimedia program focused on building up protective factors and reducing risk factors for substance use among elementary school-aged children. Dr. Jesse Dallery will present the latest results from his line of research developing and evaluating an Internet-delivered intervention, grounded in science-based contingency management principles, targeting smoking cessation. Finally, Dr. Kathleen Carroll will present results from a recently completed trial evaluating a computer-based Cognitive Behavior Therapy intervention.

SYMPOSIA

Thursday, June 19

*Preclinical research on the discovery of glutamatergic therapeutics
for the treatment of addiction*

Chairs: David A. White and Athina Markou

As our understanding of the mechanisms mediating addiction-related behaviors has evolved, increased consideration has been given to the importance of glutamatergic neurotransmission in the development and persistence of drug addiction, as well as relapse to drug taking. Further, research has demonstrated that virtually all drugs of abuse interact with glutamatergic systems in the brain. As a result, medications targeting glutamatergic mechanisms show great potential for the treatment of drug addiction. The goal of this symposium is to present current preclinical research involving glutamatergic systems and its significance in the discovery of pharmacotherapies for the treatment of dependence upon drugs of abuse (e.g. nicotine, alcohol, cocaine). Dr. Yamamoto will discuss the impact of exposure to substituted amphetamines on glutamatergic mechanisms and resultant neurotoxicity. Dr. Bilbao will present data on the role of NMDA and AMPA receptors in alcohol and cocaine addiction. Dr. Szumlinski will present findings on mGluR-Homer-PI3K signaling mechanisms and discuss the possible clinical relevance of such drug-induced adaptations. Dr. Jones will discuss allosteric modulation of metabotropic glutamate receptors (GluRs) as a novel approach to treatment of drug abuse and other CNS disorders. Finally, Dr. Markou will discuss and summarize, with input from the audience and the speakers, relevant advances in this area of research and the clinical implications for developing novel treatments for drug addiction.

Pharmacogenetics of medications for the treatment of addictions

Chairs: Ivan D. Montoya and Joni Rutter

Phenotype assessment has provided information about patient characteristics associated with pharmacotherapy response. It has been suggested that much of the individual variability in the safety and efficacy of medications for the treatment of SUDs may be influenced by genetic factors. The area of pharmacogenetics /pharmacogenomics is a relatively new discipline that may help to shed light on the individual mechanisms associated with the safety and efficacy of medications for the treatment of SUDs. Pharmacogenetics involves the study of individual differences in pharmacotherapy responses based upon genetic approaches and it includes the study of genes encoding drug metabolizing enzymes, transporters, receptors and other drug targets. For example, it has been reported that transdermal nicotine is more effective than placebo among smokers who carry the D2 dopamine receptor gene (DRD2) A1 allele, the DBH*A allele, or the OPRM1 Asp40 variant. With regard to bupropion response for smoking treatment, COMT haplotypes at rs737865 and rs165599 may predict a favorable outcome. Genes that code the enzymes involved in the metabolism of opioids may influence the dose and response to agonist treatments for opioid dependence. Although there is no efficacious medication for cocaine and marijuana dependence, genetic variants in the dopamine and cannabinoid systems, respectively, may influence the response to some potential pharmacotherapies for these disorders. The purpose of this symposium is to review the current knowledge about the genetic factors that may account for the differences in the medical safety and treatment response to medications proven effective or under testing for the treatment of addictive disorders. It is the hope that results from pharmacogenetics research will help clinicians to individualize the pharmacological treatment of patients with SUDs and make them safer and more effective by matching the medications to the genetic characteristics of the individual.

WORKSHOPS

Sunday, June 15

Organizing a special interest group on stress and addiction

Chairs: Rajita Sinha and Helen Wu

There is increasing evidence of the role of stress in the development, relapse and compulsive drug-seeking aspects of addictive disorders. Tremendous strides have been made in understanding the basic science that connects stress and the addictions, and epidemiological and population based research emphasizes the role of family and environmental stress factors in the development and maintenance of addictive disorders. Furthermore, evidence from human laboratory and clinical outcome studies reveals that specific stress responses play an important role in compulsive drug seeking and relapse. New therapies to treat addictive disorders are also being developed and tested to address the association between stress and addiction. Findings from these multiple lines of research have been presented in recent CPDD conferences. However, informal discussions among CPDD members revealed a need to organize and provide a forum for interested CPDD members where conceptual and methodological issues pertaining to this area of research may be discussed on an ongoing basis. Thus, the goal of this workshop is to organize and establish a CPDD “Special Interest Group on Stress and Addiction.” In particular, (a) consensus on defining and operationalizing *stress*, (b) ways to validate and measure it in the experimental and real world context, and (c) the effects of drugs of abuse on stress pathways will be targeted for discussion in the workshop. Additional methodological issues will be solicited from attendees so that these may be addressed in future meetings. As there remain many unanswered questions on the association between stress and addiction, there is a growing consensus that providing such a forum will advance discoveries in this area, and ultimately have a significant impact on both the prevention and treatment development in the field of addiction.

DEA’s drug chemical evaluation section: The scientists behind the badge.

The role of the scientific staff within DEA and resources for CPDD

Chairs: Christine A. Sannerud and Srihari R. Tella

This workshop will illuminate and demystify the scientific and regulatory functions and data collection efforts of DEA’s scientific staff in our efforts to support determinations under the Controlled Substances Act (CSA). DEA will discuss both general and specific information used to determine placement under the CSA, including the substance potential for abuse, and/or dependence liability, medical use and safety. We will also review our role in laboratory data collection for drug and chemical control, and give an overview of other ongoing data collection projects, including the National Forensic Laboratory Information System (NFLIS database). Other issues to be discussed are international treaties obligations and our role in international organization, an overview of the requirements and process for drug quotas, precursor chemical control and exemptions. DEA will also provide an overview of current drug control projects and reviews and the Schedule I researcher registration process. After all, every researcher handling controlled substances and chemicals needs a contact in DEA!

WORKSHOPS

From an acute care model to a recovery managed care model:

What do we know and where do we go from here?

Chairs: Ken Winters and Anne Helene Skinstad

Substance use disorders are chronic progressive disorders that are often treated within an acute care model. With the recent emphasis on recovery-oriented models of care, it is becoming more widely accepted that clients need continued support to change their lifestyle. But how much support do we have for the change in treatment philosophy, and how should recovery be defined? In this symposium, Peter E. Nathan will summarize the status of existing research on long term care for substance use disorders; Laurel M. Mangrum will present data from two recovery managed programs in Texas; Paul Moberg will summarize the results from their NIDA-funded project on the effectiveness of recovery high schools; Gary Olson will present a case study involving the rearrangement of a treatment program to enable it to fit within a recovery managed care system for his long-term clients; and Michael Flaherty will look to the future and present on data from six years of specific efforts to build recovery models of care and over 30 years of clinical and research experience.

Monday, June 16

Challenges for abuse liability testing from drug development to FDA approval

Chairs: Michael A. Nader and Beatriz Rocha

A group consisting of representatives from more than 20 pharmaceutical companies has collaborated and worked through the industry trade association (PhRMA) to organize a one-day "Dialogue Session" with the FDA Controlled Substances Staff (CSS). The purpose of the meeting is to have open discussion about some of the challenges faced by the pharmaceutical industry in developing CNS-active drugs, and to understand the current position and recommendations of the CSS. The meeting was held in February, 2008. The discussion is organized around a series of four hypothetical case studies with the intent of demonstrating some of the complexities in designing preclinical and clinical programs and issues in interpretation of data to assess abuse potential. This session at CPDD will review some of the scenarios discussed at the dialogue session and summarize the key conclusions, recommendations, and areas for potential methodologic refinement. The information obtained from this symposium will be highly informative to CPDD members conducting abuse liability testing.

Academic success and tenure in tight times

Chairs: Kristen Huntley, Nadine Rogers, Eliane Lazar-Wesley and Mark Swieter

This workshop will provide an opportunity to hear about factors used in tenure decisions and other evaluations of success in academic research settings. Senior scientists involved with making these decisions will present their perspectives on what makes an impression, both positive and negative. Each presenter will provide information about the things they look for when making evaluations. Presentations and discussions will be informal and provide an opportunity for substantive audience participation with the panel.

WORKSHOPS

Adolescent substance abuse treatment: Current findings and implications for juvenile justice settings

Chairs: Lyn Stein and Michael Dennis

Current meta-analytic findings in adolescent substance abuse research will be reviewed. Speakers with specialty in juvenile and criminal justice settings will then present some of their own work and comment on implications of meta-analytic work to juvenile justice settings (JJS). Links will be made between what the current research indicates is useful in treating adolescents in the JJS, and what is suggested in order to advance the field in future research endeavors. The session concludes with a brief SASATE (see <http://www.chestnut.org/li/apss/SASATE/>) meeting. Significance: Advancing the field of substance abuse treatment research for juvenile offenders. Aim 1: Summarize current cutting-edge research in adolescent substance abuse treatment. Aim 2: Present current substance abuse treatment research in criminal and juvenile justice settings specifically. Aim 3: Develop suggestions for future research in order to advance the field of substance abuse treatment research for juvenile offenders. Aim 4: Moderator, Michael Dennis, will review the discussion generated and then lead us into the SASATE meeting.

A step-by-step guide to analysis of epidemiological field survey data on minority health disparities and male-female differences in NIDA-related outcomes

Chairs: James Anthony and Silvia S. Martins

The main specific aim of this two-hour workshop is to introduce or to remind workshop attendees of some basic and advanced epidemiological research approaches that are required for correct estimation of point estimates, 95% confidence intervals, and significance tests, when the source of data is a complex multi-stage field survey design, and the research purpose is to shed light on male-female or minority group differences in the NIDA research domains of drug use and drug dependence. To begin, the workshop chairs will provide an overview of the basic concepts, terms of reference, principles, and approaches to be illustrated, and will present some examples of recent field survey discoveries about minority and male-female differences in drug involvement and drug dependence, including some yet-to-be-solved mysteries that require more probing research. During the last 90 minutes, workshop attendees will rotate through small group sessions, led by various speakers listed below, with a brief introduction and then hands-on experience with statistical software tools used for correct estimation (STATA, SAS, MPlus). The speakers will guide the small group through the analysis steps, with the aid of a team of workshop assistants, all of whom are current analysis-experienced fellows in NIDA-supported research training programs (T32, F31, F32, D43) directed by the workshop chair. Four small group sessions will be at the introductory level (i.e., basic models); two will be for advanced users (alternating logistic regressions; IRT and MIMIC modeling).

WORKSHOPS

NIDA international research posters

Chair: Steven W. Gust

This workshop will be similar to the ones conducted previously by the NIDA International Program, consisting of a poster session presenting drug abuse research being conducted outside of the United States. The primary goal is to provide a venue for CPDD members to meet, exchange ideas, and explore areas of mutual scientific interest with potential collaborators from other countries. Approximately 150 investigators will present research projects from around the globe, and NIDA divisions, offices, and programs will present posters outlining their international priorities and activities. Forging new collaborations among U.S. and foreign investigators is one of the primary goals of the NIDA International Program.

Tuesday, June 17

14th Annual Contingency Management Working Group

Chairs: Stacey Sigmon and Kelly Dunn

The Annual Meeting of the Contingency Management Working Group represents an opportunity each year at CPDD for the dissemination and discussion of current research in the area of contingency management interventions for treating drug abuse. Contingency management procedures have been consistently demonstrated to be efficacious in reducing use of a wide range of drugs across a variety of populations, and the behavioral approach represents one of the most effective interventions for the treatment of substance abuse. At the 14th Annual Meeting of the Contingency Management Working Group in 2008, junior and senior researchers will present preliminary data from ongoing studies.

What's new at NIDA and NIH: A peek into the black box

Chairs: Nadine Rogers, Eliane Lazar-Wesley, Kristen Huntley and Mark Swieter

This workshop is intended to provide an opportunity for participants to learn about new policies and procedures at NIH and NIDA that are relevant to them. Topics will include new policies for new investigator's summary statements, changes in the peer review process at NIDA and the Center for Scientific Review (CSR), tips on how to write a good grant application, and ways to get help on application preparation. Other topics and questions of interest to the audience will be addressed. This is very much an interactive, audience-directed activity. We see this workshop as a public service to the CPDD community, with the issues we discuss determined by audience interest. Although we will have a list of topics of interest, as is always the case with these presentations, audience members may ask about the budget, recent Advisory Council Reports, new research directions at NIDA, various NIH mechanisms, or any other subject.

Innovative technology transfer and information dissemination strategies:

Results from five ATTC-sponsored initiatives

Chairs: Anne Helen Skinstad and Paula K. Horvatic

According to Miller and colleagues (2005) "...there are sound, scientific, ethical, and compassionate reasons to learn and deliver evidence-based treatments (EBT) ..." (p.267). While no one would disagree with this statement, a recent Institute of Medicine report found that less than ten percent of substance use disorder treatments are evidence-based (IOM, 2006). For the past fourteen years, the regional SAMHSA-funded Addiction Technology Transfer Centers

WORKSHOPS

(ATTTCs) have served as a bridge between practitioners and researchers by collecting data that identify successful practices and developing strategies to lessen the gap between research and practice. In this workshop, four ATTTCs will present the results of five technology transfer projects that have been effective in changing practitioners' clinical practices, impacting clinical supervisors' skills and abilities regarding implementing EBPs, improving non-Native counselors' skills with Native Americans with substance use disorders, disseminating EBPs to an international audience of treatment providers, and determining the best methods for infusing the science of addiction into undergraduate courses. Specifically, Dr. Skinstad will introduce the Toolbox Training program; Dr. Horvatic will report on the successful sequence developed to facilitate technology transfer of MI; Dr. Duane Mackey will introduce South Dakota's statewide "*Native American Cultural Educational Program for Non-Native Counselors*"; Dr. Freese will discuss the effectiveness of the partnership between PSATTTC/UCLA and the United Nations in developing empirically based treatment training curricula for participants from 20 countries; and Ms. Roget will highlight data from a national addiction educator survey that examined the teaching of the neuroscience of addiction in undergraduate/graduate courses.

The following organizations have generously supported the work of the College on Problems of Drug Dependence during the past year:

American Legacy Foundation

Catalyst Pharmaceutical Partners

Centre de Recherche-Pierre Fabre

CSAT (Center for Substance Abuse Treatment)

Glaxo Smith Kline

Jazz Pharmaceuticals

NIDA (National Institute on Drug Abuse)

Pfizer Inc.

Reckitt Benckiser Pharmaceuticals, Inc.

Shire US Inc.

Society for Research on Nicotine and Tobacco